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Chapter 1
The burden of childhood pneumonia
Pneumonia is an infection of the alveoli in the lower respiratory tract. Together with 
bronchiolitis (infection of the bronchioles), pneumonia forms the biggest share of lower 
respiratory tract infections (RTI) in children. Pneumonia mostly presents with fever, cough 
and/or respiratory distress. Even though the term pneumonia is often used as a synonym 
of bacterial infection, a large proportion of the lower RTIs in young children are of viral 
origin. In primary care, out of all febrile children, less than 1% has a bacterial infection.1 In 
the emergency department (ED) this proportion goes up to 10 – 15%, of whom 30-70% is 
diagnosed with a pneumonia.2-5
Worldwide, lower RTIs are the leading cause of death in children after the neonatal period 
and under the age of five. Each year, an estimated 800,000 children under five die worldwide 
due to lower RTIs (mortality rate 119/100,000 per year).6,7 There are large disparities globally in 
pneumonia mortality, with the highest burden of disease in the global south. In high-income 
countries the mortality rate has dropped dramatically over the past decades (Figure 1).8 This 
is mainly due to the introduction of antibiotics, improved hygiene and access to healthcare, 
and more recently the introduction of vaccination against Haemophilus influenzae type b 
(Hib) since the 1990s and against pneumococcal disease (PCV, Pneumococcal Conjugate 
Vaccine) since the years 2000.6,9,10 Currently, mortality rate due to lower RTIs in western 
Europe is 1.7/100,000.6
Despite these relatively low mortality rates, lower RTIs in children still cause a high burden 
of disease in Europe. Fever and respiratory complaints are the main reason for children to 
be brought to a doctor and account for 30-50% of all paediatric ED visits.11-13 In children 
under five, lower RTIs are responsible for >100.000 primary care consultations and >7.000 
ED visits in the Netherlands annually.14,15 A substantial proportion of those children need 
hospital admission, posing a burden on the child and its family, but also to healthcare in 
terms of costs.
BNW_Josephine_v1.indd   8 19-Sep-20   14:50:48
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General introduction
Figure 1. Deaths from pneumonia and from other causes in childhood. Data from the United States, trend is com-
parable to western Europe.8
Antimicrobial resistance on the rise
The introduction of antibiotics was the main driver of the reduction in pneumonia mortality 
worldwide. However, the use of antibiotics also has its downsides. Misuse and overuse of 
antibiotics fuels antimicrobial resistance (AMR) that threatens the health of the general 
public.16,17 A recent study has shown that resistant bacteria in the European Union region 
were responsible for >27,000 deaths in 2015, a number that has more than doubled since 
2007.18 Especially in eastern Europe, bacteria become more and more resistant to commonly 
used antibiotics. This calls for urgent action, and the World Health Organization (WHO) 
and European Commission have declared AMR as a top public health threat.17,19 To reduce 
inappropriate antibiotic use, antibiotic stewardship programmes have been launched 
worldwide, but few of them include the ED.20 Most studies on antibiotic prescription in 
febrile children have focused on primary care or in-hospital settings.21,22
Management of children in the ED
The management of children in the ED usually follows different steps, each with its key 
decision-makers (Figure 2). First, parents bring their child into the ED for medical consultation, 
in the Netherlands mostly after referral by a general practitioner (GP). Next, triage is 
performed to determine the level of urgency of the child’s illness, usually by a nurse. A 
nurse also does a first clinical assessment, including the measurement of vital signs. Then a 
doctor takes the clinical history, examines the child and may decide to perform additional 
diagnostic tests. Based on all the obtained information, the doctor decides on treatment 
1
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and disposition of the child. Before leaving the ED, discharge information is provided to 
the parents, including instructions on when to return to the hospital. Even though many 
of these decisions are made jointly between the healthcare workers and parents, the main 
responsibility of the decisions varies throughout the process.
Figure 2. Care pathway and key decision makers in the paediatric ED.
Identifying children in need of antibiotics
Given the dual risk of bacterial pneumonia on the one hand and of antimicrobial resistance 
on the other hand, it is crucial to identify and treat only those children that really need 
antibiotic treatment. However, this is very difficult in clinical practice. Children often present 
with symptoms like fever and cough, which are not specific for viral or bacterial disease. 
Other clinical features like vital signs can help identify severe illness, but are not specific for 
bacterial causes of disease either. Multiple studies have shown the lack of diagnostic accuracy 
of clinical signs and symptoms to identify bacterial infections, including pneumonia.1,4,23
For a long time, the chest X-ray was considered the gold standard to diagnose bacterial 
pneumonia. However, more recent evidence revealed its limitations, especially the high 
inter-observer variability and the inability to distinguish viral from bacterial causes of 
disease.24,25 Therefore, current guidelines for community-acquired pneumonia in children 
do not recommend routine use in most children in the outpatient setting. The British Thoracic 
Society (BTS) and the Infectious Diseases Society of America (IDSA) advise to restrict the use 
of a chest X-ray to children with moderate to severe signs and symptoms of pneumonia, 
who are at risk of developing complications.26,27 Both guidelines were released in 2011, and 
the Dutch guideline for fever in children followed the same advice (published in 2013).28
There are several other diagnostic tools available, but they all have their limitations.29 
Sputum is difficult to obtain in children, so bacterial sputum cultures are not feasible. Blood 
cultures are not useful, because the prevalence of bacteraemia in children with pneumonia 
is very low.30 Viral PCR testing is mostly performed on samples of the upper airways like the 
BNW_Josephine_v1.indd   10 19-Sep-20   14:50:49
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nasopharynx. These results can support the diagnosis of viral disease, but the connection 
between the flora of the upper and lower airways is unclear and bacterial co-infection cannot 
be excluded.31 The Dutch guideline for fever in children only recommends routine viral testing 
in the influenza or Respiratory Syncytial Virus (RSV) season.28 Lastly, biomarkers identifying 
the host-response to infection are available and used in children suspected of a pneumonia.32 
The most common biomarkers used for this purpose are C-reactive protein (CRP), and – less 
frequently – procalcitonin.33,34 However, both have limited diagnostic accuracy in identifying 
bacterial disease. New markers are being developed, but not yet available in routine clinical 
practice.35-37
Outcome-based research
The difficulty of diagnosing bacterial infections can lead to misclassification of diagnoses, 
reducing the comparability of studies on febrile children.38 To avoid this, some authors 
have argued to focus research more on the outcomes or consequences of the disease than 
on the diagnosis itself.39 In other words, they propose to shift from trying to identify the 
causative pathogen to focusing on the consequences of the infection in clinical practice. 
These consequences are 1) does this child require antibiotic treatment? and 2) does this child 
need to be hospitalized? (Figure 3) In the case of RTIs: a child with a bacterial pneumonia can 
often be managed with antibiotics in the outpatient setting, while children with bronchiolitis 
do not need antibiotic treatment, but may even need supportive care at an intensive care 
unit.39
Figure 3. Classification of diagnosis and management of fever and RTIs, adapted from Irwin et al.39
1
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Clinical decision support for fever and pneumonia
In order to aid physicians in managing children with fever and RTIs, multiple decision 
support tools exist. Mostly common are clinical guidelines, that are available for fever in 
general 28,40, and for pneumonia in particular.26,27 Even though these guidelines provide 
useful recommendations for daily practice, they are based on studies of varying degrees of 
evidence and on expert opinion. Moreover, they provide rather general advice that often 
leaves room for interpretation, and they do not provide decision support at the individual 
patient level. Another form of decision support can be provided by clinical prediction models, 
that provides a risk prediction at the individual level. In contrast to the development of clinical 
guidelines, there are strict methodological steps in the development of prediction models, 
as mentioned in Table 1.41 Across the field of medical research, many prediction models are 
derived, but few of them are validated and even fewer are translated into decision rules and 
implemented in daily clinical practice.42,43 Several prediction models exist for diagnosing 
childhood pneumonia, among others the Feverkidstool that has been derived and validated 
by Nijman et al.2 This prediction model combines clinical signs and symptoms and a CRP-level 
to predict the probability that a child has a pneumonia, another serious bacterial infection 
(SBI), or no bacterial infection. The model has been externally validated in different settings 
in The Netherlands and the United Kingdom (step 3 in Table 1), showing good diagnostic 
accuracy for both pneumonia and other SBIs (area under the receiving operator curve 0.83-
0.85 for pneumonia and 0.81 for other SBI).3,44
Table 1. Steps of development and evaluation of clinical prediction rules. Cited from Reilly et al. 41
Level of evidence Definitions Implications for clinicians
1. Derivation of 
prediction rule
Identification of predictors using 
multivariate model
Needs validation and further evaluation 
before using clinically in actual patient 
care
2. Narrow validation of 
prediction rule
Verification of predictors when tested 
prospectively in one setting; blinded 
assessment of outcomes
Needs validation in varied settings; may 
use predictions cautiously in patients 
similar to sample studied
3. Broad validation of 
prediction rule
Verification of predictive model in 
varied settings with wide spectrum of 
patients and physicians
Needs impact analysis; may use 
predictions with confidence in their 
accuracy
4. Narrow impact 
analysis of prediction 
rule used as decision 
rule
Prospective demonstration in one 
setting that use of prediction rule 
improves physicians’ decisions (quality 
or cost-effectiveness of patient care)
May use cautiously to inform decisions 
in settings similar to that studied
5. Broad impact analysis 
of prediction rule used 
as decision rule
Prospective demonstration in varied 
settings that use of prediction rule 
improves physicians’ decisions for 
wide spectrum of patients
May use in varied settings with 
confidence that its use will benefit 
patient care quality or effectiveness
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Decision support of parents after ED discharge
In addition to healthcare providers, parents are key players in the decisions on managing 
children with fever and RTIs (Figure 2). This starts with the decision to care for the child at 
home or to seek medical attention and when to do so, but this decision process continues 
after an ED visit. Given the difficulty of distinguishing bacterial pneumonia from self-limiting 
viral illness, uncertainty about the diagnosis often remains after evaluation of the febrile 
child in the ED. It is therefore crucial that parents are supported in their decisions on how 
to manage their child at home and on when to return to the ED. However, parents often 
have difficulty in recognizing specific alarming symptoms in their febrile child 45, and have 
poor understanding of clinical information and discharge instructions provided by the ED 
staff.46,47 In order to reduce unnecessary ED visits, but also to prevent missing serious illness, 
parents need clear discharge information on how to monitor recovery or deterioration of 
their child’s illness after the ED visit.48,49
Aims of this thesis
This thesis aims to evaluate and improve clinical decision-making for the diagnosis and 
treatment of childhood pneumonia in the ED. In particular, it aims to answer the following 
research questions:
Variability in management of childhood pneumonia in the emergency department
1. What is the current practice in diagnosis and treatment of children with fever and respiratory 
tract infections in the European emergency department, in particular regarding the 
measurement of vital signs, performance of chest X-rays and antibiotic prescription?
2. Can we explain variability in antibiotic prescriptions for respiratory tract infections by 
differences in the population?
Supporting treatment decisions for childhood pneumonia
3. Can clinical prediction models guide antibiotic treatment decisions for childhood 
pneumonia?
4. Can we safely reduce antibiotic prescription in children under five suspected of a 
lower respiratory tract infection in the emergency department, by implementing the 
Feverkidstool as a clinical decision rule?
5. Can we improve the diagnosis of serious bacterial infections if we update the Feverkidstool 
by replacing CRP by new biomarkers?
1
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Supporting parents’ decisions for their child with fever
6. What are parents’ views on, and experiences of managing their febrile child and what 
are their behaviour and needs when in search of information about fever?
7. How do parents evaluate a developed hospital discharge information package about 
fever in children?
Outline
The first part of this thesis describes current variability in the management of children with 
fever and/or suspected lower RTIs in the ED. The NICE guideline for fever in children under 
five recommends to measure four vital signs routinely in all febrile children. In chapter 
2.1 we describe variability in measuring vital signs in febrile children in European EDs, 
and the adherence to specific NICE guideline recommendations. For this analysis we use 
a population of febrile children from 28 European EDs within the REPEM (Research in 
European Pediatric Emergency Medicine) network. In chapter 2.2 we describe the use of 
chest X-ray in diagnosing pneumonia in children, and the influence of the chest X-ray on 
antibiotic prescription. For this purpose, we use the usual care data of a multicentre trial 
in children under five in eight EDs in The Netherlands (STRAP trial). In chapter 2.3, we 
use the international REPEM population to quantify and explain the variability in antibiotic 
prescription in European EDs.
In the second part of this thesis we investigate the role of clinical prediction models in 
supporting decisions on antibiotic treatment for childhood pneumonia. In Chapter 3.1 
we review the available clinical prediction models for childhood pneumonia, including the 
Feverkidstool. Most models are based on chest X-ray as the reference standard. However, 
since this is no longer used as a gold standard, we validate the available prediction models 
for a clinical diagnosis of pneumonia. We also explore possible thresholds for supporting 
treatment decisions to be used in clinical practice. Chapter 3.2 presents the results of 
a stepped wedge, cluster randomized trial in which the Feverkidstool was used to guide 
antibiotic treatment in children under five suspected of a lower RTI in the ED (STRAP trial). In 
chapter 3.3 the economic impact of the Feverkidstool is described, also providing cost data 
of children with lower RTIs in the ED in general. In chapter 3.4 we update the Feverkidstool 
by replacing CRP with the ImmunoXpert, a host-protein based assay combining CRP, tumour 
necrosis factor-related apoptosis-inducing ligand (TRAIL) and interferon γ induced protein-10 
(IP-10).
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The last part of this thesis focuses on the role of parents in the management of febrile 
children. In chapter 4.1 we use qualitative research methods to explore parents’ views on 
and experiences of managing their febrile child. We also assess their behaviour and needs 
when in search of information about fever. Based on this, we develop and evaluate a hospital 
discharge information package about fever in children.
1
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ABSTRACT
Vital signs can help clinicians identify children at risk of serious illness. The NICE guideline 
for fever in under-fives recommends a routine measurement of temperature, heart rate, 
capillary refill and respiratory rate in all febrile children visiting the Emergency Department 
(ED). This study aims to evaluate the measurement of paediatric vital signs in European 
EDs, with specific attention to adherence to this NICE guideline recommendation. In a 
prospective observational study we included 4560 febrile children under 16 years from the 
ED of 28 hospitals in 11 European countries (2014–2016). Hospitals were academic (n = 17), 
teaching (n = 10) and non-teaching (n = 1) and ranged in annual paediatric ED visits from 
2700 to 88,000. Fifty-four percent were male, their median age was 2.4 years (IQR 1.1–4.7). 
Temperature was measured most frequently (97%), followed by capillary refill (86%), heart 
rate (73%), saturation (56%) and respiratory rate (51%). In children under five (n=3505), a 
complete measurement of the four NICE-recommended vital signs was performed in 48% 
of patients. Children under one year of age, those with an urgent triage level and with 
respiratory infections had a higher likelihood of undergoing complete measurements. After 
adjustment for these factors, variability between countries remained.
Conclusion: Measuring vital signs in children with fever in the ED occurs with a high degree 
of practice variation between different European hospitals, and adherence to the NICE 
recommendation is moderate. Our study is essential as a benchmark for current clinical 
practice, in order to tailor implementation strategies to different European settings.
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INTRODUCTION
Fever is the most common reason for children to be brought to an emergency department 
(ED)1-3, with causes ranging from self-limiting illnesses of childhood to serious bacterial 
infections (SBIs) that can prove fatal.3-5 Vital signs can help clinicians identify children at risk 
of serious illness. Even though the level of evidence for the diagnostic accuracy of vital signs 
is varying, their importance is widely acknowledged.6 Vital signs form the basis of Paediatric 
Early Warning Scores (PEWS) that are widely used to monitor disease severity of children in 
the inpatient setting.7 Moreover, they are included in several prediction models for serious 
infections and in disease-specific guidelines for the ED setting.3,8-12 The NICE guideline for 
the assessment and initial management of fever in children under five recommends a routine 
measurement of temperature, heart rate, capillary refill and respiratory rate in all children 
presenting to the ED with a fever.13 These recommendations have been adopted throughout 
a large number of European hospitals.
Not measuring vital signs may pose the patient at risk of underestimating the severity of 
illness and may delay appropriate treatment.14 From adult research and single-country studies 
we know that incomplete and inaccurate recording of vital signs is common.15-17 This problem 
may be even larger in Europe, given the diversity of the countries, cultures and healthcare 
systems. However, international data on recording of vital signs across Europe in children are 
lacking.18 Information on the measurement of vital signs is crucial in order to fuel research 
on serious illness and to target quality improvement initiatives in paediatric emergency 
medicine. This research aims to evaluate the current practice of measuring vital signs in febrile 
children in European EDs and, more specifically, the level of adherence to the NICE guideline 
recommendation to routinely measure four distinct vital signs.
METHODS
Study design and population
We performed a prospective observational study in 28 EDs in 11 European countries, including 
patients under the age of 16 and with a fever as their presenting complaint. Children were 
excluded if they presented to the ED repeatedly for the same problem within 7 days, if they 
were treated with antibiotics in the 7 days before the ED visit, or if they had a documented 
allergy to antibiotics. For the current study, children with comorbidities were also excluded, as 
disease-specific characteristics may influence their management. In the whole population, we 
evaluated the measurement of vital signs. In children under five, we assessed the adherence 
2.1
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to the recommendations to measure four distinct vital signs from the NICE guideline ‘Fever 
in under 5s: assessment and initial management’.13
Data collection
Data collection took place between October 2014 and February 2016 within the network 
of Research in European Pediatric Emergency Medicine (REPEM). Detailed methods have 
been published earlier.19 In short, all participating 28 EDs recorded medical information for 
all attending children with fever for one random day each month. We recorded general 
characteristics of patients (age, sex, weight, height, comorbidities), vital signs (heart rate, 
respiratory rate, temperature, oxygen saturation, capillary refill time) and information 
regarding diagnosis and management. Data were extracted from routine patient records, 
and filled in on an electronic study case report form (CRF) by the local investigator after 
the sampling day (Electronic Supplementary Material 1). Comorbidities and diagnoses were 
recorded according to pre-specified categories. We neither used ICD-codes for the recording 
of diagnoses, nor had we access to data after the ED visit. Consequently, ‘diagnosis’ in 
this manuscript refers to a presumed diagnosis at ED discharge. All items in the CRF were 
mandatory to fill in, with the option to choose ‘unknown’. Unknown values on vital signs 
were seen as ’not measured’, and were therefore considered to be outcomes rather than 
omissions. Local investigators were aware of the sampling days and the general scope of the 
study as a registry of febrile children, but vital sign measurement was not known as a specific 
point of interest. Hospital information was collected using a survey, including questions on 
guideline use. We collected data on hospital setting (inner city/rural/mixed), hospital type 
(academic/teaching/non-teaching), triage system, and number of annual paediatric ED visits, 
similar to other studies on the organization of care (Electronic Supplementary Material 2).20 
Setting reflects the population in the catchment area of the hospital. Academic hospitals are 
connected to a university, teaching hospitals are non-university hospitals that provide training 
for paediatrics residents, non-teaching hospitals do not provide training of residents.
Definitions
Not every study hospital used the same triage system, but they all classified children according 
to a five-point scale, ranging from ‘non-urgent’ to ‘immediate’, making comparisons possible. 
Owing to the small number of cases, patients in the ‘immediate’ and ‘very urgent’ categories 
were grouped together. Tachycardia and tachypnoea were defined according to the advanced 
pediatric life support (APLS) guideline.21 Fever was defined as temperature ≥38 °C, hypoxia 
as peripheral oxygen saturation level of ≤ 94%. Crowding of the ED was defined for each 
hospital according to their number of total paediatric ED visits on the sampling day (less than 
usual/as usual/more than usual). We defined a usual number of total visits as the interquartile 
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range of the number of total visits across the different sampling days per hospital. If on a 
sampling day the number of total visits was lower than the 25th percentile for that hospital, 
crowding was less than usual, if the number was higher than the 75th percentile, the ED was 
more crowded than usual.
Adherence to the NICE guideline was based on the following indicator: “Measure and 
record temperature, heart rate, respiratory rate and capillary refill time as part of the routine 
assessment of a child with fever.”.13 Adherence to the NICE guideline was defined as the 
complete measurements of those four vital signs in children under 5 years old.
Statistical analysis
We used descriptive analyses to evaluate the frequency of measurement for all of the available 
vital signs in the study population. We examined practice variations between countries, 
age groups, triage levels and diagnoses, visualizing the measurement of vital signs by heat 
maps. We used diagnosis in these analyses as a proxy of presenting complaint (next to 
the fever) and suspicion of severity, assuming that children with RTIs would present with 
respiratory symptoms, enteric infections with vomiting or diarrhoea and that children with 
fever without source, urinary tract infections and sepsis/meningitis mostly present without 
specific symptoms but with a higher suspicion of invasive infections. We compared the 
frequency of detecting abnormal vital signs between countries that frequently measured 
vital signs and countries that measured them less often.
In assessing adherence to the NICE guideline, we measured the frequency of complete 
measurements in children under five from all hospitals that used the NICE recommendations. 
We tested the influence of age, triage level, diagnosis and crowding of the ED on adherence 
using a multilevel logistic regression model that included hospital as a random variable. 
Analyses were performed using SPSS (IBM, version 24) and R (version 3.5.2).
RESULTS
Population characteristics
In total, 5255 children were included in the complete cohort, all presenting with fever and 
without prior antibiotic treatment or repeated ED visits. In the current study, we included 
4560 children. Exclusion was mostly because of comorbidities (Fig. 1). Of the included 
children, 53.8% were male and the median age was 2.4 years (interquartile range 1.1–4.7). 
Table 1 shows their baseline characteristics and provides information regarding patients’ way 
of referral and follow-up. Baseline characteristics of children with comorbidities has been 
2.1
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published earlier.19 In general, these children were more ill and older than children without 
comorbidities. Of the 28 participating hospitals, 17 were academic hospitals, 10 teaching 
hospitals and one non-teaching hospital (Table 2). They varied from inner city hospitals 
(n = 17) to regional (n = 2) and mixed hospitals (n = 9) and their number of annual paediatric 
ED visits ranged from 2700 to 88,000. Most hospitals used a local triage system (n = 8) or 
the Manchester Triage System (n = 7, Table 2). All except the Spanish hospitals used the 
recommendation to routinely measure vital signs as mentioned in the NICE guideline.
Fig. 1 Flowchart of inclusion
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Table 1. Baseline characteristics of the population, n = 4560
General characteristics n/N (%)a
Male sex 2451/4557 (53.8%)
Age in yearsb 2.4 (1.1–4.7)
Season
- Spring 1110/4560 (24.3%)
- Summer 766/4560 (16.8%)
- Autumn 1024/4560 (22.5%)
- Winter 1660/4560 (36.4%)
Way of referral
- General practitioner 395/4524 (8.7%)
- Self 3966/4524 (87.7%)
- Other healthcare professional 163/4524 (3.6%)
Triage level
- Immediate or very urgent 197/3850 (5.1%)
- Urgent 1042/3850 (27.1%)
- Standard 1866/3850 (48.5%)
- Non-urgent 745/3850 (19.4%)
Abnormal vital signs
Fever (temperature ≥ 38 ºC) 2403/4435 (54.2%)
Tachycardiac 1138/3341 (34.1%)
Tachypnoeac 665/2333 (28.5%)
Hypoxia (oxygen saturation ≤ 94%) 85/2567 (3.3%)
Prolonged capillary refill (> 3 s) 67/4560 (1.5%)
Disposition
- Discharged home 4035/4559 (88.5%)
- Observation unit <24h 187/4559 (4.1%)
- Admitted to ward 321/4559 (7.0%)
- Admitted to ICU 11/4559 (0.2%)
Footnote:
a Unless stated otherwise
b Median (interquartile range)
c According to APLS guidelines
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Overall measurement of vital signs and per country
The measurement of vital signs occurred in varying degrees, both when comparing the 
different vital signs with each other and across participating countries. Overall, temperature 
was measured most frequently (97%, 4435/4560, 95% confidence interval 97–98%), ranging 
between countries from 70% (78/111) in Hungary to 100% in Denmark and England (n = 24 
and n = 145 respectively). Capillary refill was next (86%, 85–89%), followed by heart rate 
(73%, 72–75%), saturation (56%, 55–58%), and respiratory rate (51%, 50–53%), although 
the latter two had much wider ranges between countries. Figure 2a contains a heat map 
visualizing the frequency of vital sign measurements in participating countries. Variability 
between countries is apparent throughout all of the different vital signs and is most striking 
for respiratory rates. Temperature was the most consistent, as it was measured in more than 
90% of cases in all countries but one.
Measurement of vital signs per triage level, age group and diagnosis
In the hospital in Turkey, no routine triage was performed. In the remaining hospitals, 99% 
(3825/3852) of children were triaged upon their arrival to the hospital. Children requiring 
‘very urgent’ or ‘immediate’ care had their vital signs measured most frequently (Fig. 2b). 
Differences across triage levels were greatest for heart rate, saturation and respiratory rate 
and amounted to about 30%-points between the ‘very urgent/immediate’ and ‘standard’ 
categories (heart rate: 93% vs. 64%, saturation: 90% vs. 59%, respiratory rate: 65% vs. 
37%).
Differences in measurement across age groups were smaller (Fig. 2c). Only heart rate and 
saturation were more frequently measured in infants than in children >5 years of age (heart 
rate: 83% vs. 71%; saturation 78% vs. 47%).
We observed an association between the measurement of vital signs and diagnosis (Fig. 
2d). Most children (3307/4461, 74%) had respiratory tract infections (RTIs); only 15 children 
had sepsis or meningitis. Temperature and capillary refill were measured quite consistently 
across the different infectious foci (97% and 86% of cases respectively), but the remaining 
vital signs exhibited a considerable variability. Saturation was measured substantially more 
often in lower RTIs and in patients with sepsis/meningitis than in other cases. Heart rate was 
recorded in all patients with sepsis/meningitis (15/15) and in 86% (416/486) of those with 
lower RTIs. For fevers of unknown origin, on the other hand, heart rate measurements were 
included in the work-up of only 61% (174/284) of cases. Respiratory rates were measured in 
less than half of patients for four out of seven infectious foci and were done most frequently 
in patients with lower RTIs, amounting to 64% (310/486) of cases.
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Fig. 2 Heat maps indicating the frequency of vital sign measurements in % (a) per country; (b) per triage level; (c) 
per age group; (d) per diagnosis.
a
n 
hospitals
n (%) Temperature
Capillary 
refill
Heart 
rate
Saturation
Respiratory 
rate
Legend
Italy 3 446 (10) 0%
Portugal 3 698 (15) 10%
Spain 4 631 (14) 20%
Romania 2 282 (6) 30%
Turkey 1 708 (16) 40%
Switzerland 2 428 (9) 50%
The Netherlands 5 161 (4) 60%
France 5 926 (20) 70%
Hungary 1 111 (2) 80%
Denmark 1 24 (0.5) 90%
England 1 145 (3) 100%
Total 
population
4560 
(100)
97 86 73 56 51
b
n (%) Temperature
Capillary 
refill
Heart 
rate
Saturation
Respiratory 
rate
Legend
Non-urgent 743 (19) 30%
Standard 1845 (48) 40%
Urgent 1042 (27) 50%
Immediate / Very urgent 195 (5) 60%
70%
80%
90%
Total populationa
3825 
(100)
97 83 69 66 43 100%
c
n (%) Temperature
Capillary 
refill
Heart 
rate
Saturation
Respiratory 
rate
Legend
5 - 16 years 1054 (23) 40%
1 - 5 years 2478 (54) 50%
3 - 12 months 867 (19) 60%
0 - 3 months 160 (4) 70%
80%
90%
Total populationb
4559 
(100)
97 86 73 56 51 100%
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d
n (%) Temperature
Capillary 
refill
Heart 
rate
Saturation
Respiratory 
rate
Legend
Fever without focus 284 (6) 30%
Other 199 (4) 40%
Urinary tract 125 (3) 50%
Enteric 531 (12) 60%
Upper respiratory 2821 (63) 70%
Lower respiratory 486 (11) 80%
Sepsis/meningitis 15 (0.3) 90%
100%
Total populationc
4461 
(100)
97 86 74 57 52
Footnote:
Superscript lowercase letters indicate the following: a Turkey (n=708) and 27 other cases excluded for missing triage 
level; b 1 patient missing age; c 99 (2%) missing diagnosis. Categories (country, diagnosis and triage level) are ranked 
from top to bottom according to how often all of the vital signs were measured. Vital signs are in turn organized from 
left to right based on their frequency of measurement overall. Green indicates highest frequency of measurement 
per figure; red indicates lowest frequency of measurement.
Frequency of abnormal findings
The incidence of abnormal vital signs when measured was generally low. Of all patients 
with a measured temperature, 2403 (54.2%) had a fever at the time of evaluation in the 
ED (Table 1). Out of these children, 889 (37%) had a temperature of 39 °C or more. Other 
than that, heart rate was most often abnormal, in 34.1% of cases. Twenty-nine percent of 
children were found to be tachypnoeic, hypoxia was found in 3.3% of cases and prolonged 
capillary refill in 1.5%.
We observed no correlation between the frequency of measurement of a vital sign per 
country and the proportion of abnormal values (out of all values measured in that country). 
So, less frequent measurement of a vital sign was not related to a higher proportion of 
abnormal values detected.
Adherence to guideline recommendation
From all hospitals using the NICE recommendations 1450/3014 (48%) of children under 
five underwent a complete measurement of these vital signs (95% CI 46 to 50%). A 
complete measurement was most frequent in children with lower RTIs and sepsis, although 
at a moderate compliance of 55% and 46% respectively (193/350 for lower RTIs and 5/11 
for sepsis; Table 3). Multivariable analysis showed that children with RTIs had complete 
measurements significantly more often than children with fever without focus (odds ratio for 
upper RTI 1.75 (1.10–2.77), for lower RTI 3.75 (2.21–6.37); Table 3). Also, younger children 
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were more likely to have all recommended vital signs measured than children over one 
year of age. Last, children with high triage urgency had full measurements slightly more 
often than non-urgent children (immediate/very urgent OR 1.62 (0.95–2.76), urgent level 
OR 1.36 (0.96–1.95)). Crowding of the ED had no significant effect on the frequency of 
complete measurement of vital signs. After adjusting for diagnosis, age and triage urgency, 
a substantial variability between hospitals remained (data not shown).
Table 3. Determinants of full measurement of NICE-recommended vital signs in children under five.
Full chart measured n/N (%)a OR (95% CI)b
Diagnosis
- Fever without focus 72/170 (42%) Reference
- Other 53/134 (40%) 0.94 (0.50-1.77)
- Urinary tract infection 37/83 (45%) 1.19 (0.56-2.54)
- Enteric 142/352 (40%) 1.26 (0.75-2.12)
- Upper RTI 922/1856 (50%) 1.75 (1.10-2.77)
- Lower RTI 193/350 (55%) 3.75 (2.21-6.37)
- Sepsis-meningitis 5/11 (46%) 1.93 (0.49-7.65)
Triage level
- Non-urgent 180/526 (34%) Reference
- Standard 368/1117 (33%) 0.75 (0.54-1.05)
- Urgent 358/715 (50%) 1.36 (0.96-1.95)
- Immediate or very urgent 98/163 (60%) 1.62 (0.95-2.76)
Crowding of PED
- Usual number of daily visits 519/1267 (41%) Reference
- Less visits than usual 168/463 (36%) 0.83 (0.62-1.10)
- More visits than usual 296/775 (38%) 0.98 (0.77-1.24)
Age groups
- 0 to 3 months 81/139 (58%) 1.76 (1.06-2.92)
- 3 to 12 months 392/728 (54%) 1.38 (1.09-1.75)
- 1 to 5 years 976/2146 (46%) Reference
a based on population under five from hospitals using NICE recommendations, n = 3014
b multivariable analysis, clustered by hospital, based on complete cases, n = 2433;
RTI = respiratory tract infection; PED = paediatric emergency department
2.1
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DISCUSSION
Main findings
In this study of febrile children at 28 European EDs, we observed that of all vital signs, 
temperature is most frequently measured and respiratory rate least frequently, but with a high 
degree of variability between countries. Most centres have adopted the recommendation 
of the NICE guideline ‘Fever in under 5s: assessment and initial management’ to always 
measure temperature, heart rate, respiratory rate and capillary refill, but compliance to this 
recommendation was moderate. Febrile children that are under 1 year of age, with high triage 
urgency and those with RTIs were more likely to have a full set of vital signs measured.
Interpretation and comparison to existing literature
Fever was an inclusion criteria for our study, which explains the high frequency of completed 
temperature in our database and the high proportion of abnormal temperatures. The relatively 
high proportion with abnormal heart rate can be explained by the physiological relationship 
between temperature and heart rate.22,23 Respiratory rate was least frequently measured 
and with large variation across subgroups. Other studies have suggested reasons for such 
variability, like crying or distress of a child, or limitations in the counting technique.11,24,25 
We had no information on the child’s well-being or the devices used for measurement of 
respiratory rate, but these factors may have contributed to the observed low frequency of 
measurement of this vital sign. Although ED crowding has been associated with decreased 
quality of care 26, we found no association between ED crowding and adherence to the vital 
signs measurement recommendation in our study.
We observed an overall adherence of 48% to the NICE recommendation to measure four 
vital signs in all children under five, in our study in 2014-2016. This is lower than reported 
by a previous audit study in primary care in the UK (62%) after educational sessions and 
introduction of a template to record vital signs in the electronic health record.15 An audit 
among paediatric EDs in the UK found that temperature was similarly measured as in our 
study (94%), but reports lower numbers for capillary refill time (53%) and higher rates 
for heart rate (94%) and respiratory rate (89%) measurements.16 It may be striking that 
full measurement of vital signs children under five was most frequently done in children 
suspected of RTIs, rather than in those with suspected urinary tract infections and fever 
without focus. Even though the discharge diagnosis is often unknown at the moment of vital 
sign measurement, it is likely to assume that children with these last two diagnoses might 
present without specific symptoms. These children may have more diagnostic uncertainty 
and be at higher risk of complicated disease. Less than half of the children with suspected 
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sepsis – although represented by a small number in our study – received the full set of vital 
sign measurements needed for compliance with the NICE guidelines.
Patient characteristics can only partly explain the observed practice variations. Professional 
adherence to guideline recommendations can also be influenced by local policy or professional 
experience. Even though most participating centres mentioned that their guidelines were 
based on the NICE guideline, in the process of translation from the UK to another setting, 
the evidence probably is weighed according to the local setting and practice. This may induce 
further practice variation across centres.18
Strengths & limitations
This study had the advantage of a sizeable, prospectively generated database containing 
large amounts of high quality patient information from 28 hospitals of various sizes and 
hospital types, from 11 different countries in Europe. Compared to the available literature in 
European paediatric emergency medicine, this number of included hospitals and countries is 
large, supporting the generalizability of our findings. However, some countries and hospitals 
included more patients than others, which might have influenced results. Furthermore, 
countries were represented by different numbers of hospitals (some countries only by one 
hospital), which adds uncertainty to whether measurements are a reflection of national or 
local policies.
 The study was performed in hospitals of the REPEM research collaboration, ensuring high 
quality data.27 Their interest in research indicates that they are likely to uphold a high standard 
of care. The staff of participating hospitals were only aware of the general study design as 
a registry of febrile children, so a special focus on vital sign measurement during the study 
period is unlikely. Lastly, because this research treated missing variables as decisions not 
to perform certain measurements, some room remains for human error in data collection. 
However, all items in the data collection form were mandatory, with the option to fill in 
‘missing’. During the preparation of this manuscript the local investigators confirmed that 
‘missing’ values were indeed ‘not recorded’.
Clinical and research implications
Our numbers on compliance to the NICE recommendation obtained from 28 European EDs 
calls for better recording of vital signs in children. Not measuring vital signs may pose children 
at risk of underestimating the severity of their illness or delaying necessary treatments.14 Even 
though almost all included centres had adopted the NICE recommendation to measure vital 
signs in all febrile children, compliance in less than half of cases is striking. Even in children 
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with sepsis, fever without source or urinary tract infections in less than 50% of cases the 
full set was measured. Therefore, special attention should be given to children presenting 
with fever without specific symptoms, since vital sign measurements may contribute most 
to the identification of severe infections in this patient group. Although measurement is 
influenced by age and triage, it might be questioned whether triage appropriately selects 
children with severe disease.28
Future research should focus on identifying reasons for non-compliance, including cultural and 
healthcare factors at the individual, organizational and national level.18 Qualitative research 
could provide more in-depth information on the reasons for the observed discrepancies in 
vital sign measurements across Europe. At the same time, more evidence is needed on the 
diagnostic value of vital signs in different settings and patient groups and their impact on 
health outcomes. Such research could provide evidence for targeted measuring of vital signs 
in children that benefit most from complete measurements.
Conclusion
Measuring vital signs in children with fever in the emergency department occurs with a high 
degree of practice variation between different European hospitals and is done more often in 
younger children, those with a higher triage urgency or who have respiratory tract infections. 
The overall adherence to the NICE recommendation to measure four vital signs in all febrile 
children under five is moderate. Our practice variation study is essential as a benchmark for 
current clinical practice. It can guide future research into the drivers and consequences of the 
observed under-recording of vital signs. Moreover, it can be used to tailor implementation 
strategies of the NICE recommendation to different European settings.
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SUMMARY
Background Prevalence of serious bacterial infections in children in countries in western 
Europe and the USA is low. Antibiotic stewardship aims at a more rational use of antibiotics 
but information on the frequency of antibiotic prescription to children in emergency 
departments is scarce. We aimed to quantify and explain variability in antibiotic prescription 
in children attending European paediatric emergency departments.
Methods We did a cross-sectional, observational study of children aged between 1 month 
and 16 years who presented with fever to one of 28 European emergency departments on one 
random sampling day per month between Nov 1, 2014, and Feb 28, 2016. The surveyed sites 
were spread across 11 countries and included 17 academic hospitals with 3000 to up to 80 
000 annual visits to their paediatric emergency departments. We determined the proportion 
of children without comorbidities who received antibiotic prescriptions by country, focus of 
infection, and type of antibiotic. We then did a detailed analysis of the same population, using 
a multilevel logistic regression analysis, into the variability in prescriptions across hospitals, 
focusing particularly on respiratory tract infections and correcting for a combination of result-
dependent factors. Random group assignment was done by computer randomisation.
Findings Of 5177 children in total, 617 children had comorbidities. Of the 4560 children 
without comorbidities, 1454 (32%) received antibiotics. This percentage varied from 19% 
to 64% across countries. Of these 1454 prescriptions issued, 893 (61%) were second-line 
antibiotics. Antibiotic prescription for respiratory tract infections, the most common infection 
type, in children without comorbidities was most variable across countries (15–67% for 
upper respiratory tract infections and 24–87% for lower respiratory tract infections) and 
was associated with age (odds ratio [OR] 1.51, 95% CI 1.08–2.13), fever duration (OR 1.45, 
1.01–2.07), blood concentrations of C-reactive protein (OR 2.31, 1.67–3.19), and chest x-ray 
results (OR 10.62, 5.65–19.94, for focal abnormalities; OR 3.49, 1.59–7.64, for diffuse 
abnormalities). After correcting for patient characteristics, diagnostic assessment, and hospital 
characteristics, antibiotic prescription for respiratory tract infections remained highly variable 
across emergency departments (standardised antibiotic prescription ratio 0.49–2.04).
Interpretation Antibiotic prescription in European emergency departments is highly variable, 
with frequent use of second-line antibiotics. To ensure successful antibiotic stewardship 
initiatives in Europe aimed at reducing unnecessary prescription of antibiotics, variability of 
prescription across hospitals should be considered, drivers of suboptimal antibiotic prescription 
at the local level need to be identified, and European guidelines need to be devised.
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INTRODUCTION
Fever is one of the most frequent reasons for children to visit the emergency department.1 
A small proportion (5–15%) of these children have a serious bacterial infection, of which 
respiratory tract infections cause the highest mortality.2 Variability in the management of 
respiratory tract infections suggests that there is overdiagnosis of bacterial infections and 
overtreatment with antibiotics,3-5 fuelling antibiotic resistance.6 To reduce inappropriate 
antibiotic use, antibiotic stewardship programmes have been launched worldwide7 but few 
of them include the emergency department.8 Studies on antibiotic prescription in febrile 
children often focus on primary care or in-hospital settings.9,10 Information about antibiotic 
prescription in emergency department settings is mostly derived secondarily from studies 
of selected populations, and it is not supported by primary studies.11 To implement effective 
interventions for antibiotic stewardship, having access to data from emergency departments 
on antibiotic prescription and understanding the factors that influence antibiotic prescription 
in this setting is then crucial. This cross-sectional, observational study aims to fill this gap 
by answering the following questions: (1) what is the current proportion of antibiotic 
prescriptions given to febrile children visiting European paediatric emergency departments; 
and (2) can differences in patient characteristics, diagnostic assessment, or hospital setting 
explain the variability in antibiotic prescription?
METHODS
Study design and participants
We did a cross-sectional, observational study at European paediatric emergency departments 
(figure 1). 28 hospitals participating in the Research in European Pediatric Emergency Medicine 
(REPEM) network were invited.12 We included children aged between 1 month and 16 years 
who visited the emergency department with fever as the reason for consultation, irrespective 
of additional symptoms, between Nov 1, 2014, and Feb 28, 2016. We excluded patients if 
they repeatedly visited the emergency department for the same problem within 7 days, if they 
had used antibiotics 7 days before their visit to the emergency department, and if they had 
an antibiotic allergy. This study was approved by the medical ethics committee of the Erasmus 
Medical Center (MEC-2014–419) and local feasibility was approved by the ethics committees 
of all participating hospitals. The need for obtaining written informed consent was waived, 
except by the ethics committee of Cruces Hospital, Bilbao, Spain. These local researchers 
obtained written informed consent from all their participants. The protocol development and 
conduct of the study was done without collaboration with patient groups.
2.3
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Figure 1: Study profile
Procedures
Each month, hospitals were randomly assigned one sampling day. Hospitals were divided 
into ten groups, and each group was randomly assigned to one calendar day each month 
via computer randomisation. All hospitals participated in data collection for 12 consecutive 
months. A sampling day ran from 0730 h to 0730 h (24 h) and there was a period of 
2–6 weeks between sampling days. To avoid inclusion bias, we collected data from all 
children who met our inclusion criteria and visited the emergency department on the random 
sampling days. Data were prospectively collected via an electronic questionnaire (appendix) 
that included general characteristics of the patient, method of referral, triage level, clinical 
signs and symptoms, additional diagnostics (table 1), presumed focus of infection at time of 
discharge from the emergency department, treatment, and disposition. All questionnaire 
items were mandatory but always included the option “not known”. Each hospital had 
one or two physicians dedicated to data collection. 1 week before each sampling day, the 
responsible physician for each hospital was informed of the date, and a reminder email 
with instructions for data collection was sent by the principal investigator on the sampling 
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day. After a sampling day, data integrity was evaluated by the principal investigator and the 
local physicians who collected the data were provided with feedback on completeness and 
potential errors, in order to optimise the data collection process. Information on immunisation 
coverage for 2014–16 was retrieved from the WHO UNICEF Review of National Immunization 
Coverage 1980–2017 database. We used the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) guidelines to report this study.
Outcome measures
Our primary analysis was the proportion of children who received an antibiotic prescription 
on discharge from the emergency department. We grouped the prescribed antibiotics into 
first-line and second-line antibiotics. The first-line antibiotics were amoxicillin, narrow-
spectrum penicillins (benzylpenicillin and flucloxacillin), first-generation cephalosporins, 
and erythromycin. The second-line antibiotics were doxycycline, broad-spectrum penicillins 
(ampicillin, coamoxiclav, and piperacillin plus tazobactam, excluding amoxicillin), second-
generation and third-generation cephalosporins (cefuroxime, cefotaxime, and ceftriaxone), 
sulfonamide plus trimethoprim, macrolides excluding erythromycin, aminoglycosides, 
fluoroquinolones, vancomycin, and metronidazole.13
Statistical analysis
In the descriptive analyses, we compared children with and without comorbidities. 
Relevant comorbidities were defined as cardiovascular, respiratory, renal, haematological 
or immunological, neuromuscular, genetic defects, malignancy, and multiple comorbidities. 
When information about comorbidities was missing, we assumed that no relevant 
comorbidity was present. In addition, we evaluated the proportion of children who were 
prescribed antibiotics by country and by focus of infection in children without comorbidities. 
In these and further analyses, children with comorbidities were excluded because of an 
increased risk for serious infections or a more serious disease course. We used a multilevel 
logistic regression model (clustered by hospital) to calculate the influence of patient-level 
determinants, diagnostic assessment, and specific hospital determinants on antibiotic 
prescription for respiratory tract infections in more detail. For this analysis, we excluded 
children with another focus of infection, children with missing data on the outcome of 
antibiotic prescription, and children from hospitals with missing information on hospital 
determinants. The null model included an intercept only. Model 1 included patient-level risk 
factors for serious bacterial infections, based on clinical prediction rules and guidelines14-16 
from the UK National Institute for Health and Care Excellence: age, sex, fever duration, 
ill appearance, temperature, tachycardia, tachypnoea, oxygen saturation, capillary refill 
time, decreased consciousness, work of breathing, petechiae, meningeal signs, focus of 
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infection, referral method, and the season of the emergency department visit. In model 
2, diagnostic assessment was added to the analysis, which included the performance and 
results of C-reactive protein tests and chest x-rays. We tested the linearity of the associations 
of continuous predictors with the main outcome of antibiotic prescription using splines. 
Potentially meaningful interactions were included in the model if they improved the model 
fit. For the final model, we considered hospital characteristics that have been suggested in 
previous publications to influence antibiotic prescription,17-19 namely: national health-care 
system, hospital type (academic, teaching, or non-teaching), crowding (number of emergency 
department visits on sampling days), specialist responsible in the emergency department, 
first doctor evaluating the child, mode of supervision, availability of guidelines for respiratory 
tract infections, and vaccine coverage. We considered paediatric health-care systems (where 
>75% of children are under the primary care of a paediatrician), general practice systems 
(general practitioners offer primary care to >75% of children), or combined systems.19 
Supervision could be direct (supervising specialist is physically present at the emergency 
department), indirect (supervising specialist is not at the emergency department but can be 
reached by phone and come to the emergency department if needed within 20–30 min), 
or a combination of direct and indirect supervision.20 We selected hospital variables for our 
final model on the basis of the validity of the data, the plausibility of the predictor influencing 
antibiotic prescription, and the added value of the predictor in our model. We calculated 
the standardised antibiotic prescription ratio (between observed and expected number of 
antibiotic prescriptions in a hospital) on the basis of the null model (crude prescription) and 
the final model (adjusted prescription), illustrated by a bar plot. A number of 1 indicates 
the average prescribing hospital based on the model, a number above 1 indicates excess 
prescriptions, and a number below 1 means fewer prescriptions than expected on the basis 
of the model predictions. For regression analysis, missing data were imputed ten times using 
the mice package in R (version 3.3.2). An imputation model was used to draw plausible data 
values from a distribution specifically designed for each missing data point, including all 
available variables, general information, clinical signs and symptoms, diagnostics, treatment, 
and disposition. Analyses were done on all ten datasets and results were pooled.
Role of the funding source
There was no funding source for this study. The corresponding author had full access to all 
the data in the study and had final responsibility for the decision to submit for publication. 
All authors approved the final version of the manuscript submitted for publication.
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RESULTS
A total of 5177 children from 28 emergency departments in 11 countries were included 
in the analysis of baseline characteristics (figure 1, table 1, appendix). Their median age 
was 2.5 years (IQR 1.1–4.9) and 2838 (55%) were male. 256 (5%) children were triaged as 
needing immediate or very urgent care and most children were self-referred. 17 hospitals 
were academic and the other 11 were teaching or non-teaching hospitals. 17 hospitals were 
in city centres and the rest were regional or mixed (serving a region incorporating both 
rural and urban areas) hospitals. The capacities of the hospitals ranged from fewer than 
5000 paediatric annual emergency department visits (six hospitals) to more than 25 000 (12 
hospitals). In most hospitals, a paediatrician-in-training was the first doctor to evaluate febrile 
children, supervised by a fully trained paediatrician or a paediatric emergency physician. 
1757 (34%) children underwent additional diagnostics, most often urinalysis. The most 
common focus of infection was the upper respiratory tract (3105 [60%] children; figure 2), 
and only 19 (<1%) children had sepsis or meningitis. The presumed cause of infection was 
most often reported as viral (3278 [63%] children). Children with comorbidities (617 [12%]) 
were generally older and more ill than those without comorbidities, as evidenced by their 
higher triage levels and higher number of abnormal signs and symptoms. These children were 
subjected to more diagnostic tests and were more frequently admitted for hospital treatment 
or monitoring but received antibiotics just as often as children without comorbidities (1454 
[32%] of 4560 children without comorbidities received prescriptions vs 206 [33%] children 
with comorbidities; table 1).
Table 1: Baseline characteristics of the enrolled population
Without comorbidity (n = 4560) With comorbidity (n = 617)
Proportion of 
patients (n[%])*
Patients with 
missing data 
(n[%])
Proportion of 
patients (n[%])*
Patients with 
missing data 
(n[%])
General characteristics
Male sex† 2451 (54%) 3 (<1%) 387 (63%)
Median age (years)† 2.4 (1.1-4.7) 1 (<1%) 3.2 (1.5-5.9)
Season†
 Spring 1110 (24%) 127 (21%)
 Summer 766 (17%) 86 (14%)
 Autumn 1024 (23%) 160 (26%)
 Winter 1660 (36%) 244 (40%)
Way of referral† 36 (1%) 10 (2%)
 General practitioner 395 (9%) 57 (9%)
 Self 3966 (87%) 509 (83%)
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Table 1:  (continued)
Without comorbidity (n = 4560) With comorbidity (n = 617)
Proportion of 
patients (n[%])*
Patients with 
missing data 
(n[%])
Proportion of 
patients (n[%])*
Patients with 
missing data 
(n[%])
 Other 163 (4%) 41 (7%)
Triage level† 710 (16%) 34 (6%)
 Immediate or very urgent 197 (4%) 59 (10%)
 Urgent 1042 (23%) 246 (40%)
 Standard 1866 (41%) 192 (31%)
 Non-urgent 745 (16%) 86 (14%)
Signs and symptoms
Ill appearance† 431 (10%) 60 (1%) 88 (14%) 14 (2%)
Median duration of fever in days (IQR) 1 (0.5-2.1) 58 (1%) 1 (0.5-2) 13 (2%)
Mean temperature in °C (SD) 38 (1) 125 (3%) 38.1 (1) 18 (3%)
Mean oxygen saturation in %† (SD) 98 (2.5) 1993 (44%) 97 (3.4) 165 (27%)
Tachycardia† 1138 (25%) 1219 (27%) 185 (30%) 147 (24%)
Tachypnoea† 665 (15%) 2227 (49%) 128 (21%) 301 (49%)
Increased work of breathing† 352 (7%) 40 (1%) 128 (21%) 7 (1%)
Prolonged capillary refill time 67 (2%) 650 (14%) 11 (2%) 100 (16%)
Decreased level of consciousness† 23 (1%) 17 (<1%) 13 (2%) 4 (1%)
Petechiae present† 41 (1%) 62 (1%) 11 (2%) 9 (1%)
Meningeal signs present 10 (<1%) 84 (2%) 3 (<1%) 8 (1%)
Additional diagnostics
Median concentration of blood 
C-reactive protein in mg/L (IQR) 16.2 (5.4-51.8) 3820 (84%) 25.3 (5.4-51.8) 457 (74%)
Leukocyte count x109/L 11.8 (7.8-16.3) 3855 (85%) 12 (1-16.7) 469 (76%)
Median concentration of procalcitonin 
in ng/mL (IQR) 0.21 (0.10-0.78) 4422 (97%) 0.26 (0.14-0.20) 582 (94%)
Blood culture† 224 (5%) 56 (9%)
Urinalysis† 841 (18%) 140 (23%)
X-ray done† 431 (10%) 131 (21%)
Lumbar puncture done 34 (1%) 7 (1%)
Treatment
Antibiotic prescription 1454 (32%) 61 (1%) 206 (33%) 7 (1%)
Disposition† 6 (<1%) 1 (<1%)
 Discharged 4035 (88%) 471 (76%)
 Observation unit <24 h 187 (4%) 48 (8%)
 Admitted to ward 321 (7%) 90 (15%)
 Admitted to intensive care unit 11 (<1%) 6 (1%)
Comorbidities are cardiovascular, respiratory, renal, haematological or immunological, neuromuscular, genetic defects, 
malignancy, or multiple comorbidities. *Unless stated otherwise. †Significantly different between children with and 
without comorbidities (p<0.05).
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Figure 2. Frequency of probable focus (A) and cause (B) of infection in all 5177 children studied.
For full data, see appendix.
893 (61%) of the prescriptions issued to children without comorbidities were second-line 
antibiotics (table 2, appendix). The overall proportion of antibiotic prescriptions ranged 
from 19% to 64% across countries. Overall, countries with high antibiotic prescriptions also 
prescribed second-line antibiotics more often. We then analysed the proportion of children 
without comorbidities who received a prescription by focus of infection (figure 3). The five 
most common foci of infection were identified in 4247 (93%) of these children. 22 (4%) 
of 531 children with enteric infections received antibiotics, with low variability between 
countries. Children with urinary tract infections were prescribed antibiotics most frequently 
(116 [93%] of 125). Children with respiratory tract infections, comprising 73% (n=3307) of the 
evaluated patients without comorbidities, accounted for 83% (1208 of 1454) of all antibiotic 
prescriptions. The mean proportion of prescriptions for lower respiratory tract infections 
was higher than that for upper respiratory tract infections (227 [47%] of 486 vs 981 [35%] 
of 2821 children respectively), with high variability in prescription between countries for 
both. Antibiotics were prescribed for 37% of respiratory tract infections in children without 
comorbidities (n=1208). Variation in prescriptions for upper respiratory tract infections was 
15–67% across hospitals, and 24–87% for lower respiratory tract infections.
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Table 2. Antibiotic prescriptions per country in children without comorbidities
Proportion of children 
prescribed antibiotics
Proportion of prescription 
for second-line antibiotics Children with missing data
Total population 1454/4560 (32%) 893/1454 (61%) 61/4560 (1%)
Per country
 Turkey 450/708 (64%) 363/450 (81%) 46/708 (6%)
 UK 57/145 (39%) 45/57 (79%) 1/145 (1%)
 Hungary 41/111 (37%) 29/41 (71%) 4/111 (4%)
 Italy 149/446 (33%) 120/149 (81%) 6/446 (1%)
 Romania 87/282 (31%) 81/87 (93%) 2/282 (1%)
 Spain 161/631 (26%) 68/161 (42%)
 Portugal 177/698 (25%) 56/177 (32%) 2/698 (<1%)
 Denmark 6/24 (25%) 2/6 (33%)
 Netherlands 37/161 (23%) 18/37 (49%)
 France 208/926 (22%) 70/208 (34%)
 Switzerland 81/428 (19%) 41/81 (51%)
Countries are ordered from high to low percentage of antibiotic prescriptions. Second-line antibiotics are represented 
as percentage out of the total number of antibiotic prescriptions per country.
Figure 3: Variability in antibiotic prescription across countries for the most frequent foci of infection in 4560 children 
without comorbidities.
For full data, see appendix.
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We based our multilevel analysis on children with respiratory tract infections from the 26 of 
28 hospitals (n=3180) for which information on hospital determinants was available. Figure 
4A presents the crude number of antibiotic prescriptions (standardised prescription) based on 
the null model. An increased standardised prescription ratio indicates that more antibiotics 
are prescribed than expected and a decreased standardised prescription ratio indicates that 
fewer antibiotics are prescribed than expected, based on the average prescribing hospital. In 
the intermediate models (appendix), we added patient characteristics, diagnostic assessment, 
and hospital characteristics, leading to the final model (table 3). Older age and longer 
duration of fever were associated with an increased likelihood of antibiotic prescription. 
Other significant predictors were high blood concentrations of C-reactive protein and 
focal or diffuse abnormalities in the chest x-ray. At hospital level, we were limited to two 
variables: hospital type and national health-care system. Even though these factors did 
not significantly influence antibiotic prescription individually, they yielded the best model 
fit. All factors included in the analysis could only explain part of the variability in antibiotic 
prescription between hospitals. After adjustment for all factors in the model, the rank of 
hospitals according to proportion of prescriptions issued changed and the variability in 
prescription by hospital was slightly decreased (figure 4B). However, substantial variability 
in prescription remained, ranging from half to twice the number of prescriptions as the 
average prescribing hospital in our dataset. Even though specific determinants of antibiotic 
prescription could be identified in the whole population of patients, differences in patient 
mix, diagnostic assessment, or hospital characteristics could not explain all variability in 
antibiotic prescription.
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Figure 4: Standardised antibiotic prescription for respiratory tract infections per hospital
(A) Null model (crude standardised antibiotic prescription). (B) Final model (adjusted standardised antibiotic prescription 
for patient characteristics, diagnostic assessment, and hospital characteristics). Hospital determinants for Hôpital 
Antoine Béclère (Paris, France) and Hospital de Mendaro (Mendaro, Spain) were not available, so they were not 
included in this analysis. 1 Erasmus Medical Center Sophia Children’s Hospital. 2 Hôpital Robert Debré. 3 Maasstad 
Ziekenhuis. 4 Sint Franciscus Ziekenhuis. 5 Hôpital Necker–Enfants Malades.
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Table 3. Final multilevel model for antibiotic prescription in children with respiratory tract infections
Final model Odds Ratio (95% CI)
Intercept 0.66 (0.16-2.84)
Patient characteristics
Age (years)* 1.51 (1.08-2.13)*
Age (years)* ‡ 0.65 (0.35-1.21)
Female sex 0.88 (0.73-1.07)
Season (spring=reference)
 Summer 0.81 (0.59-1.11)
 Autumn 1.13 (0.84-1.53)
 Winter 0.87 (0.65-1.15)
Way of referral (general practice= reference)
 Self-referral 1.25 (0.82-1.92)
 Other 0.76 (0.39-1.46)
Triage level (very urgent=reference)
 Urgent 0.9 (0.5-1.63)
 Standard 0.69 (0.38-1.24)
 Non-urgent 0.65 (0.34-1.25)
Ill appearance 0.97 (0.66-1.44)
Duration of fever (days)* 1.45 (1.01-2.07)*
Duration of fever (days)* ‡ 0.6 (0.27-1.33)
Temperature (°C)* 1.43 (0.99-2.08)
Temperature (°C)* ‡ 0.69 (0.24-1.94)
Temperature (°C)* § 1.27 (0.02-83.24)
Oxygen saturation (%)* 0.96 (0.86-1.07)
Tachycardia 1.09 (0.85-1.39)
Tachypnoea 0.9 (0.69-1.18)
Increased work of breathing 0.69 (0.43-1.09)
Prolonged capillary refill (>3s) 1.26 (0.58-2.73)
Decreased level of consciousness 0.3 (0.07-1.34)
Petechiae 1.96 (0.72-5.33)
Meningeal signs 1.75 (0.06-54.57)
Focus (lower RTI vs upper RTI) 1.19 (0.8-1.76)
Diagnostic assessment
C-reactive protein tested 1.04 (0.71-1.54)
C-reactive protein concentration (mg/l)* 2.31 (1.67-3.19)*
X-ray result (not done =reference)
 Normal 0.68 (0.42-1.11)
 Focal abnormalities 10.62 (5.65-19.94)*
 Diffuse abnormalities 3.49 (1.59-7.64)*
Hospital
Hospital type (teaching vs academic) 1 (0.49-2.04)
Health-care system (paediatric system=reference)
 Combined system 1.28 (0.46-3.6)
 General practice system 1.21 (0.4-3.64)
Tachycardia and tachypnoea were defined according to the Advanced Paediatric Life Support guidelines.21 
RTI=respiratory tract infection. *Standardised value. †Significant predictor. ‡Second coefficient (non-linear term: 
spline with 3 or 4 degrees of freedom). §Third coefficient (non-linear term: spline with 3 or 4 degrees of freedom).
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DISCUSSION
Our study provides insights into the prescription of antibiotics to febrile children on the basis 
of a prospective registry across a wide range of European emergency departments. Our 
results indicate that antibiotic prescription varies substantially between countries and 
hospitals and that second-line antibiotics are frequently used. We also identified that 
respiratory tract infections are the most common type of infection with highest variability 
in antibiotic prescription between paediatric emergency departments. The variability of 
antibiotic prescription for respiratory tract infections cannot be fully explained by differences 
in patient characteristics, diagnostic assessment, and measured hospital characteristics. The 
main strength of our study is that it provides a prospective European registry of antibiotic 
prescription collected in a standardised way in 11 countries, enabling comparisons across a 
large part of Europe. Hospitals were invited through the REPEM network, which ensured 
broad European participation and high-quality data. The selected hospitals have an interest 
in research collaboration and might therefore be more homogeneous in the type of care 
they provide or have a higher standard of care than hospitals that were not included. The 
number of included hospitals per country does not match the country’s population size.22 
Even though we included very diverse hospitals in terms of type and size, the true antibiotic 
prescription in European emergency departments might be even higher and more variable 
than we observed. The size of the hospital largely matches the number of included patients 
per hospital, suggesting no major selection bias. Hospitals Erasmus Medical Center, 
Netherlands, and Cukurova, Turkey, sampled on more days immediately before or after the 
assigned sampling days. Since these extra days were still random, we assume this did not 
introduce selection bias in our study. A registry study might be susceptible to the Hawthorne 
effect but local physicians were only aware of the general scope of this study (registry of 
febrile children) and not particularly about the monitoring of antibiotic prescription. There 
are some limitations to this approach. First, four of 11 countries participated with only a 
single hospital, so we were not able to take clustering at country level into account. Second, 
some hospitals had small sample sizes (five hospitals included <50 patients), thereby limiting 
the power to show large differences between hospitals. Nevertheless, our results still showed 
substantial variability, so this limitation did not hamper our conclusions. Third, we did not 
include the risk of serious bacterial infection per country in our model because it is already 
related to clinical signs and symptoms that we did include. Finally, the large proportion of 
unexplained variability might indicate that there are other contributing factors that we did 
not include in our model. The statistical limitation of the number of hospital factors that we 
could include might be one cause of the large remaining unexplained variance. As we have 
corrected extensively for many known possibly influential factors, we still believe our analysis 
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lead to valid conclusions. Overall antibiotic prescription variation in our study is consistent 
with previous reports (27% and 55%),17,23 in particular for upper respiratory tract infections.24 
Antibiotic prescription for respiratory tract infections and for lower respiratory tract infections 
is generally reported to be higher than we observed.25 Studies on fever without a source 
usually focus on children below 3 months of age, whereas the minimum age of our population 
was 1 month, explaining why our observed antibiotic prescription was lower than in other 
studies.16 Large variability in antibiotic prescription between European countries has been 
reported previously but did not focus on paediatric emergency care.26 The fact that 
prescription variability was highest for children with respiratory tract infections in our study 
could have several reasons. First, respiratory tract infections might include multiple diagnoses, 
such as acute otitis media, bronchiolitis, or pneumonia, for which there are different specific 
guidelines and different likelihoods of bacterial or viral origin.14,27 We had no information 
available on these specific diagnoses but since we collected data in each hospital throughout 
a full year, we believe all of these types of respiratory tract infections were represented in 
our data for all countries. The criteria for diagnoses could have varied between hospitals, 
hence a standardised diagnostic protocol for presumed focus of infection and confirmed 
diagnosis (where possible) might assist in future studies. Second, and probably most 
important, is the lack of a gold standard for the diagnosis of bacterial respiratory tract 
infections. When a decision on treatment is made, there is often diagnostic uncertainty and 
bacterial causes can often not be excluded, influencing diagnostic assessment and the 
likelihood of antibiotic prescription.5 Although we found some specific drivers of antibiotic 
prescription, they could only explain a small proportion of the observed variability between 
hospitals. Similar results were obtained by a large US observational study, showing broad 
unexplained variability in antibiotic prescription for respiratory tract infections across primary 
paediatric practices.3 The influence of patient characteristics (age and duration of fever) and 
diagnostic tests on antibiotic prescription we found was generally consistent with previously 
reported predictors of bacterial infections.15,16 The effect of different infection foci (lower vs 
upper respiratory tract infection) was strongly correlated with the effect of the chest x-ray 
result. A notable finding was our observation that focal as well as diffuse abnormalities in 
the chest x-ray strongly increased the chance of antibiotic prescription, even though their 
low diagnostic value has been well described.28 We did not include procalcitonin in our 
analyses, since this test was only done in isolated cases in less than half of the participating 
hospitals, reflecting the infrequent use of the biomarker test in routine practice during the 
study period. We were particularly interested to ascertain whether hospital characteristics 
affected antibiotic prescription and if they could explain variability. We were able to include 
two specific hospital factors in our model that define differences across local practices in 
the evaluation of febrile children: hospital type and national health-care system. These factors 
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added most to our model in terms of reducing variance and were assumed to be meaningful. 
By including health-care system and method of referral in our model, we aimed to cover 
aspects of the primary care system but we did not have detailed data on primary care in 
each country because this analysis was beyond the scope of our study. Other potential factors 
were excluded from the model. Emergency department crowding had a negligible effect on 
antibiotic prescription and our data were not very consistent for this parameter.29 All hospitals 
had guidelines for the diagnosis and treatment of respiratory tract infections but we lacked 
information on the contents or implementation of these guidelines. There was low variability 
in immunisation coverage, so we assumed that this factor could not explain any substantial 
variance in antibiotic prescription. Coverage of vaccination against Haemophilus influenzae 
type B was more than 90% in all participating countries without variation, according to the 
WHO UNICEF Review of National Immunization Coverage 1980–2017 database. 
Pneumococcal conjugate vaccine coverage was above 75% in all countries with available 
data, a threshold that has been described as sufficient to uphold herd immunity.30 Only 
Romania did not carry out pneumococcal conjugate vaccination at the time of data collection. 
Children were included throughout the entire 24 h of the sampling day—ie, also in evening 
and night shifts, both on weekdays and weekends. Choosing sampling days at random aimed 
to reduce systematic effects introduced by shift schedules, such as variable capacity of 
supervision. Our findings that antibiotic prescription for respiratory tract infections is 
dependent on the hospital and that second-line antibiotics are widely used are crucial for all 
clinicians, researchers, and policy makers who plan interventions to reduce unnecessary 
prescription of antibiotics, particularly second-line drugs. Our study was not designed to 
evaluate the validity of the decision to prescribe an antibiotic; however, the finding of large 
unexplained variability across hospitals does suggest overprescription. Given that most 
antibiotics are prescribed to children with respiratory tract infections but this occurs with 
high variability, strategies aiming to reduce antibiotic prescription could be most beneficial 
in this patient group. Particularly, overuse of second-line antibiotics should be addressed as 
a priority in such strategies. Successful national examples25 should be extrapolated to a wider 
setting by international implementation studies and by developing European guidelines. The 
expected effect of an intervention can nevertheless vary per setting, since not all factors that 
affect antibiotic prescription have yet been explained and baseline prescription varies 
between emergency departments. This variation not only affects sample size calculations 
for different settings but also emphasises the need for multicentre studies on the outcomes 
of strategies aiming to reduce the inappropriate use of antibiotics. To ensure successful 
antibiotic stewardship initiatives at the European level, factors associated with suboptimal 
antibiotic prescription in individual hospitals and nationally need to be identified.
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Antibiotic prescription
Antibiotic prescription N = 4560 n (%) missing, n (%)
Overall antibiotic prescription 1454 (31.9) 61 (1.3)
Details of antibiotic prescription N = 1454
Broad spectrum antibiotics 893 (61.4) 36 (2.5)
Class of antibiotics 36 (2.5)
-- Penicillines 1089 (74.9)
-- Other betalactam antibiotics 171 (11.8)
-- Macrolides 100 (6.9)
-- Other antibiotics 14 (1)
-- Combination of classes 44 (3)
Route of administration 23 (1.6)
-- oral 1193 (82)
-- intravenous 120 (8.3)
-- intramuscular 118 (8.1)
Frequency of probable focus and cause of infection (data for figure 2)
Probable focus of infection
Upper respiratory 3105 (60%)
Lower respiratory 647 (13%)
Enteric 578 (11%)
Fever without source 337 (7%)
Urinary tract 156 (3%)
Cutaneous 127 (3%)
Other 41 (0.8%)
Viral childhood illness 28 (0.5%)
Sepsis/meningitis 19 (0.4%)
Bone/joint 14 (0.3%)
Inflammatory disease 8 (0.2%)
Missing 117 (2%)
Total 5177
Probable cause of infection
Probable viral 2724 (53%)
Probable bacterial 1346 (26%)
Definite viral 554 (11%)
Uncertain 284 (5%)
Definite bacterial 237 (5%)
Other 16 (0.3%)
Missing 16 (0.3%)
Total 5177
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Variability in antibiotic prescription across countries for the 5 most common 
foci of infection in children without comorbidities (data for figure 3)
Population 
n Upper RTI Lower RTI Enteric
Fever without 
source Urinary tract
Focus n 2821 486 531 284 125
Turkey 708 393/584 (67%) 27/31 (87%) 1/45 (2%) 1/5 (20%) 25/25 (100%)
United Kingdom 145 31/93 (33%) 6/10 (60%) 0/7 (0%) 0/4 (0%) 4/4 (100%)
Hungary 111 23/70 (33%) 10/15 (67%) 1/14 (7%) 0/2 (0%) 6/6 (100%)
Italy 446 91/259 (35%) 36/48 (75%) 7/70 (10%) 1/35 (3%) 9/13 (69%)
Romania 282 68/182 (37%) 11/32 (34%) 2/51 (4%) 0/3 (0%) 6/8 (75%)
Spain 631 97/387 (25%) 31/58 (53%) 4/55 (7%) 7/79 (9%) 16/16 (100%)
Portugal 698 103/435 (24%) 37/98 (38%) 1/67 (1%) 1/16 (6%) 17/18 (94%)
Denmark 24 2/9 (22%) 3/6 (50%) 0 0/5 (0%) 1/1 (100%)
France 926 126/487 (26%) 41/109 (38%) 2/144 (1%) 5/95 (5%) 17/19 (89%)
The Netherlands 161 10/68 (15%) 12/24 (50%) 2/35 (6%) 1/11 (9%) 4/4 (100%)
Switzerland 428 37/247 (15%) 13/55 (24%) 2/43 (5%) 1/29 (3%) 11/11 (100%)
Total 4560 981/2821 (35%) 227/486 (47%) 22/531 (4%) 17/284 (6%) 116/125 (93%)
Total n top 5 foci of infection 4247/4560 (93%)
Total n RTIs 3307/4560 (73%)
Total proportion antibiotics prescribed 1454/4560 (32%)
Antibiotics prescribed for RTIs out of all antibiotics 1208/1454 (83%)
2.3
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ABSTRACT
Objectives
Pneumonia is the most common bacterial infection in children at the emergency department 
(ED). Clinical prediction models for childhood pneumonia have been developed (using chest 
x-ray as their reference standard), but without implementation in clinical practice. Given 
current insights in the diagnostic limitations of chest x-ray, this study aims to validate these 
prediction models for a clinical diagnosis of pneumonia, and to explore their potential to 
guide decisions on antibiotic treatment at the ED.
Methods
We systematically identified clinical prediction models for childhood pneumonia and assessed 
their quality. We evaluated the validity of these models in two populations, using a clinical 
reference standard (1. definite/probable bacterial, 2. bacterial syndrome, 3. unknown 
bacterial/viral, 4. viral syndrome, 5. definite/probable viral), measuring performance by the 
ordinal c-statistic (ORC). Validation populations included prospectively collected data of 
children aged 1 month to 5 years attending the ED of Rotterdam (2012-2013) or Coventry 
(2005-2006) with fever and cough or dyspnoea.
Results
We identified eight prediction models and could evaluate the validity of seven, with original 
good performance. In the Dutch population 22/248 (9%) had a bacterial infection, in 
Coventry 53/301 (17%), antibiotic prescription was 21% and 35% respectively. Three models 
predicted a higher risk in children with bacterial infections than in those with viral disease 
(ORC ≥0.55) and could identify children at low risk of bacterial infection.
Conclusions
Three clinical prediction models for childhood pneumonia could discriminate fairly well 
between a clinical reference standard of bacterial versus viral infection. However, they all 
require the measurement of biomarkers, raising questions on the exact target population 
when implementing these models in clinical practice. Moreover, choosing optimal thresholds 
to guide antibiotic prescription is challenging and requires careful consideration of potential 
harms and benefits.
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INTRODUCTION
Community-acquired pneumonia is the second largest cause of childhood mortality 
worldwide.1 Despite improvements over the past decades, lower respiratory tract infections 
are still responsible for 103.3 deaths per 100,000 people in children under five years globally, 
with large differences across regions.2 Respiratory tract infections are also a common 
reason for emergency department (ED) visit and the most frequent indication for antibiotic 
prescription in children.1,3 Discriminating bacterial infections that require antibiotic treatment 
from viral, self-limiting disease is one of the biggest diagnostic challenges in childhood 
pneumonia. Chest x-ray is no longer recommended as the gold standard for bacterial 
pneumonia,4 and routinely available biomarkers are not pathognomonic for this diagnosis.5 At 
the same time, accurate diagnosis of bacterial infection is crucial, since misuse of antibiotics 
is associated with increased antimicrobial resistance, which in turn also causes morbidity and 
mortality.6 Current antibiotic prescription for suspected pneumonia in Western countries 
ranges from 23-59% with wide acknowledgement that a considerable proportion of these 
antibiotics are not necessary.3,7
In order to standardize the evaluation and treatment of children suspected of pneumonia, 
clinical decision support systems could be useful tools to classify children into a high or 
low risk profile.8 Multiple clinical prediction models for childhood pneumonia have been 
developed. Even though their current use in clinical practice is limited, they may play a role 
as treatment decision support, thereby improving rational antibiotic prescription. However, 
since those models are mainly developed with chest x-ray as their reference standard, it is 
unclear if they can also validly predict a clinically based diagnosis of pneumonia. Moreover, 
the question is whether these models can be translated into clinical practice by guiding 
decisions on antibiotic treatment.
This study aims to systematically search available clinical prediction models for childhood 
pneumonia in ED settings in high-income countries, to evaluate their validity using a new, 
clinical diagnosis reference standard, and to explore their potential to guide decisions on 
antibiotic treatment.
3.1
BNW_Josephine_v1.indd   87 19-Sep-20   14:51:12
88
Chapter 3.1
METHODS
Selection and quality assessment of prediction models
A systematic search for prediction models of childhood pneumonia was performed in 
Embase, Medline Ovid, Web of science, PubMed and Google scholar in September 2017. 
We included studies on diagnosis and treatment of uncomplicated childhood pneumonia 
in ED settings in Western countries published since 2000 (see search strategy and exclusion 
criteria, S1 Text). JvdM and BK performed the selection independently, discrepancies were 
discussed within the research group and decided using consensus.
We evaluated the clinical prediction models for their quality and diagnostic value. Quality 
assessment was performed by JvdM and checked by RO, using the QUADAS-2 tool for 
diagnostic studies.9 We assessed their level of validation using the guideline proposed by the 
Evidence-Based Working Group10 with one added category as described by Reilly,11 ranging 
from level 1 ‘derivation of the model without validation’ to level 5 ‘proven by broad impact 
analysis’.
Validation study
Validation populations
We retrospectively evaluated the validity of the identified prediction models in two study 
populations.12,13 Population 1 included 248 children aged 1 month to 5 years presenting at the 
ED in 2012-2013 with fever and cough or dyspnoea, from a prospective study at the Erasmus 
MC - Sophia, Rotterdam, the Netherlands.12 Population 2 included 301 children aged 3 
months to 5 years presenting with fever and respiratory symptoms at a paediatric assessment 
unit at the University Hospitals Coventry and Warwickshire NHS Trust, United Kingdom (UK), 
in 2005-2006.13 In both databases children with comorbidity related to increased risk of 
bacterial infection or complications were excluded, such as severe neurological impairment, 
immunodeficiency and severe pulmonary or cardiac defects. Follow-up was available for 
both populations, reducing the risk of missing (untreated) serious infections. The studies 
in these populations were approved by the Medical Ethics Committee of the Erasmus MC 
(Rotterdam) and the Coventry Local Research Ethics Committee. Written informed consent 
was obtained for both populations.12,13
Reference standard
As chest x-ray is no longer recommended as a gold standard in clinical practice, the diagnosis 
of bacterial pneumonia is mostly a clinically based diagnosis. A model that may reflect 
this clinical approach, is an algorithm published by Herberg et.al., classifying the potential 
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aetiology of febrile illness in children.14 For this study, we used a reference standard adapted 
to this model, classifying patients’ cause of respiratory tract infection from bacterial to viral 
(see S1 Figure). First, we pre-specified what working diagnosis would be classified as ‘bacterial 
syndrome’, ‘viral syndrome’ or ‘unknown bacterial/viral’, the first step of the algorithm. 
Then we categorized all patients based on their working diagnosis as documented in the 
different databases. We used the working diagnosis that was attributed by the attending 
clinician at the end of the ED visit, based on patient assessment and routine diagnostic 
tests. As a second step, we used identification of bacteria or viruses and CRP-level (>60 
mg/l or ≤60mg/l) to further differentiate the clinical diagnosis. Diagnostic tests from routine 
care included viral PCR of nasopharyngeal swab and blood cultures, as performed at the 
discretion of the clinician. Given a low number of pathogens identified we had few definite 
diagnoses, so we classified patients into to five categories: definite or probable bacterial 
(1), bacterial syndrome (2), unknown bacterial or viral (3), viral syndrome (4) and definite 
or probable viral (5). For example, a child presenting with bronchiolitis (viral syndrome at 
first step), no virus or bacteria identified and a CRP-level of >60mg/l would be classified as 
having a viral syndrome. A child with a working diagnosis of pneumonia (unknown viral/
bacterial at first step), the CRP-level would lead to either bacterial syndrome (in case of high 
CRP), viral syndrome (in case of low CRP) or remain unknown bacterial/viral (in case of no 
CRP performed). Patients with a bacterial and viral co-infection were classified as bacterial 
infection, given the consequences for treatment.
Statistical analysis
Missing data and outliers
Missing values were imputed 10 times using the mice package in R (version 3.3.2), resulting 
in 10 separate datasets with complete (imputed) information. The imputation model included 
information about clinical signs and symptoms, referral, diagnostic tests and treatment. We 
performed all analyses of the validation on the 10 imputed datasets and then averaged the 
results.15 When a variable of a prediction model was completely missing in our database, 
multiple imputation was not possible and we used a proxy (e.g. ‘retractions’ as a proxy 
variable for ‘dyspnoea’, if ‘dyspnoea’ was not available). For continuous variables, the 
prevalence of that variable in the original derivation population of the prediction model 
was used (mean imputation).16 CRP-level was truncated at the level of 225 mg/L, following 
the study of Nijman.17
Evaluation of validity of prediction models
We evaluated the validity of those prediction models of which more than 50% of the 
predictors were available in our database, assuming this as a minimum for credible 
3.1
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predictions.16 We calculated the risk of bacterial pneumonia using each of the included 
prediction models for all children in our study populations, illustrated by histograms and 
boxplots. To measure performance, we calculated the ordinal c-statistic (ORC) – a measure 
similar to the area under the receiver-operating-curve (AUC), but for ordinal instead of 
dichotomous outcomes. This statistic can be interpreted as the probability that two cases 
of randomly selected outcome categories are correctly ranked.18 We defined models with 
an ORC of at least 0.55 as performing well and explored their potential to guide antibiotic 
prescription. For this purpose, we evaluated the harms and benefits of withholding antibiotics 
in low-risk patients, compared to the observed usual care in which treatment decisions were 
based on clinical judgment and routine diagnostic tests. Benefit was defined as the potential 
reduction of antibiotic prescription and harm as the potential risk of under treatment. Under 
treatment was defined as children that were classified as having a bacterial infection and 
who had been treated with antibiotics, but whom the prediction model classified as low-risk. 
We explored different thresholds for the prediction models to define low-risk and evaluated 
their effect on harms and benefits. All analyses were performed using SPSS (IBM version 
24.0) and R (version 3.3.2).
RESULTS
Identification, quality and original performance of prediction models
We identified 4324 unique articles (after removal of duplicates). Based on title and abstract 
4176 articles were excluded as not relevant (see S2 Figure). After full-text selection and 
searching references, 11 articles were eligible for inclusion (see Table 1). Eight were primary 
derivation studies, describing different prediction models,17,19-25 three were validation or 
impact studies of three of these models12,26,27 and one derivation study also included the 
validation of another model.25 Even though VandenBruel’s model was derived mainly in 
general practice setting, it was also validated in an ED setting, and therefore included in our 
study. Most studies included children up to the age of 16, but the majority of the included 
patients in all studies were under five. Most studies had radiographic pneumonia as their 
reference standard, except for VandenBruel’s study that used hospitalization for radiographic 
pneumonia as its reference standard (Table 1). All prediction models aimed to improve 
clinical decision-making in the child suspected of bacterial pneumonia. Three studies mainly 
focused on decisions on diagnostic tests;19,21,23 the other studies also mentioned the potential 
of the models to improve management decisions on antibiotic treatment, admission or 
referral.17,20,22,24,25
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In general the quality of the prediction models was moderate (see Table 1 and S3 Figure) with 
3 models having some risk of bias19,21,24 and one study with concerns about the applicability.20 
Nijman’s model was evaluated most thoroughly including impact analysis.17 The models by 
VandenBruel, Lynch and Oostenbrink were broadly validated in previous studies;19,20,24 those 
by Mahabee-Gittens, Neuman, Craig and Irwin were only derived or validated in one setting 
by the original authors.21-23,25
Three prediction models provided a risk classification (high versus low risk), based on the 
presence of specific symptoms.20,21,23 Of these models, sensitivity at model development 
was moderate to good, with varying specificity (see Table 1). Only VandenBruel’s model was 
validated in different settings, performing poorly due to high sensitivity and low specificity 
in three settings, the opposite in another setting, and in a last setting both poor sensitivity 
and specificity.26 The other four prediction models provided a probability (predicted risk in %) 
of pneumonia, based on a multiple logistic regression model.17,19,24,25 These models showed 
moderate to good performance at development (AUC ranging from 0.67 to 0.84) as well 
as in the validation studies.22,24,26 3.1
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Validation study
Table 2 shows the baseline characteristics of the two populations. Using the clinical diagnosis, 
bacterial infection rate ranged from 9-17% and 38-41% were classified as ‘unknown’. Of 
this latter category 74-87% recovered without antibiotics. We included seven prediction 
models in our validation study. We did not assess validity of Craig’s model as only 14/28 
variables were present in both databases. Lynch – having only 2/4 variables available – was 
not validated in the Coventry database. The supplementary S1 Table gives an overview of 
all variables and proxies of the validated prediction models. Mahabee-Gittens published a 
regression model providing a probability, but the coefficients to calculate this probability 
were not available from the author 23. We therefore used the presence of one or more of 
the included variables classifying patients at high risk of bacterial pneumonia. VandenBruel 
published a general prediction model for febrile children, and one for pneumonia; for this 
review we only used the pneumonia model 20. Neuman used a decision tree to classify 
patients into 3 categories (high/intermediate/low risk of pneumonia) 21. In this model ‘history 
of fever’ discriminated intermediate from low risk, but since fever was an inclusion criteria 
of all our validation populations, only high and low risk patients were identified, based on 
the first step of the decision tree (oxygen saturation <92%).
Table 2. Baseline characteristics of validation populations.
Rotterdam, n=248 Coventry, n=301
Predictor variables median (IQR) or n(%) median (IQR) or n(%)
Age (months) 14 (7-27) 19 (12-31)
Gender (male) 148/248 (60%) 174/301 (58%)
Temperature (C°) 38.2 (37.4-39.1) 38.2 (37.5-39.1)
Duration of fever (days) 3 (2-4) not available
Tachypnea 81/183 (44%) 154/258 (60%)
Tachycardia 66/207 (32%) 191/294 (65%)
Oxygen saturation (%) 98 (97-100) 97 (95-98)
Ill appearance 35/149 (23%) 1/301 (0%)
Dyspnoea 106/248 (43%) 81/301 (27%)
Decreased breath sounds 12/136 (9%) not available
Crackles 30/127 (24%) not available
Focal rales 67/151 (44%) not available
Retractions 68/107 (64%) not available
Nasal flaring 29/58 (50%) not available
Prolonged capillary refill (>2sec) 10/53 (19%) 58/187 (31%)
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Table 2.  (continued)
Rotterdam, n=248 Coventry, n=301
Diagnostics and treatment
CRP measured 94/248 (38%) 109/301 (36%)
CRP (mg/L) 16 (7-42) 45 (19-122)
X-ray performed 42/248 (17%) 67/301 (22%)
Antibiotics prescribed 51/248 (21%) 105/301 (35%)
Clinical diagnosis (S1 Figure)
Definite or probable bacterial 18/248 (7%) 37/301 (12%)
Bacterial syndrome 4/248 (2%) 16/301 (5%)
Unknown 94/248 (38%) 122/301 (41%)
Viral syndrome 59/248 (24%) 72/301 (24%)
Definite or probable viral 73/248 (29%) 54/301 (18%)
IQR = interquartile range
Performance of prediction models
The performance of the three models with a risk classification (high/low risk) is shown 
in Figure 1a. The white bars indicate the number of children with predicted low risk of 
pneumonia and the grey bars the number of patients with predicted high risk, across the 
five reference standard categories (bacterial to viral infection). For example, when we used 
Mahabee-Gittens’ model to predict the risk of having a bacterial pneumonia in our two 
validation populations, we observed that this model predicts most children as having a 
high risk of pneumonia (grey bars), including most children with viral infections. Using 
VandenBruel’s model, we observed low as well as high predicted risks across all 5 diagnosis 
categories. Almost all children were assigned to a low risk group using Neuman’s model, 
including children with bacterial infections.
Figure 1b shows the performance of the prediction models providing a probability. Again, 
predictions are shown across the five diagnosis categories for each model and for both 
populations, illustrated by a boxplot. Lynch’s model predicted high risk of pneumonia (around 
90%) for all children, with little variation across the different outcome categories (see S4 
Figure), and did not contribute to discrimination between bacterial or viral disease. The 
models by Oostenbrink, Nijman and Irwin assigned higher risks to children with bacterial 
infections than to the children with viral infections, confirmed by a moderate ordinal c-statistic 
of ≥0.55 (see Figure 1b).
3.1
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Figure 1. Performance of prediction models.
Footnote:
DPB = definite or probable bacterial, BS = bacterial syndrome, U = unknown, VS = viral syndrome, DPV = definite or 
probable viral; ORC = ordinal c-statistic; SD = standard deviation;
To assess the clinical relevance of these findings, we explored the potential of the last three 
models to define low-risk patients possibly not needing antibiotic treatment. For example, 
applying a risk threshold of 10% using Nijman’s model would classify 130 children (52%) in 
the Rotterdam population as being at low risk of bacterial pneumonia (see Table 3, details in 
S2 Table). Of these children 16 were currently treated with antibiotics. If this threshold would 
be used in clinical practice, and antibiotics would be withheld in all low-risk children, the 
overall antibiotic prescription rate would reduce from 21% (observed antibiotic prescription) 
to 14% (expected antibiotic prescription) in the Rotterdam population and from 35% to 16% 
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in the Coventry population (Table 3). The potential risk of under treatment (e.g. withholding 
antibiotics in children with a bacterial infection who were currently treated with antibiotics) 
would be 2% (Rotterdam) and 5% (Coventry). Similar benefits and harms were observed 
when applying the models of Oostenbrink and Irwin. A threshold of 15% would lead to 
greater reduction in antibiotic prescription, but at a higher risk of under treatment.
Table 3. Clinical consequences of using prediction models to guide antibiotic prescription
Rotterdam, 
n=248
Coventry, 
n=301
Observed antibiotic prescription, n (%) 51 (21%) 105 (35%)
Predictions by Nijman’s model
Threshold 10% Rotterdam Coventry
Number of children below threshold (low-risk group) 130 (52%) 193 (64%)
Expected antibiotic prescription when guided by threshold (benefit) 35 (14%) 49 (16%)
Expected under treatment when prescription was guided by threshold (harm)a 5 (2%) 15 (5%)
Threshold 15%
Number of children below threshold 167 (67%) 229 (76%)
Expected antibiotic prescription when guided by threshold 28 (11%) 36 (12%)
Expected under treatment when prescription was guided by threshold 8 (3%) 22 (7%)
Predictions by Oostenbrink’s model
Threshold 10% Rotterdam Coventry
Number of children below threshold 69 (28%) 94 (31%)
Expected antibiotic prescription when guided by threshold 44 (18%) 77 (26%)
Expected under treatment when prescription was guided by threshold 0 (0%) 8 (3%)
Threshold 15%
Number of children below threshold 110 (44%) 178 (59%)
Expected antibiotic prescription when guided by threshold 35 (14%) 51 (17%)
Expected under treatment when prescription was guided by threshold 2 (1%) 13 (4%)
Predictions by Irwin’s model
Threshold 10% Rotterdam Coventry
Number of children below threshold 100 (40%) 155 (51%)
Expected antibiotic prescription when guided by threshold 38 (15%) 64 (21%)
Expected under treatment when prescription was guided by threshold 5 (2%) 15 (5%)
Threshold 15%
Number of children below threshold 120 (48%) 198 (66%)
Expected antibiotic prescription when guided by threshold 33 (13%) 48 (16%)
Expected under treatment when prescription was guided by threshold 8 (3%) 22 (7%)
a Number of children with a bacterial infection who were treated with antibiotics, but who were classified as low-risk 
according to the used prediction model and threshold
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DISCUSSION
We identified eight clinical prediction models for childhood pneumonia by literature review. 
Following changing perspectives on a relevant reference standard for childhood pneumonia, 
we could assess the validity of seven of them for a clinical diagnosis of bacterial, unknown 
bacterial/viral or viral infection. Three models – with good original performance and quality 
– assigned a higher risk to children with bacterial infection than to those with viral infection, 
with the potential of proper selection of children who may recover without antibiotics.
An important strength of our study is the broad validation of multiple prediction models in 
prospective cohorts including over 500 patients in two different European acute care settings. 
Our populations were rather heterogeneous in terms of their clinical characteristics, increasing 
the generalizability of our findings. A limitation is the heterogeneity of the information 
available, and missing values in general, which is related to the use of already existing datasets. 
We have accounted for this by multiple imputation or by using proxies where possible. 
Another limitation is the retrospective classification of the clinical diagnosis, based on the 
working diagnosis by the treating physician not blinded for clinical features and diagnostic 
tests. Because none of these clinical features or tests alone determined classification into 
a final diagnosis category, we believe this potential bias is limited. Diagnostic tests were 
performed at the discretion of the treating clinician, and included chest x-rays mainly. For 
22 patients a definite viral or bacterial test was recorded to be positive, however, we had 
no data on the total performed viral/bacterial tests. Previous studies in these settings have 
shown that these are performed in about 10% of febrile children.12,13 Validity assessment of 
the model by Mahabee-Gittens was limited by the absence of the original coefficients. Of 
Irwin’s model only 3 out of 5 predictor variables were present, for the other two variables 
we used mean imputation. This may have underestimated the model’s discriminative value; 
but given the small effect sizes of the missing variables, we consider this effect limited.16
We should appreciate several differences between our study populations and the populations 
the models were originally derived on. Since our populations included febrile children at the 
ED, it is not surprising that we observed less variability in the predicted probabilities in the 
validation of Neuman and Lynch’ models, since fever was one of their predictor variables. 
Furthermore, differences in pneumonia prevalence in the derivation populations (6-36%) of 
the models may explain systematic differences in predicted probabilities in 4 models.17,19,24,25,28 
In general, correcting for this involves recalibration (calibration-in-the-large) of the model to a 
new target population.28 However, this type of recalibration does not influence discrimination 
(the ordinal c-statistic), and thus not our conclusions. It may, however, explain the variable 
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impact the suggested thresholds have using the different models. Next, the type of reference 
standard (radiographic pneumonia vs. clinical diagnosis) differed between derivation and 
validation studies, as was the purpose of our study. Given the diagnostic limitations of chest 
X-rays, we chose to define our reference standard following Herberg’s classification.14 It 
must be noted that this choice was not proposed as a new gold standard, but rather used 
as a model that may reflect our best current practice. In our aim to translate prediction 
models into clinical practice, we observed that the performance varied by type of model. 
We observed that the models using the probability scale had better diagnostic performance 
(reflected by a higher ORC statistic) than those using a risk classification (high/low risk). 
This can partly be explained by the ability to adjust risk thresholds – with a direct link to the 
harm-benefit ratio – more easily in models using the probability scale. Models using a risk 
classification have a fixed threshold and lack this flexibility and may therefore show lower 
diagnostic performance when validated according to a new reference standard.
In order to improve rational use of antibiotics in children with respiratory infections, there is a 
need to improve discrimination between bacterial and viral, self-limiting disease. We showed 
that three of seven tested clinical prediction models could identify a low-risk group of children 
with self-limiting disease in an ED population fairly well and we believe those three have the 
potential to improve treatment decisions. Those models include a combination of signs of 
general illness and/or respiratory distress and biomarkers. The availability of biomarkers will 
influence the feasibility of implementation of these models in clinical practice. The models of 
Oostenbrink and Nijman include CRP measurement, Irwin’s model includes CRP, procalcitonin 
and resistin. Given the wide availability of point-of-care CRP tests the first two models will 
be most feasible for routine use in the ED.
Another important challenge to be faced before prediction models can be implemented 
as decision tools in clinical practice is to choose optimal decision thresholds, adapted to 
the appropriate target population. A balance is needed between the benefit of reducing 
unnecessary antibiotic prescription and the harm of potential under treatment of bacterial 
infections. The prior risk of severe illness in a population is an important consideration. For 
example, in settings with high prevalence of comorbidity, the course of pneumonia will 
generally be more severe and missing a serious infection will have worse consequences than 
in a low-risk population. Next, the natural course of the disease should be taken into account. 
Last, access to (good quality) healthcare is important. In a setting with limited possibility for 
patient follow-up, potential risks of under treatment will higher. Given the natural course of 
pneumonia (developing over days instead of hours), a watchful waiting approach instead of 
immediate antibiotic treatment in children with uncomplicated pneumonia with a predicted 
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risk <10-15% might be justified in settings with good access to care, in the presence of a 
proper safety-netting strategy for unexpected disease course. In low resource settings or 
high-risk populations lower thresholds may be reasonable. Before implementing treatment 
interventions based on these prediction models in clinical practice, a prospective study is 
needed to evaluate the overall impact of treating children according to such a prediction 
model, compared to usual care. Such a study should assess the feasibility and safety of the 
suggested thresholds for that specific setting.
Three out of seven clinical prediction models for pneumonia could discriminate fairly well 
between a new reference standard of bacterial and viral infection in children presenting at 
the ED. However, they all require the measurement of biomarkers, raising questions on the 
exact target population when implementing these models in clinical practice. Moreover, 
choosing optimal decision to guide antibiotic prescription is challenging and requires careful 
consideration of potential harms and benefits. Future research should focus on the feasibility 
and safety of treatment based on chosen decision thresholds for specific settings.
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Supporting information
S1 Text. Search strategy and in/exclusion criteria for systematic review
Original search strategy, April 2016
Database Number of articles Number of articles after deleting duplicates
Embase.com 2676 2646
Medline Ovid 1466 310
Web of science 1462 610
PubMed publisher 52 31
Google scholar 223 158
Total 5879 3755
Embase.com 2676
(‘pneumonia’/exp OR (pneumoni* OR Bronchopneumoni* OR Pleuropneumoni*):ab,ti OR ((‘respiratory tract infection’/
de OR ‘lower respiratory tract infection’/de OR ‘viral respiratory tract infection’/de OR (((respirator* NEAR/6 infection*) 
NOT (upper NOT lower))):ab,ti) AND (‘antibiotic agent’/exp OR (antibiotic*):ab,ti))) AND (‘practice guideline’/exp OR 
‘decision making’/exp OR ‘decision support system’/exp OR ‘decision tree’/exp OR ((guideline* OR ((decision OR 
prediction*) NEAR/3 (making OR support* OR tree* OR model* OR model* OR algorithm* OR triage* OR protocol* 
OR principle* OR aid OR aids))):ab,ti OR ((guideline* OR decision* OR model OR tree OR prediction* OR model* OR 
algorithm* OR triage* OR protocol* OR principle*) NEAR/6 (develop* OR propose* OR new OR novel OR validat* 
OR Evaluat* OR implement* OR modif*)):ab,ti)) AND (child/exp OR ‘pediatrics’/de OR (preschool* OR child* OR 
schoolchild* OR infan* OR toddler* OR pediatric* OR paediatric*):ab,ti) AND [english]/lim NOT ([Conference Abstract]/
lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim)
Medline Ovid 1466
(exp “pneumonia”/ OR (pneumoni* OR Bronchopneumoni* OR Pleuropneumoni*).ab,ti. OR ((“Respiratory Tract 
Infections”/ OR (((respirator* ADJ6 infection*) NOT (upper NOT lower))).ab,ti.) AND (“antibiotic agent”/ OR (antibiotic*).
ab,ti.))) AND (exp “guideline”/ OR exp “Decision Making”/ OR “Decision Support Systems, Clinical”/ OR “Decision 
Support Techniques”/ OR “Decision Trees”/ OR ((guideline* OR ((decision OR prediction*) ADJ3 (making OR support* 
OR tree* OR model* OR model* OR algorithm* OR triage* OR protocol* OR principle* OR aid OR aids))).ab,ti. OR 
((guideline* OR decision* OR model OR tree OR prediction* OR model* OR algorithm* OR triage* OR protocol* OR 
principle*) ADJ6 (develop* OR propose* OR new OR novel OR validat* OR Evaluat* OR implement* OR modif*)).
ab,ti.)) AND (exp child/ OR infant/ OR “pediatrics”/ OR (preschool* OR child* OR schoolchild* OR infan* OR toddler* 
OR pediatric* OR paediatric*).ab,ti.) AND english.la. NOT (letter OR news OR comment OR editorial OR congresses 
OR abstracts).pt.
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Web of science 1462
TS=(((pneumoni* OR Bronchopneumoni* OR Pleuropneumoni*) OR (((((respirator* NEAR/5 infection*) NOT (upper 
NOT lower)))) AND ((antibiotic*)))) AND (((guideline* OR ((decision OR prediction*) NEAR/2 (making OR support* OR 
tree* OR model* OR model* OR algorithm* OR triage* OR protocol* OR principle* OR aid OR aids))) OR ((guideline* 
OR decision* OR model OR tree OR prediction* OR model* OR algorithm* OR triage* OR protocol* OR principle*) 
NEAR/5 (develop* OR propose* OR new OR novel OR validat* OR Evaluat* OR implement* OR modif*)))) AND 
((preschool* OR child* OR schoolchild* OR infan* OR toddler* OR pediatric* OR paediatric*)) ) AND LA=(english) 
AND DT=(article)
PubMed publisher 52
(“pneumonia”[mh] OR (pneumoni*[tiab] OR Bronchopneumoni*[tiab] OR Pleuropneumoni*[tiab]) OR ((“Respiratory 
Tract Infections”[mh] OR (((respirator*[tiab] AND infection*[tiab]) NOT (upper[tiab] NOT lower[tiab])))) AND 
(“antibiotic agent”[mh] OR (antibiotic*[tiab])))) AND (“guideline”[mh] OR “Decision Making”[mh] OR “Decision 
Support Systems, Clinical”[mh] OR “Decision Support Techniques”[mh] OR “Decision Trees”[mh] OR ((guideline*[tiab] 
OR ((decision[tiab] OR prediction*[tiab]) AND (making OR support*[tiab] OR tree*[tiab] OR model*[tiab] OR 
model*[tiab] OR algorithm*[tiab] OR triage*[tiab] OR protocol*[tiab] OR principle*[tiab] OR aid[tiab] OR aids[tiab]))) 
OR ((guideline*[tiab] OR decision*[tiab] OR model[tiab] OR tree[tiab] OR prediction*[tiab] OR model*[tiab] OR 
algorithm*[tiab] OR triage*[tiab] OR protocol*[tiab] OR principle*[tiab]) AND (develop*[tiab] OR propose*[tiab] OR new 
OR novel OR validat*[tiab] OR Evaluat*[tiab] OR implement*[tiab] OR modif*[tiab])))) AND (child[mh] OR infant[mh] 
OR “pediatrics”[mh] OR (preschool*[tiab] OR child*[tiab] OR schoolchild*[tiab] OR infan*[tiab] OR toddler*[tiab] OR 
pediatric*[tiab] OR paediatric*[tiab])) AND english[la] NOT (letter[pt] OR news[pt] OR comment[pt] OR editorial[pt] 
OR congresses[pt] OR abstracts[pt]) AND publisher[sb]
Google scholar First 200
Pneumonia guideline|”decision|prediction making|support|tree|model|model|aid|aids” 
child|children|schoolchild|infants|pediatric|paediatric antibiotic|antibiotics|”anti biotic”
allintitle:Pneumonia guideline|”decision|prediction making|support|tree|model|model|aid|aids” 
child|children|schoolchild|infants|pediatric|paediatric
Update literature search, September 2017
Database Number of articles Number of articles after deleting duplicates
Embase.com 3092 3041
Medline Ovid 1763 369
Web of science 1730 726
Google scholar 200 150
Total 6785 4286
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In- and exclusion criteria for systematic review
Characteristic Inclusion Exclusion
Design Studies assessing diagnostic accuracy or deriving 
or validating prediction models
Reviews, conference abstracts, letters, 
notes, editorials, news, comments
Participants Children aged 1month to 5 years are substantial 
part (>50%) of the population.
Out of age range, children with severe 
comorbidity
Setting Developed countries (based on the United Nations 
classification)
Emergency department
Developing countries
Primary care, in-hospital setting
Intervention Multifactor clinical prediction rule including 
clinical features (and biomarkers).
Rules without clinical features, or 
including tests not available at ED
Outcome (bacterial) pneumonia
treatment advice for pneumonia
Other diagnosis
S1. Figure. Classification of febrile illness.
Based on Herberg et al.14
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S2. Figure. Flowchart of the selection process.
S3. Figure. QUADAS-2 quality assessment.
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S4. Figure. Performance Model Lynch.
S1. Table. Missings and proxies of predictor variables.
Rotterdam, n=248 Coventry, n=301
Predictor variables Missing, n (%) Proxy Missing, n (%) Proxy
Age, months none none
Gender none none
Temperature (°C) 12 (5) 4 (1.3)
Duration of fever (days) 189 (76) 301 (100) Derivation population
Respiratory rate 65 (26) 43 (14)
Heart rate 41 (17) 7 (2)
Oxygen saturation (%) 76 (30) 15 (5)
Ill appearance 99 (40) none Toxic appearance
Dyspnea none
Decreased breath sounds 112 (45) 301 (100) NA
Crackles 121 (49) 301 (100) NA
Focal rales 97 (39) 301 (100) NA
Retractions 143 (57) 301 (100) NA
Nasal flaring 190 (77) 301 (100) Dyspnea
Prolonged capillary refill 
(>2sec)
53 (21) 114 (38)
CRP, mg/L 154 (62) 192 (64)
Normal air entry Absence of dyspnea Absence of dyspnea
Resistin, ng/mL 248 (100) Derivation population 301 (100) Derivation population
PCT, ug/L 248 (100) Derivation population 301 (100) Derivation population
NA = not assessed, no close proxy available
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S2. Table. Detailed classification of risk groups based on different prediction models.
Nijman Rotterdam
Antibiotic prescription Clinical diagnosis Total
DPB BS U VS DPV
No Predicted risk 0 - 10 % 0 2 40 28 44 114
10 - 15% 0 0 15 11 4 30
>15 % 0 0 27 19 7 53
Total 0 2 82 58 55 197
Yes Predicted risk 0 - 10 % 3 2 3 0 8 16
10 - 15% 3 0 2 0 2 7
>15 % 12 0 7 1 8 28
Total 18 2 12 1 18 51
Threshold 10% n %
Total number of children below threshold 130 52%
Number of treated children below threshold 16 6%
Number of treated children with bacterial infection below threshold 5 2%
Antibiotic prescription when guided by threshold 10% 35 14%
Threshold 15%
Total number of children below threshold 167 67%
Number of treated children below threshold 23 9%
Number of treated children with bacterial infection below threshold 8 3%
Antibiotic prescription when guided by threshold 15% 28 11%
Nijman Coventry
Antibiotic prescription Clinical diagnosis Total
DPB BS U VS DPV
No Predicted risk 0 - 10 % 4 4 67 41 21 137
10 - 15% 1 0 15 6 1 23
>15 % 3 0 20 11 2 36
Total 8 4 102 58 24 196
Yes Predicted risk 0 - 10 % 6 9 12 10 19 56
10 - 15% 5 2 1 2 3 13
>15 % 19 1 5 3 8 36
Total 30 12 18 15 30 105
Threshold 10%
Total number of children below threshold 193 64%
Number of treated children below threshold 56 19%
Number of treated children with bacterial infection below threshold 15 5%
Antibiotic prescription when guided by threshold 10% 49 16%
Threshold 15%
Total number of children below threshold 229 76%
Number of treated children below threshold 69 23%
Number of treated children with bacterial infection below threshold 22 7%
Antibiotic prescription when guided by threshold 15% 36 12%
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Oostenbrink Rotterdam
Antibiotic prescription Clinical diagnosis Total
DPB BS U VS DPV
No Predicted risk 0 - 10 % 0 2 17 16 27 62
10 - 15% 0 0 6 12 14 32
>15 % 0 0 59 30 14 103
Total 0 2 82 58 55 197
Yes Predicted risk 0 - 10 % 0 0 1 0 6 7
10 - 15% 2 0 1 0 6 9
>15 % 16 2 10 1 6 35
Total 18 2 12 1 18 51
Threshold 10%
Total number of children below threshold 69 28%
Number of treated children below threshold 7 3%
Number of treated children with bacterial infection below threshold 0 0%
Antibiotic prescription when guided by threshold 10% 44 18%
Threshold 15%
Total number of children below threshold 110 44%
Number of treated children below threshold 16 6%
Number of treated children with bacterial infection below threshold 2 1%
Antibiotic prescription when guided by threshold 15% 35 14%
Oostenbrink Coventry
Antibiotic prescription Clinical diagnosis Total
DPB BS U VS DPV
No Predicted risk 0 - 10 % 1 2 33 22 8 66
10 - 15% 1 2 24 19 12 58
>15 % 5 0 46 17 4 72
Total 7 4 103 58 24 196
Yes Predicted risk 0 - 10 % 3 5 6 4 10 28
10 - 15% 1 4 5 2 14 26
>15 % 26 3 8 8 6 51
Total 30 12 19 14 30 105
Threshold 10%
Total number of children below threshold 94 31%
Number of treated children below threshold 28 9%
Number of treated children with bacterial infection below threshold 8 3%
Antibiotic prescription when guided by threshold 10% 77 26%
Threshold 15%
Total number of children below threshold 178 59%
Number of treated children below threshold 54 18%
Number of treated children with bacterial infection below threshold 13 4%
Antibiotic prescription when guided by threshold 15% 51 17%
Irwin Rotterdam
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Antibiotic prescription Clinical diagnosis Total
DPB BS U VS DPV
No Predicted risk 0 - 10 % 0 1 29 19 38 87
10 - 15% 0 0 11 4 0 15
>15 % 0 1 42 35 17 95
Total 2 82 58 56 197
Yes Predicted risk 0 - 10 % 4 1 5 1 2 13
10 - 15% 3 0 2 0 0 5
>15 % 11 1 5 0 16 33
Total 18 2 12 1 18 51
Threshold 10% %
Total number of children below threshold 100 40%
Number of treated children below threshold 13 5%
Number of treated children with bacterial infection below threshold 5 2%
Antibiotic prescription when guided by threshold 10% 38 15%
Threshold 15%
Total number of children below threshold 120 48%
Number of treated children below threshold 18 7%
Number of treated children with bacterial infection below threshold 8 3%
Antibiotic prescription when guided by threshold 15% 33 13%
Irwin Coventry
Antibiotic prescription Clinical diagnosis Total
DPB BS U VS DPV
No Predicted risk 0 - 10 % 3 3 58 32 18 114
10 - 15% 2 0 19 5 1 27
>15 % 2 1 26 21 5 55
Total 7 4 103 58 24 196
Yes Predicted risk 0 - 10 % 7 8 10 3 13 41
10 - 15% 6 1 3 5 1 16
>15 % 17 3 6 6 16 48
Total 30 12 19 14 30 105
Threshold 10%
Total number of children below threshold 155 51%
Number of treated children below threshold 41 14%
Number of treated children with bacterial infection below threshold 15 5%
Antibiotic prescription when guided by threshold 10% 64 21%
Threshold 15%
Total number of children below threshold 198 66%
Number of treated children below threshold 57 19%
Number of treated children with bacterial infection below threshold 22 7%
Antibiotic prescription when guided by threshold 15% 48 16%
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ABSTRACT
Background
Optimising the use of antibiotics is a key component of antibiotic stewardship. Respiratory 
tract infections (RTIs) are the most common reason for antibiotic prescription in children, 
even though most of these infections in children under 5 years are viral. This study aims to 
safely reduce antibiotic prescriptions in children under 5 years with suspected lower RTI at 
the emergency department (ED), by implementing a clinical decision rule.
Methods and findings
In a stepped-wedge cluster randomised trial, we included children aged 1–60 months 
presenting with fever and cough or dyspnoea to 8 EDs in The Netherlands. The EDs were 
of varying sizes, from diverse geographic and demographic regions, and of different 
hospital types (tertiary versus general). In the pre-intervention phase, children received 
usual care, according to the Dutch and NICE guidelines for febrile children. During the 
intervention phase, a validated clinical prediction model (Feverkidstool) including clinical 
characteristics and C-reactive protein (CRP) was implemented as a decision rule guiding 
antibiotic prescription. The intervention was that antibiotics were withheld in children with 
a low or intermediate predicted risk of bacterial pneumonia (≤10%, based on Feverkidstool). 
Co-primary outcomes were antibiotic prescription rate and strategy failure. Strategy failure 
was defined as secondary antibiotic prescriptions or hospitalisations, persistence of fever 
or oxygen dependency up to day 7, or complications. Hospitals were randomly allocated 
to 1 sequence of treatment each, using computer randomisation. The trial could not be 
blinded. We used multilevel logistic regression to estimate the effect of the intervention, 
clustered by hospital and adjusted for time period, age, sex, season, ill appearance, and fever 
duration; predicted risk was included in exploratory analysis. We included 999 children (61% 
male, median age 17 months [IQR 9 to 30]) between 1 January 2016 and 30 September 
2018: 597 during the pre-intervention phase and 402 during the intervention phase. Most 
children (77%) were referred by a general practitioner, and half of children were hospitalised. 
Intention-to-treat analyses showed that overall antibiotic prescription was not reduced (30% 
to 25%, adjusted odds ratio [aOR] 1.07 [95% CI 0.57 to 2.01, p = 0.75]); strategy failure 
reduced from 23% to 16% (aOR 0.53 [95% CI 0.32 to 0.88, p = 0.01]). Exploratory analyses 
showed that the intervention influenced risk groups differently (p < 0.01), resulting in a 
reduction in antibiotic prescriptions in low/intermediate-risk children (17% to 6%; aOR 0.31 
[95% CI 0.12 to 0.81, p = 0.02]) and a non-significant increase in the high-risk group (47% 
to 59%; aOR 2.28 [95% CI 0.84 to 6.17, p = 0.09]). Two complications occurred during the 
trial: 1 admission to the intensive care unit during follow-up and 1 pleural empyema at day 
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10 (both unrelated to the study intervention). Main limitations of the study were missing 
CRP values in the pre-intervention phase and a prolonged baseline period due to logistical 
issues, potentially affecting the power of our study.
Conclusions
In this multicentre ED study, we observed that a clinical decision rule for childhood 
pneumonia did not reduce overall antibiotic prescription, but that it was non-inferior to usual 
care. Exploratory analyses showed fewer strategy failures and that fewer antibiotics were 
prescribed in low/intermediate-risk children, suggesting improved targeting of antibiotics 
by the decision rule.
Trial registration
Netherlands Trial Register NTR5326
3.2
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INTRODUCTION
Respiratory tract infections (RTIs) are the most common diagnosis in febrile children, and the 
most common reason for antibiotic prescription in children.1 In children under 5 years, most 
lower RTIs are viral.2 Although mortality caused by lower RTIs has decreased significantly 
over the past decades (currently 1.7 per 100,000 people in Western Europe),3 antimicrobial 
resistance due to unnecessary antibiotic prescription is increasing.4 High variability in antibiotic 
prescription in children with RTIs in primary as well as hospital care throughout Europe 
highlights the need for better targeting of antibiotic prescriptions in this patient group.1,5,6
One of the main challenges when attempting to safely reduce antibiotic prescriptions for lower 
RTIs in children is the absence of a gold standard for the diagnosis of bacterial pneumonia. 
Routine chest X-rays are no longer recommended for the differentiation between bacterial 
and viral causes, and treatment decisions are mostly based on clinical findings.7,8 Ongoing 
research into new biomarkers has not yet provided a new gold standard for clinical practice in 
the emergency department (ED).9-11 In the absence of a gold standard for diagnosing bacterial 
pneumonia, we need to improve the clinical detection rate of those children who may 
benefit most from antibiotic treatment of bacterial pneumonia. Clinical prediction models 
combining clinical characteristics and biomarkers may improve the identification of children 
who will benefit from antibiotic treatment for community-acquired pneumonia, but they 
are not used as decision rules in clinical practice.12,13 The Feverkidstool is a clinical prediction 
model combining clinical characteristics and C-reactive protein (CRP) to predict the risk of 
bacterial pneumonia and other serious bacterial infections in children. The model was derived 
in the ED setting in The Netherlands, and its diagnostic accuracy has been proven in external 
validation studies in The Netherlands and the United Kingdom.13,14
In this study we evaluated the impact of the Feverkidstool on clinical practice, as a last step 
in the development of a prediction model.15 We translated the Feverkidstool into a decision 
rule with pre-specified decision thresholds to guide antibiotic treatment for lower RTIs. The 
primary objective of this study was to safely reduce antibiotic prescription in children under 
5 years with suspected lower RTI at the ED, by withholding antibiotics in children at low or 
intermediate risk of bacterial pneumonia, as predicted by the Feverkidstool.
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METHODS
Study design
We performed a stepped-wedge cluster randomised trial with sequential implementation 
of a treatment strategy for antibiotic prescription based on a clinical decision rule (hereafter 
called ‘decision rule’) in febrile children with suspected lower RTI in the ED. Randomisation 
at cluster level was chosen to avoid contamination of the intervention effect to control 
patients. The stepped-wedge design was preferred as, in general, smaller sample sizes are 
needed than in conventional cluster randomised trials. Because clusters act as their own 
controls, the intervention effect can be estimated from both between and within cluster 
comparisons. The sequential implementation of the intervention was deemed superior to a 
conventional before–after design, given the incorporation of time effects.16 We performed 
the trial in 8 clusters (hospitals) between 1 January 2016 and 30 September 2018 in The 
Netherlands. By design, the trial consisted of 2 phases: a pre-intervention phase, when 
usual care was provided, and an intervention phase, wherein care was provided according 
to our intervention (diagram of trial design in Fig 1). A cluster consisted of 1 hospital that 
was randomised to 1 sequence of treatment. Each hospital was randomised to 1 sequence 
of treatment, resulting in 8 sequences. The period when all hospitals still performed usual 
care (the baseline period) was followed by a rollout period, during which the hospitals 
switched sequentially to the intervention (antibiotic prescription guided by the decision rule). 
At intervals of 4 weeks, hospitals were randomised to start the intervention between 28 
August 2017 and 12 March 2018. This timing was chosen to take the seasonality of RTIs into 
account, as most eligible patients were expected during autumn and winter. Given the short 
duration of illness, the patients included in the different time periods were different people. 
The original and the final study protocol are available as S1 Text and S2 Text. The trial was 
approved by the ethics committee of Erasmus MC (MEC-2014-332) and by the participating 
hospitals. Written informed consent was obtained from the parents of all participants by 
the treating physician, in both phases of the trial. In the pre-intervention phase, this consent 
concerned the use of clinical data and performance of follow-up; in the intervention phase, 
it also concerned the use of the Feverkidstool to guide treatment decisions. Consent was 
obtained before calculating the predicted risk of the child. The trial was registered in the 
Netherlands Trial Register (NTR) (NTR5326). As reported in the NTR, 1 cluster was added 
during the pre-intervention period, to ensure sufficient inclusions. Interim analysis after 
the first year of data collection (but before implementation of the intervention) showed 
substantially higher antibiotic prescription rates than anticipated. Based on the distribution 
of risks and actual antibiotic prescription rates during the pre-intervention period, the target 
sample size was adjusted from 1,100 to 900 children, which is also reported in the NTR. No 
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other important methodological changes were made after the start of the trial. The study 
was reported according to the CONSORT guideline for clinical trials and the extension for 
stepped-wedge cluster randomised trials (S1 Table).
Fig 1. Design of the trial.
ED, emergency department.
Participants
We included children aged 1–60 months that presented with fever (reported by parents or 
measured as >38.5° C at the ED) and cough or dyspnoea as symptoms of potential lower 
RTI at the EDs of 8 hospitals in The Netherlands. This target population included children 
with all different risk profiles, since at presentation in the ED their risk profile was unknown. 
We excluded children at increased risk of a complicated course: children with relevant 
comorbidities, antibiotic use in the week prior to ED visit, amoxicillin allergies, another 
identifiable infectious focus (cutaneous, otitis media, tonsillitis), or signs of complicated 
pneumonia at presentation (oxygen saturation < 85%, respiratory insufficiency, empyema, 
sepsis). Relevant comorbidities were immunodeficiency, congenital heart defect, chronic 
pulmonary disease, multiple handicaps, and prematurity (born before the gestational age of 
32 weeks and aged <1 year at time of presentation). Individual participants were included 
in the clusters by continuous recruitment by the treating physician in the ED. We included 
8 hospitals in 6 cities of the southwest and central area of The Netherlands (a) where 
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paediatricians were responsible for the children presenting at the ED, (b) with varying ED 
sizes (range 500–13,000 annual paediatric ED admissions), (c) from diverse geographic and 
demographic regions (inner-city and mixed rural/urban), and (d) of different hospital types 
(tertiary and general). Hospitals were separated geographically, with no exchange of staff. 
The hospitals were recruited by the principal investigator (RO).
Randomisation and blinding
Randomisation of sequences of treatment was performed in July 2017 (after recruitment of 
all 8 clusters) by a statistician using computer randomisation. The statistician was involved 
as an advisor in the trial and was based at Erasmus MC. He knew the names of the other 
participating centres at randomisation, but had no further knowledge of these hospitals 
or relation to the local researchers. Since 2 hospitals started in August 2017 with the pre-
intervention phase due to logistical reasons, these hospitals were randomised to start the 
intervention after time period 3 (Fig 1). This was accounted for in the original randomisation 
prior to the rollout period. The trial could not be blinded, because the intervention was the 
implementation and use of a decision rule by clinicians in the ED, including treatment advice 
based on the risk score that had to be calculated for each child.
Intervention
During the pre-intervention phase, all children received usual care. Usual care consisted of 
triage by a nurse, including the routine measurement of vital signs, followed by a clinical 
assessment and initiation of therapy by a physician, according to the Dutch and NICE 
guidelines for febrile children.17,18 Additional diagnostics were performed at the discretion 
of the treating physician. CRP testing was often done as part of usual care, but without 
specific thresholds for decision-making. Other blood tests or chest X-rays were not routinely 
performed in children with suspected lower RTI, in line with the Dutch guideline, which 
is based on the British Thoracic Society guideline for the management of children with 
community-acquired pneumonia.8 During usual care, antibiotics were prescribed at the 
discretion of the treating physician. Amoxicillin was usually prescribed as first-line treatment 
for community-acquired pneumonia.8
During the intervention phase, a validated clinical prediction model (Feverkidstool) was 
implemented as a decision rule guiding antibiotic prescription at the cluster level.12,13 We 
predefined decision thresholds that would guide antibiotic treatment decisions, balancing 
positive and negative likelihood ratios and the consequences of over- and undertreatment.12,19 
The intervention was a decision-rule-based treatment strategy for all children with suspected 
lower RTI in the ED, with a differential effect on risk groups. In children with a low (≤3%) or 
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intermediate (4%–10%) predicted risk of bacterial pneumonia, antibiotics were withheld. 
In children with a high predicted risk (>10%), usual care was provided, i.e., antibiotics were 
prescribed at the discretion of the physician. The Feverkidstool included the following 
predictors: age in years, sex, duration of fever in days, ill appearance (yes/no), chest wall 
retractions (yes/no), capillary refill time in seconds, hypoxia (oxygen saturation < 94%), 
tachypnoea (based on Advanced Paediatric Life Support guideline), tachycardia (idem), 
temperature in degrees Celsius, and CRP in mg/l. Ill appearance was based on the judgment 
of the treating clinician. Although ill appearance was not defined by specific criteria, in the 
development and validation of the Feverkidstool this characteristic appeared to be valid 
and consistent among different populations.12 More details about the development of the 
Feverkidstool have been published previously.12 The tool was available to all treating physicians 
as an online digital calculator. The individual predicted risk was calculated after the physician’s 
clinical assessment of the child and CRP testing, but before the treatment decision was made. 
During both phases of the study, a structured follow-up via telephone was performed 7 
days after the ED visit. During the intervention phase, children with an intermediate or high 
predicted risk received an extra follow-up call 2 days after the ED visit to timely identify 
potential deterioration of the patient. When children were still hospitalised at those time 
points, the follow-up information was collected directly from the parents and the patient’s 
electronic health record.
Outcomes
Primary outcomes were antibiotic prescription at ED discharge (yes/no) and strategy 
failure within 7 days after the initial ED visit (yes/no). Since the decision rule should not 
impact patient outcomes negatively (complying with our aim ‘to safely reduce antibiotic 
prescriptions’), we viewed antibiotic prescription and strategy failure as equally important 
co-primary outcomes. Strategy failure was a composite outcome, based on the follow-up 
on day 7 and defined as secondary hospitalisation (i.e., hospitalisation during follow-up, 
after the initial discharge), secondary or switched antibiotic prescription (during follow-
up), oxygen dependency or fever up to day 7, or the development of complications. Since 
there is no single and objective measure of failure of antibiotic treatment strategy, we used 
this predefined composite outcome for strategy failure. This outcome was chosen to cover 
different aspects of strategy failure that are important in clinical practice and may be related 
to the initial treatment strategy at the ED.20 It includes changes in the treatment strategy 
for the child (secondary or switched antibiotic treatment and secondary hospitalisation) as 
well as signs of prolonged or complicated disease (oxygen dependency or fever up to day 
7 and complications). Changes in treatment strategy during follow-up were made without 
specific recommendations in the study protocol. Reasons for switching antibiotic prescription 
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were not systematically recorded. Switching of antibiotics due to adverse drug reaction was 
considered a strategy failure. We used a short follow-up period of 1 week, assuming that 
a secondary hospitalisation within this time frame was related to the respiratory illness. All 
secondary prescriptions and secondary hospitalisations were considered a strategy failure. 
Secondary outcomes were the level of compliance to the intervention and the number of 
complications. Compliance was defined as the number of children in whom the Feverkidstool 
was calculated and who were treated according to the decision rule out of the total number 
of children included during the intervention phase. Complications were defined as the 
presence of pleural empyema, parapneumonic effusion (any size), pulmonary abscess, or 
respiratory insufficiency (need for mechanical ventilation) by day 7. No changes were made 
to the outcomes after the trial commenced.
Statistical methods
Sample size
We calculated the needed sample size for the 2 co-primary outcomes based on methods 
by Hussey and Hughes, without accounting for multiple testing.16 We based our sample 
size calculation on the complete target population of children with suspected lower RTI 
in the ED, including all risk groups. Based on previous studies,14 we assumed that 50% 
of the population would be at low risk, 30% at intermediate risk, and 20% at high risk, 
with antibiotic prescription rates of 35% (in the low-risk group), 40% (intermediate-risk 
group), and 85% (high-risk group). The decision rule was expected to affect risk groups 
differently: we estimated no difference in antibiotic prescription in the high-risk patients, 
and a reduction of 10–15 percentage points in the low-risk and intermediate-risk patients, 
leading to an overall reduction of antibiotic prescriptions of 10 percentage points. The 
intracluster correlation coefficient (ICC) was unknown, but we assumed a power of 90% 
at independency (i.e., no correlation between clusters, ICC of 0) would result in a power of 
80% or more in multilevel analysis. We assumed different cluster sizes (small, intermediate, 
and large clusters) and 3-level seasonal variation in inclusion of patients. All assumptions are 
listed in S3 Text. Based on these assumptions, we originally estimated a needed sample size of 
1,100 children with a suspected lower RTI. Interim analysis of inclusions during the first year 
showed a higher baseline prescription rate than was assumed. An interim power calculation 
based on this rate resulted in a needed sample size of 900 children to show superiority of 
the decision rule for antibiotic prescription with a power of 0.9 and an alpha of 0.05 (see 
S1 Text). This number was also sensitive to show non-inferiority of the intervention in terms 
of strategy failure with a non-inferiority margin of 5%: It could detect a 2-fold increase of 
secondary hospitalisation (the part of strategy failure with available baseline data: 5% at the 
time of original sample size calculation) with a power of 0.8 and alpha of 0.05. The interim 
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power analysis was performed before introduction of the intervention, so it was blinded to 
the outcomes of the trial.21
Primary analyses
We used multilevel generalised linear mixed models to calculate the impact of the intervention 
on our 2 primary outcomes: antibiotic prescription and strategy failure. Hospitals were added 
as a random effect to take clustering at the hospital level into account. Time period (1–9) 
was added as a fixed effect to adjust for a secular time trend introduced by the design of the 
study.22 In the primary analyses we adjusted for pre-specified factors that may have influenced 
participation in the study or compliance to the protocol, i.e., age, sex, fever duration, season, 
and ill appearance. We tested the linearity of the associations between continuous predictors 
and outcomes. Detailed models can be found in the pre-specified statistical analysis plan (S4 
Text). We performed an intention-to-treat analysis, i.e., the intervention population contained 
all of the children in the intervention phase, including those cases where doctors did not 
comply to the protocol (Fig 2). We analysed the outcome strategy failure in all children with 
follow-up information on strategy failure available. We also performed per-protocol analyses 
to evaluate the impact of the decision rule on the primary outcomes in cases of compliance 
to the protocol. For this per-protocol analysis, the intervention group consisted only of those 
children in whom the physicians complied to the protocol (Fig 2).
Secondary analyses
We report the level of compliance to the intervention and the number of complications 
during both phases of the study.
Pre-specified sensitivity analyses
We pre-specified 4 sensitivity analyses. First, to estimate the effect of the imputation of 
missing covariates on our primary analyses, we planned a sensitivity analysis on all covariates 
with >10% missing values, using different assumptions. Second, to evaluate the effect of 
loss to follow-up on the outcome strategy failure, we planned a sensitivity analysis assuming 
that (a) strategy failure occurred in all children with missing follow-up or (b) strategy failure 
occurred in none of those children. Third, to evaluate the effect of the longer baseline and 
post-rollout periods, we performed a sensitivity analysis of the primary outcome that only 
used data from 4 weeks before until 4 weeks after the rollout period (31 July 2017–8 April 
2018), resulting in 9 time periods of equal length. Fourth, the level of routine measurement 
of CRP in the pre-intervention phase differed between hospitals. To adjust for this factor, we 
performed a sensitivity analysis on the data of only those hospitals that did perform routine 
CRP measurement in the population throughout both phases of the study.
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Exploratory subgroup analysis. We performed an exploratory subgroup analysis of the primary 
outcomes in the different risk groups. Because our intervention was to withhold antibiotics in 
children at low or intermediate risk of bacterial pneumonia, we expected the most effect on 
primary outcomes in those risk groups. However, our study was not powered for subgroup 
analyses, so we performed these post hoc as exploratory analyses, to generate hypotheses 
for the interpretation of the overall primary results. We analysed the primary outcomes 
in the low- and intermediate-risk groups combined (≤10%) versus the high predicted risk 
(>10%) group, testing for a difference in effect using an interaction term (intervention × risk 
group). For these analyses we used the data of all children in whom the Feverkidstool—and 
thereby the risk group—could be calculated (complete case analysis), because we could not 
select subgroups based on imputed data. We did not perform other post hoc analyses.
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Fig 2. Flowchart of inclusion.
CRF, case report form; ED, emergency department.
Missing data
We assumed missing data to be missing at random, and handled missing covariates by 
means of multiple imputation using the mice package in R (version 3.3.4). The imputation 
model included all of the variables needed for the primary and sensitivity analyses, as well as 
additional information on diagnosis, treatment, disposition, and follow-up. Outcome variables 
(antibiotic prescription and strategy failure) were not imputed, except for the sensitivity 
analysis evaluating the effect of loss to follow-up on the outcome strategy failure. In this 
sensitivity analysis we used single imputation only for the outcome variable strategy failure, 
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assuming 100% failure if the variable was missing in one dataset versus 0% failure in another 
dataset. We did not impute predicted risk for the selection of risk groups in the exploratory 
analyses. If parents could not be reached for a follow-up on day 7 via telephone, follow-up 
information was retrieved from the child’s electronic health record.
RESULTS
Recruitment
The baseline period ran from 1 January 2016 to 27 August 2017, and from 28 August 2017 
to 12 March 2018 (the rollout period) the hospitals started the intervention phase one by 
one every 4 weeks; we collected data until 30 September 2018, when the target sample 
size was reached (Fig 1). All hospitals adhered to their allocated sequence of treatment 
and the planned rollout dates. All hospitals that were assessed for eligibility were recruited 
(n = 8); after recruitment, all 8 were randomised to a treatment sequence and included in 
the analyses (Fig 1). In total, 1,704 children were assessed for eligibility, and 1,027 children 
included in the trial (375 not included in the pre-intervention phase, 302 in the intervention 
phase). Of the included children, 28 children met the exclusion criteria, leaving 999 children 
for analyses of the primary outcome antibiotic prescription. Of these, 46 (5%) were lost to 
follow-up. Because the outcome strategy failure was based on follow-up, and because we 
did not impute outcome variables, the remaining 953 children were included in the analyses 
for strategy failure. Details of patient flow in the trial can be found in Fig 2, and details of 
inclusion at the cluster level in Fig 1. The main reason for non-inclusion of patients was that 
the ED was too busy to enrol patients in the trial. The children not included were generally 
less severely ill, reflected by a lower urgency at triage, fewer antibiotic prescriptions, and 
fewer hospitalisations (S2 Table).
Baseline data
The majority of children were male (n = 611, 61%), their median age was 17 months 
(interquartile range [IQR] 9 to 30), and most were referred to the ED by a general practitioner 
(Table 1). One-third of children appeared ill upon ED presentation, and the majority were 
tachycardic or tachypnoeic or exhibited chest wall retractions. Half of children were 
hospitalised, for a median duration of 3 days, mainly for oxygen therapy. During the pre-
intervention phase, CRP testing was not routinely performed in all children, depending on 
differences in usual care in the participating hospitals. One hospital was a tertiary care centre; 
the others were general hospitals (see S3 Table for baseline characteristics per hospital). 
Annual admissions to the paediatric EDs ranged from 500 to 13,000 (Fig 1).
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Table 1. Baseline characteristics of the study population.
Characteristic
Pre-intervention
n = 597
Intervention
n = 402
General characteristics
Male sex 364/597 (61%) 246/402 (61%)
Age in months 17 (9–30) 17 (9–31)
Season
Spring 76/597 (13%) 114/402 (28%)
Summer 55/597 (9%) 49/402 (12%)
Autumn 198/597 (33%) 88/402 (22%)
Winter 268/597 (45%) 151/402 (38%)
Way of referral to ED
General practitioner 441/578 (76%) 295/379 (78%)
Self 66/578 (11%) 45/379 (12%)
Other healthcare professional 71/578 (12%) 39/379 (10%)
Triage level
Immediate or very urgent 306/506 (60%) 182/332 (55%)
Urgent 146/506 (29%) 121/332 (36%)
Standard or non-urgent 54/506 (11%) 29/332 (9%)
Signs and symptoms
Ill appearance* 220/572 (38%) 138/400 (35%)
Duration of fever in days 2 (1–4) 2 (1–4)
Temperature in °C 38.8 (38.1–39.5) 38.9 (38.1–39.5)
Hypoxia (oxygen saturation < 94%) 144/595 (24%) 74/401 (18%)
Tachycardia 416/595 (70%) 274/402 (68%)
Tachypnoea 487/581 (84%) 315/402 (78%)
Retractions 376/578 (65%) 237/401 (59%)
Dyspnoea 432/581 (74%) 290/402 (72%)
Wheezing 233/565 (41%) 132/395 (33%)
Prolonged capillary refill (≥2 seconds) 96/553 (17%) 19/401 (5%)
Management
C-reactive protein test performed 372/597 (62%) 380/402 (95%)
C-reactive protein in mg/l 19 (7–44) 18 (7–38)
Chest X-ray performed 109/597 (18%) 49/402 (12%)
Discharge diagnosis
Pneumonia 204/594 (34%) 110/401 (27%)
Bronchiolitis 117/594 (20%) 79/401 (20%)
Upper RTI 197/594 (33%) 156/401 (39%)
Viral induced wheeze 69/594 (12%) 49/401 (12%)
Other 7/594 (1%) 7/401 (2%)
Hospitalisation 329/597 (55%) 181/402 (45%)
Length of stay in days 3 (2–5) 3 (2–5)
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Table 1.  (continued)
Characteristic
Pre-intervention
n = 597
Intervention
n = 402
Reason for hospitalisation
Oxygen therapy 235/329 (71%) 132/180 (73%)
Intake of antibiotics 8/329 (2%) 2/180 (1%)
Nebuliser bronchodilator 10/329 (3%) 4/180 (2%)
Monitoring 69/329 (21%) 39/180 (22%)
Other 7/329 (2%) 3/180 (2%)
Type of antibiotic prescribed
Amoxicillin 152/179 (85%) 84/101 (83%)
Amoxicillin/clavulanic acid 8/179 (4%) 6/101 (6%)
Azithromycin 17/179 (9%) 4/101 (4%)
Cefuroxime 2/179 (1%) 1/101 (1%)
Other 0/179 (0%) 5/101 (5%)
Unknown 0/179 (0%) 1/101 (1%)
Footnote:
Categorical variables are presented as number/total (percentage), and continuous variables as median (interquartile 
range). The pre-intervention and intervention populations in a stepped-wedge trial cannot be directly compared, 
but should be adjusted for a secular time trend.22
*Based on physician’s judgment (yes/no).
ED, emergency department; RTI, respiratory tract infection.
Primary and sensitivity analyses
Overall antibiotic prescription was not reduced in the intervention phase (30% versus 25%; 
adjusted odds ratio [aOR] 1.07, 95% CI 0.57 to 2.01, p = 0.75; Table 2). Antibiotic prescription 
rates per hospital and per time period are provided in S4 Table. Strategy failure decreased 
from 23% in the pre-intervention phase to 16% in the intervention phase (aOR 0.53, 95% 
CI 0.32 to 0.88, p = 0.01). The per-protocol analysis gave similar results as the intention-
to-treat analysis, showing that non-compliance to the decision rule did not influence the 
observed effect on the primary outcomes. Also the results of the sensitivity analysis with 
truncated baseline and post-rollout periods were comparable to the analyses on the whole 
population (Table 2). Two pre-planned sensitivity analyses were not needed: adjusting for 
missing covariates and adjusting for level of CRP measurement in pre-intervention phase. 
All covariates for the primary analyses had less than 10% missing values (Table 1), so we 
assume that no bias was introduced by multiple imputation. There was no difference in the 
level of CRP measurement between hospitals that performed CRP routinely during the pre-
intervention phase and those that did not. Loss to follow-up had no effect on the outcome 
strategy failure, as shown by the sensitivity analyses that assumed different outcomes for 
those lost to follow-up (Table 2). Secondary antibiotic prescription was the most frequent 
reason for strategy failure (Table 2).
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Footnotes:
Bolding indicates statistical significance.
*Main model: clustered by hospital, adjusted for time period. Time-adjusted intracluster correlation coefficient for 
antibiotic prescription = 0.04, for strategy failure = 0.
†p-Values based on multivariable logistic regression.
‡Adjusted model: main model further adjusted for age, sex, season, ill appearance, and duration of fever.
§Using data from 4 weeks before until 4 weeks after the rollout period, resulting in 9 time periods of equal length, 
truncating the prolonged baseline and post-rollout periods.
¶Complications were 1 admission to intensive care unit in the pre-intervention phase and 1 pleural empyema in the 
intervention phase (both unrelated to study intervention).
**Including 1 admission to the intensive care unit in the pre-intervention group.
NA, not applicable.
Secondary analyses
In 43/402 (11%) cases, the clinician was not compliant with the decision rule (Table 2). Two 
complications occurred during the trial: in the pre-intervention phase 1 child was admitted 
to the intensive care unit during follow-up for mechanical ventilation; in the intervention 
phase 1 child developed pleural empyema at day 10. Both complications were unrelated to 
the study intervention, since both patients treated with antibiotics at the first ED visit.
Exploratory subgroup analysis: risk groups
We had complete information on all Feverkidstool predictors in 331/597 (55%) of the children 
in the pre-intervention phase. CRP was the most frequent missing variable (225/597, 38%). 
The complete case analysis showed that the effect of the decision rule was different across 
risk groups (p < 0.01; Table 3). Antibiotic prescription was lower in the low and intermediate 
risk groups combined (≤10% predicted risk) during the intervention phase, whereas in the 
high-risk group prescription rates were higher, but not statistically significantly so. The 
reduction in strategy failure was observed in the high-risk group (Table 3), mainly via fewer 
secondary antibiotic prescriptions and less frequent fever at day 7 (S5 Table).
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DISCUSSION
We showed that a clinical decision rule did not reduce overall antibiotic prescription in 
children with suspected lower RTI in the ED, but that it did reduce strategy failure. Exploratory 
subgroup analyses showed that the intervention influenced the outcomes in the risk groups 
differently.
Our primary aim was to safely reduce antibiotic prescription in children under 5 years 
with suspected lower RTI at the ED. We hypothesized that introducing a decision rule as 
an intervention would safely reduce antibiotic prescriptions in these children. This target 
population included children with all different risk profiles, since at presentation in the ED 
their risk was unknown. The first primary endpoint of reducing antibiotic prescription was 
not met. The other primary endpoint of not increasing strategy failure was met. Moreover, 
we observed a reduction in strategy failure, suggesting that antibiotic prescriptions were 
more appropriately targeted to children who benefited from antibiotics. This additional 
hypothesis was supported by our exploratory subgroup analysis, showing a safe reduction 
in antibiotic treatments in the low/intermediate-risk group and a (non-significant) increase 
of prescriptions and a reduction of strategy failures in the high-risk children. This suggests 
a shift in antibiotic prescriptions from the low/intermediate-risk children towards the high-
risk children who had more clinical benefit from the antibiotics. Our power calculation was 
based on the complete target population of children with suspected lower RTI, assuming 
a distribution of risk based on previous research. Post hoc sensitivity analysis of the sample 
size calculation showed that our study was sufficiently powered (power of 0.8), also when 
accounting for clustering at varying ICC values (range 0.01–0.26) and adjusted for multiple 
testing. However, we observed a smaller proportion of low/intermediate-risk children in 
our study population than expected. The shift in antibiotic prescriptions towards high-risk 
children and the observed smaller proportion of low/intermediate-risk children in our study 
may explain why we did not detect an overall reduction in antibiotic prescription. However, 
it must be noted that this finding was based on complete case analysis only and that our 
study was not powered for subgroup analyses.
We used a composite outcome to define strategy failure. Composite outcomes can be 
problematic, if the effect of the intervention is mainly driven by less important components.20 
In our study we found that a reduction in secondary antibiotic prescriptions was the main 
component of the reduction in strategy failures in the high-risk children and in those in whom 
we could not calculate the risk score (S5 Table). In low/intermediate-risk children, secondary 
prescription slightly increased, but without increasing oxygen need or fever at day 7 (proxies 
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for disease severity). There was no increase in complications during the intervention phase. 
These observations show that our intervention was safe, with reduced strategy failure on 
clinically important outcomes.
In this trial we used a threshold of 10% to define low/intermediate- versus high-risk patients, 
based on previous observed diagnostic performance,12 which appeared to be safe. Given the 
relatively low observed antibiotic prescription rate in the high-risk group, a higher threshold 
may also be reasonable and more specific, but may carry a risk of increasing strategy failure. 
These considerations highlight the difficulty in obtaining the optimal balance between 
reducing overuse of antibiotics (important from a public health perspective) and at the same 
time striving for the best clinical outcomes for the individual patient.19
Other impact studies of decision rules for infections in children that combine biomarkers 
and clinical characteristics are scarce. In a previous impact study, the Feverkidstool was 
used as a decision rule to guide diagnostic decisions in febrile children in a tertiary hospital. 
This resulted in a more standardised diagnostic approach, but did not improve the study’s 
secondary patient outcomes, namely antibiotic treatment and hospitalisation.14 A study of 
Lab-score (a decision rule combining biomarkers) failed to prove its impact on antibiotic 
prescription in infants with fever without source.23 Two studies have been reported in non-
Western countries on the impact of decision rules on antibiotic prescription.24,25 A bacterial 
pneumonia score reduced antibiotic prescription without increasing treatment failure,24 but 
requires neutrophil testing and a chest X-ray, both of which are not recommended routinely 
for the management of children with suspected lower RTIs. In Tanzania an algorithm including 
clinical features, CRP, and procalcitonin (PCT) reduced antibiotic prescription from 94.9% 
to 11.5% and improved clinical outcomes in febrile children in primary care.25 Most other 
studies focused on the impact of single point-of-care biomarkers on antibiotic prescription. 
A large study in Vietnam showed a reduction of antibiotic use after CRP testing for non-
severe acute RTIs in adults as well as in children.26 In the European ambulatory care setting, 
there is evidence that CRP testing can reduce immediate antibiotic prescription in children 
when appropriate guidance is provided to the healthcare professional.27,28 A randomised 
controlled trial from Switzerland studied PCT-guided treatment, but found no effect on 
antibiotic prescription rates.29
To our knowledge, this is the first multicentre randomised trial designed to measure the 
impact of a clinical decision rule on antibiotic prescription in children with suspected lower 
RTI in the ED. A major strength is that our trial studied the impact of a decision rule on 
usual care. Because the trial was conducted in different settings, mostly general hospitals, 
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we believe our findings are generalisable to general paediatric practice. We had complete 
information on the outcome antibiotic prescription, good compliance to the protocol, a 
high follow-up rate, and sufficient power. The sensitivity analyses showed similar results 
as our primary analyses, confirming the robustness of our findings. There are also some 
limitations. Logistical problems in starting the trial in 2 hospitals resulted in a longer baseline 
period before rollout, potentially affecting the power of our study (Fig 1). However, the 
sensitivity analysis truncating this prolonged baseline period gave results similar to our main 
analysis, so we believe our overall estimates are valid. Another limitation is the amount of 
missing Feverkidstool variables in the pre-intervention phase, especially CRP. This did not 
influence our primary analyses (as CRP was not needed in these models), but limited the 
number of included patients in the subgroup analyses, where the calculated risk of the 
Feverkidstool was required. This may have introduced some bias in the subgroup analyses. 
Next, not all eligible children could be included in the trial. Doctors in the ED often are 
under time pressure, leaving insufficient time or attention to recruit patients for a trial, as 
has been acknowledged by other paediatric ED trials.5,23 Comparison of the included and 
non-included children showed that severely ill children were included more frequently. This 
was the same in both phases of the study, and the rate of eligible children whose families 
declined participation was also stable over the study phases. Therefore, we believe there was 
no selection bias introduced by a lack of allocation concealment at the individual level. We 
believe that we did not miss any children with severe infections, so our results on strategy 
failure and complications are generalisable.
Although we could not prove an overall reduction of antibiotic prescription, our study implies 
that guiding antibiotic treatment by a decision rule based on the Feverkidstool is non-
inferior in terms of safety in non-complex cases of suspected lower RTI. Moreover, patient 
outcomes may be improved by better targeting of antibiotics. Implementation of the decision 
rule in clinical practice would require measuring (point-of-care) CRP, which is not routinely 
done in all patients with fever and respiratory symptoms.30 However, we recommend a low 
threshold for CRP measurements and risk assessments for bacterial pneumonia in these 
children, and withholding antibiotics in children with a predicted risk of ≤10%, provided 
that careful safety-netting and good access to healthcare are in place.31 To avoid the risk of 
over-prescription in children with a predicted risk of >10%, this approach should be closely 
monitored. Future research should focus on the safety of higher decision thresholds and on 
the impact in settings with higher antibiotic prescription rates at baseline, or with a larger 
proportion of low-risk children. Our observed 30% antibiotic prescription rate at baseline for 
suspected lower RTIs is lower than what has been described in other European EDs, where 
antibiotic prescription rates range from 52% to 78%.5,6,13,32 Even though the populations in 
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many studies cannot be directly compared, a recent paper showed that after adjustment for 
differences in population, large variability in antibiotic prescription remains.1 We expect that 
the effect of our intervention on antibiotic prescription may therefore be larger in settings 
with a higher baseline prescription rate, or in populations with a larger proportion of low-
risk children.
A clinical decision rule for childhood pneumonia did not reduce overall antibiotic prescription, 
but was non-inferior in terms of strategy failure. Exploratory analyses showed that the 
intervention reduced antibiotic prescriptions in low/intermediate-risk children, and that it 
reduced overall strategy failures, suggesting improved targeting of antibiotics by the decision 
rule.
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SUPPORTING INFORMATION
Available as online web appendix on website of PLOS Medicine:
- S1 Table. CONSORT checklist.
- S1 Text. Final approved trial protocol, version 7 (10 August 2018).
- S2 Text. Original approved trial protocol version 3 (03 April 2014).
- S4 Text. Pre-specified statistical analysis plan (14 December 2018).
S2 Table. Comparison of included and non-included children.
Included Non-included
n=999 n=677
General characteristics
Male sex 610/999 (61%) 432/674 (64%)
Age in months* 17 (9 - 30) 12 (6 - 24)
Triage level*
- Immediate or very urgent 488/908 (54%) 251/641 (39%)
- Urgent 267/908 (29%) 266/641 (41%)
- Standard or non-urgent 83/908 (9%) 124/641 (19%)
Antibiotic prescription* 280/999 (28%) 106/677 (16%)
Hospitalization* 510/999 (51%) 242/677 (36%)
* significant difference between included and non-included children, based on t-test for continuous outcomes and 
based on chi-squared test for categorical outcomes.
3.2
BNW_Josephine_v1.indd   139 19-Sep-20   14:51:43
140
Chapter 3.2
S3
 T
ab
le
. B
as
el
in
e 
ch
ar
ac
te
ris
tic
s 
pe
r 
ho
sp
it
al
.
O
ve
ra
ll
H
o
sp
it
al
 A
H
o
sp
it
al
 B
H
o
sp
it
al
 C
H
o
sp
it
al
 D
H
o
sp
it
al
 E
H
o
sp
it
al
 F
H
o
sp
it
al
 G
H
o
sp
it
al
 H
n
 =
 9
99
n
 =
 1
96
n
 =
 8
5
n
 =
 4
6
n
 =
 1
6
4
n
 =
 3
1
n
 =
 9
8
n
 =
21
1
n
 =
 1
68
n 
/ m
ed
ia
n
%
/I
Q
R
G
en
er
al
 h
os
pi
ta
l
G
en
er
al
 h
os
pi
ta
l
Te
rt
ia
ry
 h
os
pi
ta
l
G
en
er
al
 h
os
pi
ta
l
G
en
er
al
 h
os
pi
ta
l
G
en
er
al
 h
os
pi
ta
l
G
en
er
al
 h
os
pi
ta
l
G
en
er
al
 h
os
pi
ta
l
G
en
er
al
 c
h
ar
ac
te
ri
st
ic
s
M
al
e 
se
x
61
1
61
%
11
4
58
%
58
6
8%
31
67
%
97
59
%
17
55
%
5
4
55
%
13
8
65
%
10
1
6
0%
A
ge
 in
 m
on
th
s
17
9 
- 
30
13
8 
- 
25
18
10
 -
 3
3
22
11
 -
 3
7
15
8 
- 
30
19
12
 -
 2
7
14
9 
- 
26
20
10
 -
 3
4
16
9 
- 
28
Se
as
on
- 
Sp
ri
ng
19
0
19
%
39
20
%
16
19
%
7
15
%
29
18
%
3
10
%
16
16
%
38
18
%
42
25
%
- 
Su
m
m
er
10
4
10
%
21
11
%
4
5%
4
9%
16
10
%
2
6%
9
9%
19
9%
29
17
%
- 
A
ut
um
n
28
7
29
%
43
22
%
22
26
%
18
39
%
56
3
4%
12
39
%
32
33
%
70
33
%
3
4
20
%
- 
W
in
te
r
43
1
43
%
93
47
%
43
51
%
17
37
%
6
6
4
0%
14
45
%
41
42
%
8
4
4
0%
63
38
%
W
ay
 o
f 
re
fe
rr
al
- 
G
en
er
al
 p
ra
ct
it
io
ne
r
73
9
74
%
14
8
76
%
56
6
6%
19
41
%
13
7
8
4%
18
58
%
8
4
8
6%
13
6
6
4%
13
8
82
%
- 
Se
lf
11
1
11
%
11
6%
4
5%
11
24
%
8
5%
1
3%
3
3%
61
29
%
12
7%
- 
O
th
er
11
0
11
%
30
15
%
7
8%
11
24
%
17
10
%
12
39
%
11
11
%
13
6%
9
5%
Si
g
n
s 
an
d
 s
ym
p
to
m
s
Ill
 a
pp
ea
ra
nc
e
35
9
36
%
8
0
41
%
25
29
%
12
26
%
89
5
4%
7
23
%
37
38
%
6
8
32
%
4
0
24
%
D
ur
at
io
n 
of
 f
ev
er
 in
 d
ay
s
2
1-
4
2
1 
- 
4
3
1 
- 
4
3
1 
- 
5
2
1 
- 
3
2
1 
- 
4
2
1 
- 
4
2
1 
- 
3
2
1 
- 
3
Te
m
p
er
at
ur
e
38
.8
38
.1
 -
 3
9.
5
38
.9
38
.2
 -
 3
9.
5
38
.8
38
.1
 -
 3
9.
1
39
.1
38
 -
 3
9.
7
38
.9
38
.1
 -
 3
9.
6
38
.5
37
.5
 -
 3
9.
2
38
.6
37
.8
 -
 3
9.
2
39
.0
38
.5
 -
 3
9.
6
38
.6
38
 -
 3
9.
4
H
yp
ox
ia
 (s
at
 <
9
4%
)
21
8
22
%
36
18
%
14
16
%
10
22
%
4
4
27
%
3
10
%
30
31
%
56
27
%
25
15
%
Ta
ch
yc
ar
di
a
69
1
69
%
12
4
63
%
6
0
71
%
32
70
%
12
3
75
%
23
74
%
71
72
%
13
3
63
%
12
4
74
%
Ta
ch
yp
ne
a
8
0
4
8
0%
14
0
71
%
69
81
%
35
76
%
13
9
85
%
18
58
%
87
89
%
16
9
8
0%
14
5
8
6%
Re
tr
ac
ti
on
s 
pr
es
en
t
61
4
61
%
10
6
5
4%
57
67
%
20
43
%
11
4
70
%
17
55
%
59
6
0%
15
0
71
%
9
0
5
4%
D
ys
pn
ea
 p
re
se
nt
72
3
72
%
13
3
6
8%
6
4
75
%
27
59
%
13
8
8
4%
21
6
8%
59
6
0%
16
1
76
%
11
9
71
%
W
he
ez
in
g
36
6
37
%
6
0
31
%
31
36
%
11
24
%
69
42
%
11
35
%
21
21
%
92
4
4%
70
42
%
Pr
ol
on
g
ed
 c
ap
ill
ar
y 
re
fil
l 
(≥
2 
se
co
nd
s)
11
6
12
%
21
11
%
4
5%
4
9%
33
20
%
0
0%
15
15
%
31
15
%
7
4%
D
ia
g
n
o
st
ic
s 
an
d
 t
re
at
m
en
t
C
R
P 
p
er
fo
rm
ed
75
6
76
%
13
6
69
%
78
92
%
39
85
%
9
0
55
%
27
87
%
8
4
8
6%
13
7
65
%
16
5
9
8%
C
R
P 
in
 m
g
/L
18
7 
- 
41
14
7 
- 
28
20
10
 -
 4
7
17
5 
- 
33
21
7 
- 
50
9
5 
- 
33
26
8 
- 
59
22
8 
- 
38
18
5 
- 
42
C
he
st
 x
-r
ay
 p
er
fo
rm
ed
15
9
16
%
17
9%
10
12
%
6
13
%
37
23
%
14
45
%
21
21
%
37
18
%
16
10
%
O
xy
ge
n 
th
er
ap
y
41
5
41
%
65
33
%
30
35
%
14
30
%
10
2
62
%
9
29
%
47
4
8%
8
0
38
%
6
8
4
0%
A
nt
ib
io
ti
c 
pr
es
cr
ip
ti
on
28
1
28
%
36
18
%
17
20
%
17
37
%
65
4
0%
6
19
%
37
38
%
63
30
%
39
23
%
H
os
pi
ta
liz
at
io
n
51
1
51
%
8
8
45
%
39
4
6%
19
41
%
11
9
73
%
10
32
%
58
59
%
91
43
%
8
6
51
%
BNW_Josephine_v1.indd   140 19-Sep-20   14:51:43
141
Clinical decision rule guiding antibiotic prescription, a randomized trial
S4 Table. Antibiotic prescription per hospital and time period.
Time 
period 1 2 3 4 5 6 7 8 9
Hospital n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
A 11/69 (16%) 0/7 (0%) 2/9 (22%) 2/12 (17%) 5/28 (18%) 5/15 (33%) 4/20 (5%) 5/17 (29%) 2/19 (11%)
B 8/33 (24%) 0/2 (0%) 1/3 (33%) 0/6 (0%) 1/16 (6%) 2/15 (13%) 1/3 (33%) 1/1 (100%) 3/6 (50%)
C 10/27 (37%) 0/1 (0%) 1/1 (100%) 1/5 (20%) 0/3 (0%) 0/1 (0%) 2/3 (67%) 1/2 (50%) 2/3 (67%)
D 35/74 (47%) 3/6 (50%) 1/8 (13%) 3/7 (43%) 6/23 (26%) 3/9 (33%) 0/4 (0%) 3/5 (60%) 11/28 (39%)
E 0/0 (0%) 0/0 (0%) 1/5 (20%) 0/3 (0%) 3/12 (25%) 0/2 (0%) 0/3 (0%) 0/1 (0%) 2/5 (40%)
F 23/52 (44%) 0/0 (0%) 1/4 (25%) 4/8 (50%) 0/9 (0%) 2/9 (22%) 2/5 (40%) 0/0 (0%) 5/11 (45%)
G 1/1 (100%) 3/17 (18%) 1/12 (8%) 5/23 (22%) 19/51 (37%) 6/20 (30%) 5/20 (25%) 5/10 (50%) 18/57 (32%)
H 27/71 (38%) 0/3 (0%) 0/2 (0%) 1/6 (17%) 1/10 (10%) 2/11 (18%) 1/13 (8%) 1/7 (14%) 6/45 (13%)
Footnote: dark grey = pre-intervention period; light grey = intervention period.
S5 Table. Detailed outcomes per risk group.
Pre-intervention Intervention
Low-intermediate risk population (≤10%) n / N (%) n / N (%)
Antibiotic prescription* 29/172 (17%) 15/234 (6%)
Strategy failure* 29/159 (18%) 39/218 (18%)
Strategy failure: reasons
- Secondary antibiotic prescription 7/159 (4%) 20/218 (9%)
- Changed antibiotics during follow-up 1/159 (1%) 0/218 (0%)
- Secondary hospitalization 7/159 (4%) 11/218 (5%)
- Oxygen need at day 7 3/159 (2%) 0/218 (0%)
- Fever at day 7 11/159 (7%) 8/218 (4%)
High-risk population (>10%)
Antibiotic prescription* 75/159 (47%) 83/140 (59%)
Strategy failure* 42/155 (27%) 20/136 (15%)
Strategy failure: reasons
- Secondary antibiotic prescription 18/155 (12%) 8/136 (6%)
- Changed antibiotics during follow-up 6/155 (4%) 5/136 (4%)
- Secondary hospitalization 3/155 (2%) 2/136 (1%)
- Oxygen need at day 7 2/155 (1%) 1/136 (1%)
- Fever at day 7 13/155 (8%) 4/136 (3%)
Feverkidstool missing†
Antibiotic prescription 75/266 (28%) 3/28 (11%)
Strategy failure 60/258 (23%) 2/27 (7%)
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S5 Table. Detailed outcomes per risk group.
Pre-intervention Intervention
Strategy failure: reasons
- Secondary antibiotic prescription 20/258 (8%) 1/27 (4%)
- Changed antibiotics during follow-up 7/258 (3%) 0/27 (0%)
- Secondary hospitalization 6/258 (2%) 0/27 (0%)
- Oxygen need at day 7 4/258 (2%) 0/27 (0%)
- Fever at day 7 23/258 (9%) 1/27 (4%)
Footnote:
* The pre-intervention and intervention populations in a stepped-wedge trial cannot be directly compared, but 
should be adjusted for a secular time-trend.22
† In these children no risk could be calculated due to missing Feverkidstool variables, therefore these populations 
cannot be compared.
S3 Text. List of assumptions for power calculation.
Original power calculation:
· 6 hospitals, 6 time periods
· Distribution risk groups: 50% low-risk, 30% intermediate-risk, 20% high-risk
· Antibiotic prescription at baseline: 23% in low-risk children, 35% in intermediate-risk 
children, 85% in high-risk children
· Effect of intervention on antibiotic prescription: 10%-point reduction in low-risk children, 
15%-point reduction in intermediate-risk children, no difference in high-risk children
· Varying cluster sizes: 2 small, 2 medium, 2 large hospitals
· Seasonality: baseline inclusion rate, 2 months 50% higher rate, 2 months 50% lower 
rate
· ICC is unknown, assume 90% power to be sufficient
Interim power calculation:
· 6 hospitals, 6 time periods
· Distribution risk groups: 50% low-risk, 30% intermediate-risk, 20% high-risk
· Antibiotic prescription at baseline: 35-45% in low-risk children, 40% in intermediate-risk 
children, 85% in high-risk children
· Effect of intervention on antibiotic prescription: 10%-point reduction in low-risk children, 
15%-point reduction in intermediate-risk children, no difference in high-risk children
· Varying cluster sizes: 2 small, 2 medium, 2 large hospitals
· Seasonality: baseline inclusion rate, 2 months 50% higher rate, 2 months 50% lower 
rate
· ICC is unknown, assume 90% power to be sufficient
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ABSTRACT
Objective
To determine whether updating a diagnostic prediction model by adding a combination assay 
(tumour necrosis factor-related apoptosis-inducing ligand, interferon γ induced protein-10 
and C reactive protein (CRP)) can accurately identify children with pneumonia or other serious 
bacterial infections (SBIs).
Design
Observational double-blind diagnostic study.
Setting
Two hospitals in Israel and four hospitals in the Netherlands.
Patients
591 children, aged 1–60 months, presenting with lower respiratory tract infections or fever 
without source. 96 of them had SBIs. The original Feverkidstool, a polytomous logistic 
regression model including clinical variables and CRP, was recalibrated and thereafter updated 
by using the assay.
Main outcome measures
Pneumonia, other SBIs or no SBI.
Results
The recalibrated original Feverkidstool discriminated well between SBI and viral infections, 
with a c-statistic for pneumonia of 0.84 (95% CI 0.77 to 0.92) and 0.82 (95% CI 0.77 to 
0.86) for other SBIs. The discriminatory ability increased when CRP was replaced by the 
combination assay; c-statistic for pneumonia increased to 0.89 (95% CI 0.82 to 0.96) and 
for other SBI to 0.91 (95% CI 0.87 to 0.94). This updated Feverkidstool improved diagnosis 
of SBIs mainly in children with low-moderate risk estimates of SBIs.
Conclusion
We improved the diagnostic accuracy of the Feverkidstool by replacing CRP with a 
combination assay to predict pneumonia or other SBIs in febrile children. The updated 
Feverkidstool has the largest potential to rule out bacterial infections and thus to decrease 
unnecessary antibiotic prescription in children with low-to-moderate predicted risk of 
SBIs.
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INTRODUCTION
Suspicion of infectious disease is one of the most common cause of paediatric emergency 
department (ED) visits.1 The proportion of bacterial infections in children with fever without 
source (FWS) and acute respiratory tract infections (RTI) is however low (respectively 0.02–13% 
and 26–28%).2-4 Next, identifying patients benefiting from antibiotic treatment remains a 
major diagnostic challenge. Consequentially, children with acute RTI receive antibiotics almost 
twice as often as the estimated prevalence.2,5,6 Antibiotic overuse is associated with increased 
antibiotic resistance, causing 25,000 deaths in Europe annually.7,8 This underlines the need to 
better differentiate between viral and bacterial infections. Therefore, several prediction models 
have been developed.9,10 The Feverkidstool, a clinical prediction model including both clinical 
parameters and C reactive protein (CRP), is a validated tool for supporting clinical decision-
making on, for example, whether or not to start antibiotics.11-13 However, further improvement of 
this diagnostic tool is warranted as it does not provide an accurate diagnosis for all patients.
We recently showed that a novel blood assay, combining concentrations of CRP with tumour 
necrosis factor-related apoptosis-inducing ligand (TRAIL) and interferon γ induced protein-10 
(IP-10), could diagnose bacterial infections more accurate than CRP alone.14-16
The dynamics of TRAIL are complementary to traditionally studied bacteria-induced proteins; 
TRAIL concentrations decrease in bacterial infection and increase in viral infections.15 The aim 
of this study is to investigate whether updating the Feverkidstool by replacing CRP with the 
combination assay can improve the diagnosis of SBI in preschool children.
PATIENTS AND METHODS
The current study builds on the prospective observational OPPORTUNITY Study performed in four 
hospitals in the Netherlands and two hospitals in Israel between 16 October 2013 and 28 January 
2015. For detailed methods, we refer to the original publication.14 In short, this study included 
clinical data, a host-protein based assay, nasal swab PCR and 28-day follow-up data from children 
aged 1–60 months with lower RTI or FWS (n=777). The study was an observational double-
blind diagnostic study. The analysis of the serum samples for the assay (index test) was done in 
the absence of any clinical or other patient-related information, and the expert panel (reference 
standard) was blinded to the decisions of their peers and to the results of the index test.
General inclusion and exclusion criteria can be found in the original publication that had 577 
children in the primary analysis. We added to our current study data of children aged 1–2 
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months that in the original OPPORTUNITY Study were included for a subanalysis (n=28), as 
this study showed accurate results of the assay in this population. Children admitted to the 
intensive care (all referred from the wards of other hospitals, n=14) were excluded as the 
Feverkidstool was developed for febrile patients presenting at the ED (online supplementary 
figure 1). Patients gave written informed consent prior to sampling. This study was designed 
and analysed without patient involvement. Patients were not invited to contribute to the 
writing or editing of this document for readability or accuracy. This manuscript follows the 
TRIPOD (Transparent reporting of a multivariable prediction model for individual prognosis 
or diagnosis) (online supplementary file 3) reporting guidelines.
Prediction model
The Feverkidstool is a polytomous prediction model that predicts the risk of pneumonia or 
other SBIs, based on the following variables: age, body temperature, heart rate, respiratory 
rate, oxygen saturation, ill-appearance, peripheral capillary refill, chest wall retractions and 
CRP (definitions presented in the statistical analysis plan, online supplementary file 1).12
Combined host-protein based assay
The assay is currently ELISA based (a point-of-care test is being developed) and combines the 
concentrations of TRAIL, IP-10 and CRP using a predetermined logistic regression formula to 
compute the likelihood score for a bacterial infection.14,15 The assay was performed on coded 
serum samples in absence of any patient-related information.
Reference standard diagnosis
Currently, no single reference standard test exists for determining the aetiology of an 
infection.17 Therefore, in the OPPORTUNITY Study, England’s National Health Service’s 
standard for evaluating diagnostic tests was followed and an expert panel reference standard 
was composed.14,18 Every recruited patient was diagnosed by three panel members affiliated to 
the country of recruitment using all available electronic Case Record Form (eCRF) information 
(clinical and laboratory information, including a 28-day follow-up), but blinded to the assay 
and Feverkidstool results and to the labels of their peers. Each expert assigned one of the 
following aetiologies to each patient: bacterial infection, viral infection, mixed infection (ie, 
bacterial and viral co-infection), non-infectious disease or indeterminate. Patients assigned as 
mixed infection were later classified as bacterial because they are clinically managed similarly. 
Patients with a bacterial reference standard diagnosis were divided into pneumonia or other 
SBIs (e.g. meningitis, urinary tract infections, bacteraemia) based on the diagnosis at hospital 
discharge assigned by the attending physician.
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Statistical analysis
General approach
We compared the diagnostic accuracy to predict SBIs of the original Feverkidstool with the 
accuracy of the Feverkidstool updated with the assay (hereafter called updated Feverkidstool). 
Statistical analyses were performed in SPSS version 21.0 for Windows and R V.3.2.2. We 
used the Mann-Whitney U test for comparison of continuous variables. Categorical outcomes 
were analysed using the χ2 test or Fisher’s exact test where expected cell counts were less 
than 5.
Model development and performance
First, we recalibrated the original Feverkidstool on our data using two separate logistic 
regressions, one for pneumonia and one for other SBIs (recalibrated Feverkidstool: logit 
(pneumonia or other SBI)= β0 + β1 (linear predictor Feverkidstool)). Then, we updated the 
Feverkidstool by adding the combination assay (updated Feverkidstool: logit (pneumonia 
or other SBI)= β0 + β2a (linear predictor Feverkidstool) + β2b (score assay)). One element 
of the assay, CRP, was also a predictor in the linear predictor Feverkidstool. To be able to 
compare the effect of using the assay (updated Feverkidstool) instead of the CRP only (original 
Feverkidstool) we standardised the effect of the CRP coefficient (as part of the linear predictor 
Feverkidstool) in this updated Feverkidstool. Therefore the linear predictor Feverkidstool was 
based on the median CRP value for all participants. The actual CRP value of patients was 
used to compute the score assay. Detailed models are presented in the statistical analysis 
plan (online supplementary file 1). The discriminative ability of the recalibrated original and 
updated models was expressed using pairwise c-statistics.19
Predicted risk thresholds
To help interpret the potential benefit of the different models along the range of predicted 
probabilities, a decision curve analysis (DCA) was performed. The DCA assesses the relative 
harm of false positives and false negatives for different probability thresholds if the models 
were used to guide antibiotic prescription.20 For predefined risk thresholds, we calculated 
sensitivity, specificity, positive and negative predictive value, positive and negative likelihood 
ratio (LR+, LR-) for the original and updated models.
Reclassification
To assess the potential added value of the updated Feverkidstool in correctly classifying 
SBIs and viral infections using defined thresholds, we did a head-to-head comparison for 
the updated Feverkidstool and the recalibrated original Feverkidstool in a reclassification 
table.21
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Missing values
Multiple imputation techniques enabled analysing all available data. Missing values in the 
variables, needed for the Feverkidstool, were imputed 10 times using the multivariate 
imputation by chained equations (MICE) algorithm in R statistical software.22 Variables used 
in the imputation model are presented in the statistical analyses plan (online supplementary 
file 1). Analyses were performed separately in the 10 imputed data sets and combined using 
Rubin’s rules.23 The Feverkidstool variable peripheral capillary refill was not recorded in the 
OPPORTUNITY Study for any patient. Because we had no information on the distribution of 
values for capillary refill, we could not include this variable in the model for multiple imputation. 
Leaving the coefficient for capillary refill out of the Feverkidstool would have led to systematic 
lower predictions (biased calibration), so we replaced this systematic missing variable by 
the mean prevalence of the prolonged capillary refill in the initial Feverkidstool derivation 
cohort (=0.039, mean imputation).24 Inconclusive diagnoses (n=71) were also imputed; a 
sensitivity analysis was performed leaving out patients with an inconclusive diagnosis.
RESULTS
Population characteristics
A total of 591 patients were available for analysis: 30 pneumonia, 66 other SBIs and 495 
viral infections (online supplementary figure 1). Children with pneumonia were older than 
children with other SBIs or with viral infections (median age of 24.5 versus 15 months) and 
children with pneumonia or other SBIs were hospitalised more often (73% and 77%) than 
children with viral infections (52%, table 1). Children with an inconclusive reference standard 
diagnosis differed from children with a conclusive diagnosis on age, biomarker values and 
antibiotic prescription (online supplementary table 1).
Table 1. Characteristics of patients included in the primary analysis
Pneumonia
(n=30)
Other SBI
(n=66)
Viral
(n=495)
Predictor variables
Age (months) 24.5 (12.7–41.3 ) 15.0 (8.0–33.0) 15.0 (7.0–28.0)
Gender, male 19 (63%) 32 (49%) 280 (57%)
Duration of fever (days) 3 (2-5) 2 (1-4) 2 (1–4)
Temperature (°C) 38.6 (38.2–39.8) 38.7(37.8–39.4) 38.5 (37.6–39.2)
n=30 (100%) n=66 (100%) n=493 (99%)
Respiratory rate 50 (34-70) 40 (31–52) 38 (30-52)
n=15 (50%) n=31 (47%) n=252 (51%)
Tachypnea 12 (80%) 17 (55%) 130 (52%)
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Table 1.  (continued)
Pneumonia
(n=30)
Other SBI
(n=66)
Viral
(n=495)
Heart rate 160 (24) 152 (27) 151 (24)
n=29 (97%) n=57 (86%) n=453 (92%)
Tachycardia 21 (72%) 29 (51%) 232 (51%)
Oxygen saturation (%O2) 98 (97-99) 99 (97–100) 98 (96–100)
n=28 (93%) n=48 (73%) n=417 (84%)
Desaturation (<94%O2) 1 (4%) 0 (0%) 24 (6%)
Chest wall retractions 6 (20%) 4 (6%) 60 (12%)
n=30 (100%) n=63 (95%) n=484 (98%)
Ill appearance 13 (43%) 25 (38%) 141 (29%)
C-reactive protein (mg/l) 176 (72–224) 102 (55–151) 15 (5–36)
Assay score 98 (76–100) 88 (68–98) 4 (1–26)
Other variables
Hospital admission 22 (73%) 51 (77%) 255 (52%)
Hospitalization duration (days) 4 (3–6) 4 (3–5) 3 (2–4)
Antibiotic treatment prescribed 30 (100%) 63 (96%) 140 (29%)
Recruiting site
Secondary care centre 27 (90%) 63 (96%) 463 (94%)
Tertiary care centre 3 (10%) 3 (4%) 32 (6%)
Focus of infection
Central nervous system 0 (0%) 0 (0%) 9 (2%)
Gastrointestinal tract 0 (0%) 1 (2%) 19 (4%)
Other 3 (10%) 11 (17%) 39 (8%)
Respiratory tract 26 (87%) 18 (27%) 250 (50%)
Systemic 0 (0%) 2 (3%) 9 (2%)
Unknown 1 (3%) 10 (15%) 169 (34%)
Urinary tract 0 (0%) 24 (36%) 0 (0%)
Data are presented as n (%), median (IQR) or mean (SD). This table includes imputed reference standard diagnoses, 
data are based on 1 of the 10 imputed datasets. If data were not available for all patients, the total number of 
available data are noted. Clinical syndrome was based on the diagnosis of the attending physician at discharge from 
the hospital. LRTI included pneumonia and bronchiolitis; URTI included laryngitis, pharyngitis, otitis media, sinusitis 
and tonsillitis. SBI, serious bacterial infection.
Model performance
The recalibrated original Feverkidstool discriminated well between pneumonia and other 
infections (c-statistic 0.84, 95% CI 0.77 to 0.92), and between other SBIs and other infections 
(c-statistic 0.82, 95% CI 0.77 to 0.86, online supplementary figure 2). This performance is 
similar to previous Feverkidstool validations.11,12 Updating the Feverkidstool with the assay 
improved discrimination between bacterial and other infections, reflected by an improved 
c-statistic for pneumonia to 0.89 (95% CI 0.82 to 0.96), and for other SBIs to 0.91 (95% CI 
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0.87 to 0.94) (online supplementary figure 2). A sensitivity analysis of the cohort without 
imputed reference standard diagnoses showed similar results, with improved prediction of 
pneumonia and other SBIs (online supplementary table 2).
Predicted risk thresholds
The DCA shows the net benefit of starting antibiotics using predictions of the updated instead 
of the original Feverkidstool, depending on the choice of probability threshold. Children with 
low–moderate predicted risks ≤40% for pneumonia or other SBIs had most benefit from the 
updated Feverkidstool (figure 1). For example, if all children with a predicted risk of >20% 
would be treated with antibiotics, the net benefit of the updated Feverkidstool increases with 
0.2 from the 0.2 net benefit in the original Feverkidstool for predicting pneumonia to 0.4 net 
benefit. For predicting other SBI the net benefit increases from 0.1 (original Feverkidstool) to 0.5 
by the updated Feverkidstool. In absolute numbers this would mean that by using the updated 
Feverkidstool at a threshold of 20%, we achieve 20 to 50 more correct treatment decisions 
(out of 100 patients) than when using the original Feverkidstool. Table 2 gives more detailed 
insight on effects of the updated model in diagnostic value using several thresholds. Using a 
rule of thumb of LR+ of 5 and LR– of 0.2,25 thresholds of 10% and 2.5% using the updated 
model seem better applicable for ruling in and out of both pneumonia and other SBIs.
Figure 1. Decision curve analysis
a.     b.
        
Decision curve analysis with the net benefit of starting antibiotics to none of the patients (black line), to all patients 
(grey line), the original Feverkidstool (red line), and the updated Feverkidstool (blue line), depending on the choice of 
probability threshold for starting antibiotics for pneumonia (a) and other SBI (b). FKT; Feverkidstool.
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Reclassification
Table 3 shows the clinical consequences if the updated Feverkidstool was used instead of the 
original Feverkidstool. In total, the updated Feverkidstool for pneumonia reduced the number 
children with a falsely predicted high or intermediate risk from 234 to 143 (39%) compared 
to the original Feverkidstool, and from 427 to 197 (54%) for children with other SBI.
Table 3. Diagnostic reclassification by the updated Feverkidstool compared to the original Feverkidstool
a. Reference standard diagnosis:
Pneumonia (n=30)
Reference standard diagnosis:
No pneumonia (n=561)*
Updated Feverkidstool
predicted risk for pneumonia
Updated Feverkidstool
predicted risk for pneumonia
Low Intermediate High Low Intermediate High
Original Feverkidstool 
predicted risk for 
pneumonia‡
Low 3 1 1 304 20 3
Intermediate 1 2 4 100 46 27
High 0 0 18 14 14 33
b. Reference standard diagnosis:
Other SBI (n=66)
Reference standard diagnosis:
No other SBI (n=525)†
Updated Feverkidstool
predicted risk for other SBI
Updated Feverkidstool
predicted risk for other SBI
Low Intermediate High Low Intermediate High
Original Feverkidstool 
predicted risk for 
other SBI§
Low 1 0 0 98 0 0
Intermediate 1 2 6 190 55 25
High 0 4 52 40 51 66
The Feverkidstool classification was compared to the majority reference standard for the prediction of pneumonia (A) 
and other SBIs (B). Head-to-head comparison of the original Feverkidstool and the updated Feverkidstool. Predicted 
risks of pneumonia (A) and other SBIs (B) were low if the predicted risk was below 2.5%, intermediate between 
2.5% and 10%, and high above 10%.
*As the comparison in this table is between the presence or absence of pneumonia, it should be noted that ‘no 
pneumonia’ includes viral and other SBIs.
†As the comparison in this table is between the presence or absence of other SBI, it should be noted that ‘no other 
SBI’ includes viral and pneumonia.
‡Among the patients with a pneumonia as determined by the majority of the expert panel, six patients were correctly 
reclassified as being at higher risk using the updated Feverkidstool instead of the original Feverkidstool and one 
patient was incorrectly reclassified. For patients in whom pneumonia was absent, these numbers are respectively 128 
and 50. Reclassification improvement was 17% for patients with pneumonia (6 minus 1 of 30) and 14% for patients 
without pneumonia (128 minus 50 of 561).
§Among the patients with other SBI as determined by the majority of the expert panel, six patients were correctly 
reclassified using the updated Feverkidstool instead of the original Feverkidstool and five patients were incorrectly 
reclassified. For patients in who other SBIs are absent, these numbers are respectively 281 and 25. Reclassification 
improvement was 2% for patients with other SBIs (6 minus 5 of total 66) and 49% for patients without other SBIs 
(281 minus 25 of 525).
SBI, serious bacterial infection.
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DISCUSSION
In this study, we showed that when a clinical prediction model including CRP was updated 
with a combined host-protein based assay, SBIs were predicted more accurately in children 
presenting with a lower RTI or FWS at the hospital. We showed that children with a low-to-
moderate predicted risk benefit most from this updated model.
Strengths and weaknesses of the study
A strength of the present study is the used combination of variables. To our knowledge, this 
is the first study combining clinical parameters with both bacterial and viral biomarkers. A 
second strength is the use of an expert panel reference standard, which has the advantage of 
capturing a wide spectrum of illness severities, including difficult to diagnose cases, thereby 
reflecting the diagnostic process in clinical practice.26 Another strength is the prospective 
patient recruitment. The ethics committees approved venous blood sampling even if blood 
sampling was not indicated for routine care. Therefore, a wide spectrum of illness severity was 
captured, including difficult to diagnose cases. In addition, a strength of the Feverkidstool 
is its polytomous character. This enables the discrimination between different diseases: 
pneumonia and other SBIs versus no SBIs.27 Finally, in clinical practice different thresholds 
are needed depending on the setting. Therefore we performed a DCA to help interpret 
the differences between the models along the wide range of predicted probabilities.20
Limitations of our study should also be addressed. First, the number of bacterial cases 
was relatively low. Therefore, it was not possible to refit the individual coefficients for all 
Feverkidstool variables. The aim of the current study was to see whether the new assay had 
additional value to the original well validated Feverkidstool rather than to build an optimal 
diagnostic model. Second, one of the Feverkidstool variables, capillary refill, was not available 
for any of the participants. Therefore, multiple imputation was impossible. Leaving capillary 
refill out by entering 0 for all capillary values would have resulted in an unfair reduction of 
model calibration. We think imputation of the mean was the best available option.24 Even 
though this may have limited the discriminative performance of the model, we believe the 
influence is limited, because the dichotomous variable capillary refill has little diagnostic 
value within the Feverkidstool. In addition, the aim of the current study was to compare 
the original Feverkidstool with the updated model. Imputation of capillary refill values was 
performed similarly for both models, so this had no influence on the comparisons of the 
models. Third, the reclassification is based on arbitrarily chosen thresholds (2.5% and 10%). 
These thresholds, however, mostly corresponds with LR that have been reported to be 
meaningful in decisions for febrile children: LR+ >5.0 for ruling-in SBIs and LR- <0.2 for 
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ruling-out SBIs.25 Fourth, the Feverkidstool includes important clinical variables that are 
used by every physician when deciding to start antibiotics or not. Following clinical care, 
during the expert panel reference standard process, the panel was provided with a wide 
range of clinical information, including the clinical Feverkidstool variables, but they were 
not informed about the algorithm. We, however, cannot exclude that incorporation bias - in 
which part of the test being assessed is included in the reference standard - has resulted in 
some degree of overestimation of the outcome. Fifth, due to the relatively low number of 
bacterial cases, some diseases, such as bacterial meningitis, were not observed in our study 
cohort. Information to discriminate sepsis from bacteraemia cases was not available. Sixth, 
in the current study, none of the ED patients were hospitalised at the intensive care unit. 
Further studies with higher numbers of patients with a more severe clinical presentation are 
warranted as especially in these patients early detection of SBI can be critical. Seventh, in 
this study we wanted to study the added value of the assay on top of the model that had 
also undergone impact analysis28 (ie, the original Feverkidstool (including CRP)), rather than 
developing a new model. As both the assay and the original Feverkidstool contain CRP, we 
had to solve this. Refitting the Feverkidstool’s model without CRP will not provide the answer 
to our research question on the added value of the assay to the Feverkidstool. In addition, 
the number of bacterial cases was too low to refit the original Feverkidstool. We also did 
not want to simply add the assay as a predictor in the Feverkidstool model, as this would 
downwardly bias the assay’s added value. Therefore, we essentially removed the effect of 
the CRF in the Feverkidstool by assigning the median value of CRP to the CRP single predictor 
in the Feverkidstool to all patients. To our knowledge, using the median CRP was the best 
possible approach to avoid double counting of CRP. Finally, there were 71 patients for whom 
the expert panel could not assign a final diagnosis. Such inconclusive cases are inherent to 
studies using outcomes lacking a gold standard. To make optimal use of the data from all 
recruited patients, we have imputed these reference standard diagnoses. As the imputed 
diagnoses are used for both the original and the updated Feverkidstool, we do not expect 
this influenced the results of updating the Feverkidstool. In addition, a sensitivity analysis 
in which all cases with imputed diagnoses were excluded showed comparable results.
Comparison with existing literature
The study in which the Feverkidstool was developed and the OPPORTUNITY Study had 
comparable inclusion criteria. Most importantly, both studies included children suspected 
of infection based on increased temperature.12,14 Differences in inclusion criteria should also 
be discussed. The Feverkidstool derivation cohort included Dutch children aged 1 month 
to 15 years, whereas the OPPORTUNITY Study included Dutch and Israeli children aged 1 
month to 5 years. In addition, for the Feverkidstool development study children who received 
3.4
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antibiotics before the ED visit were excluded; for the OPPORTUNITY Study antibiotic use was 
no exclusion criterion.12,14
We recently confirmed the external validity of the Feverkidstool, but when procalcitonin 
(PCT) was added to the prediction model or when CRP was replaced by PCT the accuracy for 
predicting SBIs in febrile children did not improve.11 Another study updated the Feverkidstool 
by adding PCT and resistin, resulting in minimal changes in LR+ and LR- for different risk 
thresholds.13 In contrast to the two above mentioned Feverkidstool updates, our current study 
has shown that updating the Feverkidstool with the assay does meaningfully improve the 
accuracy of the model. This further confirms our previous observation that the combination 
of CRP, TRAIL and IP-10 had higher diagnostic value in differentiating between bacterial and 
viral infections compared to PCT or CRP alone.14
Implications for clinical practice
Clinical signs and symptoms play an important role when physicians diagnose febrile children, 
but do not sufficiently differentiate between viral and bacterial infections. Therefore, the 
use of diagnostic prediction models that include both clinical parameters and biomarkers 
is intuitive and helpful. The Feverkidstool provides two risk percentages; the risk for having 
pneumonia and the risk for having other SBIs. After further validation, a digital calculator 
should be constructed to facilitate potential clinical use. Both the assay and the Feverkidstool 
are designed to predict the outcome ‘bacterial infection’, and not the general level of illness 
of the child. Therefore, the outcome can be used to guide decisions on starting antibiotics 
or not, but cannot be used to guide decisions on how to administrate antibiotics or what 
type. We showed that the updated Feverkidstool has most added value for patients in the 
low-moderate risk group, with predicted risk for SBI below 40%. At thresholds of 2.5% 
and 10%, the reclassification table showed substantial improvement in diagnosis. The cases 
with predicted risks between low to moderate (2.5 vs 40%) may be characterized by having 
intermediate values of CRP with higher diagnostic uncertainty. Adding two viral biomarkers 
to the prediction rule will provide an extra dimension to the model and therefore improves 
diagnosis especially for those cases. As a point-of-care test is under development, the 
manufacturer has not given an indication to the eventual cost yet. To optimize cost-effective 
use of the combination test, our results suggest that the added value of the assay is the 
highest in children with a predicted risk <40% as predicted by the original Feverkidstool. 
Utility studies are needed to determine the cut-off for the best clinical utility and cost-
effectiveness.
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Implications for future research
Since we have proven the accuracy of the updated Feverkidstool, the next step is to perform 
a prospective external validation, and to evaluate its impact on resource use and antibiotic 
treatment. An important aspect is to define risk cut-offs for different settings in clinical 
practice, for example, young children and children with comorbidities. In addition, in order to 
optimize resource use, new biomarkers may benefit selected patient subgroups in particular 
(eg, selected on a set of clinical characteristics/predicted risk) rather than in all febrile children. 
This targeted risk approach may also be applied to position the role of e.g. Myxovirus 
resistance protein A (MxA) and CRP.29
Conclusion
In conclusion, a new blood assay including viral and bacterial biomarkers, combined with 
a clinical prediction model, is in this study cohort, superior to the model with CRP only for 
predicting SBIs in preschool children. In children with low-to-moderate predicted risk of SBI 
in particular, the updated Feverkidstool with the assay has the potential to optimize targeted 
antibiotic prescription and to prevent unnecessary use of antibiotics.
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- Statistical analysis plan
- TRIPOD reporting guideline checklist
Figure 1. Flowchart of included patients
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Figure 2. Receiver operating characteristics (ROC) curve of sensitivity versus specificity for the original and updated 
Feverkidstool.
Area under the receiving operating curve (c-statistic) for the original and for the updated Feverkidstool for pneumonia 
and other SBI are shown in the figure. The c-statistic difference for pneumonia is 0.09 and 0.05 for other SBI. FKT: 
Feverkidstool, SBI: serious bacterial infection.
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Table 1. Characteristics of patients with and without reference standard
Clinical syndrome was based on the diagnosis of the attending physician at discharge from the hospital. LRTI included 
pneumonia and bronchiolitis; URTI included laryngitis, pharyngitis, otitis media, sinusitis and tonsillitis. Baseline 
characteristics of excluded patients are shown in the supplementary material. *p-values of differences between 
bacterial and viral infections.
Viral and bacterial 
reference standard 
diagnosis
(n=520)
Inconclusive reference 
standard diagnosis
(n=71) p-value
Predictor variables
Age (years), median (IQR) 1.2(0.6-2.4) 1.7(1.0-3.0) 0.01
Gender, male, n ( %) 289(56%) 42(59%) 0.61
Duration of fever (days), median (IQR) 2(1-4) 2(1-4) 0.80
Temperature (°C), median (IQR) 38.5(37.7-39.2) 38.6(37.8-39.3) 0.49
Respiratory rate, mean (SD) 42(16) 39(12) 0.35
 Tachypnea, n (%) 140(27%) 19(27%) 0.74
Heart rate, mean (SD) 152(24) 151(25) 0.92
Tachycardia, n(%) 248(48%) 34(48%) 0.77
Oxygen saturation %O2, median (IQR) 98(97-100) 98(96-100) 0.41
Desaturation, <94%O2, n ( %) 25(5%) 0(0%) 0.10
Chest wall retractions, n ( %) 67(13%) 3(4%) 0.045
Ill appearance, n ( %) 153(29%) 26(37%) 0.22
C-reactive protein (mg/l), median (IQR) 18(7-46) 53(18-83) <0.001
Assay score, median (IQR) 7(1-40) 35(5-88) <0.001
Other variables
Hospital admission n (%) 290(56%) 38(54%) 0.70
 Hospitalization duration (days),
 median (IQR)
3(2-4) 3(2-5) 0.08
Antibiotic treatment prescribed n (%) 180(35%) 53(75%) <0.001
Recruiting site 0.80
 Secondary care centre, n (%) 487(94%) 66(93%)
 Tertiary care centre, n (%) 33(6%) 5(7%)
Clinical syndrome 0.21
 Bacteraemia /viraemia 10(2%) 1(1%)
 Central nervous system 9(2%) 0(0%)
 Fever without source 164(32%) 16(23%)
 Gastro-enteritis 19(4%) 1(1%)
 Lower respiratory tract infection 127(24%) 17(24%)
 Upper respiratory tract infection 127(24%) 23(32%)
 Urinary tract infection 22(4%) 2(3%)
 Other 42(8%) 11(16%)
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Table 2. Sensitivity analysis of the cohort without imputed reference standard diagnoses
Presented data are c-statistics and 95% confidence intervals
Pneumonia Other SBIs
Original Feverkidstool 0.87(0.79-0.95) 0.82(0.76-0.88)
Updated Feverkidstool 0.91(0.83-0.98) 0.91(0.86-0.95)
Table 3. Description of recalibration of the Feverkidstool and the updated model
Linear predictors for pneumonia and other SBI Feverkidstool are calculated as defined previously [1]:
LP (pneumonia Feverkidstool) = -17.9 (Intercept) + 1.02 * Age (max 1 year, in years) + 0.01 * Age (if >1 year: age 
in years - 1)+ 0.13 * Sex (female) + 0.29 * Temperature (ºC) + 0.21 * Duration of fever (days) + 0.44 * Presence of 
tachypnoea - 0.04 * Presence of tachycardia + 1.59 * Oxygen saturation <94% - 0.18 * Capillary refill time (>3s) + 
0.47 * Presence of chest wall retractions + 0.16* ill appearance + 0.64 * Ln(CRP) (mg/l)
LP (other SBI Feverkidstool) = -4.7 (Intercept) -1.73 * Age (max 1 year, in years) + 0.11 * Age (if >1 year: age in 
years – 1)+ 0.70 * Sex (female) - 0.02 * Temperature (ºC) - 0.03 * Duration of fever (days) - 0.11 * Presence of 
tachypnoea - 0.02 * Presence of tachycardia - 3.29 * Oxygen saturation <94% + 0.30 * Capillary refill time (>3s) - 
3.78 * Presence of chest wall retractions + 0.27 * ill appearance + 1.14 * Ln(CRP) (mg/l)
where LP refers to the linear predictor in a (polytomous) logistic regression model.
We used the fixed intercept and coefficients within the original Feverkidstool, but used the outcome as a linear 
predictor in our logistic recalibration model and in the updated model. This resulted in the following (polytomous) 
logistic regression models:
Recalibration of original Feverkidstool:
LP1 = -0.58 + 1.28 (LP pneumonia Feverkidstool)
LP2 = -0.02 + 0.54 (LP other SBI Feverkidstool)
Updated Feverkidstool, including combination assay:
LP3 = -4.19 + 0.59 (LP pneumonia Feverkidstool, with median CRP for all patients)+ 0.05 (score Assay)
LP4 = -3.57 + 0.24 (LP other SBI Feverkidstool, with median CRP for all patients)+ 0.05 (score Assay)
Probabilities of the outcomes are calculated with:
Original Feverkidstool Risk (pneumonia) = eLP1/ (1 + eLP1 + eLP2)
Original Feverkidstool Risk (other SBI) = eLP2 / (1 + eLP1 + eLP2),
Updated Feverkidstool Risk (pneumonia) = eLP3 / (1 + eLP3 + eLP4)
Updated Feverkidstool Risk (other SBI) = eLP4 / (1 + eLP3 + eLP4), [2, 3]
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ABSTRACT
Objectives
First, to explore parents’ views on and experiences of managing their febrile child and to 
assess their behaviour and needs when in search of information about fever; second, to 
develop and evaluate a hospital discharge information package about fever in children.
Design
Mixed methods: (A) qualitative study with semistructured interviews and a focus group 
discussion (FGD) and (B) quantitative survey.
Setting
Emergency department, non-acute hospital setting and day nursery in Rotterdam, The 
Netherlands.
Participants
Parents of children <18 years (interviews, n=22), parents of children under 5 years (FGD 
(n=14), survey (n=38)).
Intervention
Information package about fever in children (leaflet and website including videos).
Outcome measures quantitative survey
Knowledge of fever and confidence in caring for a febrile child (Likert scale 0–5).
Results
Parents found fever mostly alarming, especially high fever. Help-seeking behaviour was 
based on either specific symptoms or on an undefined intuition. When parents did not feel 
recognized in their concern or felt criticised, anxiety increased as well as the threshold to 
seek healthcare for future illnesses. Information was needed, especially for situations when 
the general practitioner or social network were less easily available. This information should 
be reliable, consistent, available in multiple formats and include advice on management of 
fever at home and precise referral to medical services. Parents reported improved knowledge 
about fever (p<0.05) and mentioned improved confidence in caring for a child with fever at 
home after consulting the information package.
BNW_Josephine_v1.indd   188 19-Sep-20   14:52:02
189
Hospital discharge package for parents of a child with fever
Conclusion
Parents of children with a fever visiting the hospital are concerned about specific symptoms 
or based on an undefined intuition. Rather than telling parents that they should manage 
their child’s illness at home, healthcare professionals should recognize parental intuition and 
provide clear information on alarming signs and potential diagnoses to empower parents in 
the management of their febrile child.
INTRODUCTION
Fever in children is the most frequent reason for parents to seek medical attention.1,2 The 
majority of these children are under 5 years and have a self-limiting disease. In general 
practice, around 1% have a serious infection; in an emergency department (ED), this is 
5%–15%; the most frequent serious infection being pneumonia.3,4 However, the number of 
ED admissions continues to increase, mostly for minor illness not needing intervention.5,6
The current problem is twofold:
1. Parents are well capable of identifying their ill child by describing how their child’s illness 
differs from previous episodes (parental intuition or gut feeling).3 However, this parental 
concern is non-specific and also present in non-severe illness.7 Potential reasons might be 
a lack of knowledge about fever and anxiety about potential harmful consequences.8,9
2. At the same time, there are still children dying of serious infections due to errors or delays 
in diagnosis.10 As serious infections often cannot be distinguished from self-limiting 
disease at an early stage, it is important that parents recognise warning signs during the 
disease course.
In order to reduce unnecessary ED consultations for self-limiting disease, but also to prevent 
parents from missing a seriously ill child, parents need clear hospital discharge advice about 
managing their febrile child at home. For this advice to be effective, it should fit well with 
parent’s needs and worries.11 Even though studies have been done in general practice and 
in well-child clinics,12,13 knowledge on the necessary information about fever for parents 
visiting the ED is limited.
The aims of the study are to: (A) explore parents‘ views on, and experiences of, managing 
their febrile child; (B) to assess their behaviour and needs when in search of information 
about fever; and (C) to develop and evaluate a hospital discharge information package about 
fever in children.
4.1
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METHODS
Study design
This was a two stage project, using exploratory theory building methods for stage 1 
(development), followed by an intervention and evaluation for feasibility and piloting in 
stage 2. This methodology follows the Medical Research Council (MRC) framework for 
development and evaluation of complex interventions.14
Development
A qualitative design was used to explore parents’ views on, and experiences of, fever in 
children through the use of semistructured interviews. Based on these findings, we developed 
an information package, consisting of a leaflet (online supplementary file 1) and a website 
(www.sehzorg.nl/koortskinderen (in Dutch)), both of which included a traffic light system 
to help parents identify the risk of serious illness after hospital discharge. The website also 
contained informative videos about fever and pneumonia in general and videos illustrating 
warning and safety signs in febrile children.
Feasibility and piloting
The complete information package was evaluated to assess its feasibility during a focus group 
discussion (FGD) with parents of children under 5 years. Emerging themes that arose during 
the development phase were also further explored in the FGD. In addition, a quantitative 
survey was used to evaluate the information package in a pilot in the acute and non-acute 
setting.
Sampling and recruitment
Development
We recruited a purposive sample of parents of children under 16 years for the interviews, 
both in an acute setting (at the ED) and in a non-acute setting (outpatient department 
or ward), to obtain maximum variation within the sample. All interview participants were 
recruited in the Erasmus Medical Centre – Sophia Children’s Hospital (EMC-Sophia) and 
the Maasstad Hospital, Rotterdam, until a point of data saturation was reached. Out of 29 
eligible parents, 22 agreed to participate; seven refused for various reasons (no interest or 
time and language barrier).
Feasibility and piloting
We recruited parents of children under 5 years for the FGD through an open invitation at 
day nurseries (digitally and by posters on location) in the Rotterdam area, through social 
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media of patient organization Kind en Ziekenhuis (K&Z) and EMC-Sophia, and an article in 
a regional newspaper.15 Participants for the quantitative survey were recruited at the ED of 
the EMC-Sophia, through day nurseries and by open invitation on the information website 
between July and October 2017.
Research team
The core research team (all female) consisted of an MD/PhD student in paediatrics (JvdM), 
medical students (DvK and AdH) and a consultant in paediatrics (RO (MD, PhD)). JvdM was 
trained in qualitative methodology and we shared expertise with an international expert 
in this research area and methods (ML (MD, PhD)) and with a social scientist from patient 
organisation K&Z (ES-C).
Data collection
Development
DvK conducted the semistructured interviews between November 2016 and February 2017 
in a hospital room with only the researcher and the participant, using a flexible interview 
guide (online supplementary file 2). All interviews were audio recorded. The relatively short 
duration of 15 minutes generated sufficient information and facilitated participation, since 
they took place during waiting time in the hospital.
Feasibility and piloting
The FGD was held in February 2017 at an inner city nursery near the EMC-Sophia. We 
chose this setting as a more neutral and more natural environment for parents than a 
medical setting in order to promote open and rich conversation and to reduce the risk of 
social desirability bias. ES-C and JvdM led the FGD, using a discussion guide including open 
questions and example cases (online supplementary file 3). RO and DvK had an observer’s 
role and interacted occasionally if needed. The FGD was audiorecorded and lasted 2 hours. 
For the quantitative evaluation, we used a survey with questions on: (1) knowledge about 
fever in children and about caring for a febrile child at home (questions 1–3) and about 
parents’ confidence in their ability to provide adequate care for a febrile child and in their 
ability to seek medical attention (questions 4–6), referring to the situation before and after 
consulting the information package.16 In addition, questions were asked about clarity and 
layout of the information package (online supplementary file 4). Demographic information 
was collected from all participants.
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Data analysis
All interviews and the FGD were transcribed verbatim by DvK, including non-verbal 
information. An interim analysis of 14 interviews guided further exploration of the emerging 
themes in subsequent interviews. Thematic content analysis was used for all interviews 
and the FGD, using the qualitative software package Atlas.ti (V.7.5.7.).17,18 First, the fully 
transcribed interview/FGD was read in detail, then meaning units were defined and coded. 
Initial themes were combined into overarching themes, containing subthemes reflecting 
their components (figure 1). A pilot of three transcribed interviews and the complete FGD 
were coded by two authors independently (DvK and JvdM) and final codes and themes 
agreed on. The scores on the Likert scale of the quantitative survey were coded from 0 to 
5, mean scores were calculated and differences in pre-exposure and post-exposure scores 
were analysed using a paired sample t-test. Statistical code and dataset of the quantitative 
survey are available as online online supplementary files.
Figure 1. Coding process
Ethics
Written informed consent for the interviews and FGD was obtained from all participants.
Patient and Public Involvement
This study was performed in close collaboration with ‘Kind en Ziekenhuis’, a patient 
organization for children in hospitals, representing the patient’s perspective in study 
design, protocol development and conduction of the study. We developed and updated the 
intervention based on parent’s views and needs, as described in this paper. The intervention 
is publicly available to all end-users.
RESULTS
Participants
A total of 22 semistructured interviews were performed, half in acute setting and half 
in a non-acute setting (6 men, 16 women). Fourteen women participated in the FGD (13 
mothers, 1 aunt). The survey included 38 parents. Baseline characteristics of all participants 
are presented in table 1. Overall, most participants were female, with a median age between 
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33 and 35 years. The participants of the FGD were all female, had less children and younger 
children than the other participants. There were no differences between participants in 
the acute or non-acute setting of the interviews and survey, in terms of gender, age and 
number of children.
Table 1. Participant characteristics
Semistructured 
interviews (n = 22)
Focus group 
discussion (n = 14)
Survey study
(n = 38)
n (%) n (%) n (%)
Acute setting (ED) 11 (50) 0 10 (26)
Non-acute setting 11 (50) 14 (100) 28 (74)
Frequency of hospital consultation
<5 times 16 (73) na na
>5 times 6 (27) na na
Has chronically ill child 4 (18) 1 (7)) na
Female 16 (73) 14 (100) 35 (92)
Median age in years (range) 35 (19-48) 33 (26-42) 34 (26 - 52)
Median number of children (range) 2 ((1-6) 1 ( 0-3)* 2 (1-6)
Median age of children in years (range) 6 (0-22) 2 (0-9) category: 2 - 5
Highest education
Primary or secondary school 3 (14) 1 (7)
Community college / Intermediate vocational 
education 11 (50)
4 (29)
6 (60)†
College or University 8 (36) 9 (64) 4 (40)†
Occupation
Full time working 8 (36) 6 (43) na
Part time working 8 (36) 7 (50) na
Housewife/houseman 6 (27) 1 (7) na
Country of birth
Netherlands 19 (86) 13 (93) 5 (50)†
Other‡ 3 (14) 1 (7) 5 (50)†
Country of birth parents
Netherlands 13 (59) 11 (79) na
Netherlands - other‡ 0 2 (14) na
Other - other‡ 9 (41) 1 (7)
Median understanding Dutch language 
(scale 0 - 10, range) § 10 (6-10) 10 (8-10) 10 (8 - 10)†
* 1 participant came with sister (present as an aunt)
† only available for participants in acute setting (n=10)
‡ including: Morocco, Suriname, Turkey, Cape Verde, Pakistan, Poland, Indonesia, Italy
§ 0 = no understanding of Dutch language, 10 = excellent understanding of Dutch language
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Development phase
The interviews and FGD results can be divided into three main content areas: (A) views on 
fever and its treatment, (B) experiences of managing a child with a fever and (C) information 
seeking. Codes and (sub)themes are reported in online online supplementary file 5.
Views on fever and its treatment
Views on (causes of) fever
Most parents believed fever is caused by an infection. Parents with higher levels of education 
mainly mentioned viruses or bacteria as a cause of infection; those with less formal education 
were less likely to report the exact cause. Many parents recognized fever as a natural defence 
mechanism of the body, but it was perceived as both reassuring and alarming: “there’s a 
bacterium in the body that doesn’t belong there and by means of fever, you know, your 
body tries to destroy the bacterium. (…) But well, if it’s getting too high, you know… I’ve 
heard stories like: when it’s getting higher than 40, then it’s going to be dangerous.“ (father, 
three children, 5–10 years).
Views on paracetamol and antibiotics
Although with different views, most parents considered paracetamol safe to lower the 
temperature and relieve discomfort for the child. One mother was worried about its 
effectiveness when used too often: “A slightly increased temperature… you can also give 
it too soon, I’m talking about high fever. (…) Otherwise they don’t work anymore later on” 
(mother, two children, 4-6 years).
Parents had different views on antibiotics, often depending on their own experiences. 
Most parents mentioned it was indicated ‘only when really needed’, but with different 
explanations. “I think it’s a last choice, like: there’s nothing else, so let’s go for antibiotics.” 
(mother, 1 child, 2 years); “You [the doctor at the ED] saw his ears, I came urgently by 
ambulance because he had a febrile fit. Then at least you can give antibiotics!” (mother, 3 
children, 1–10 years). Two parents mentioned fear for resistance: “At a certain time your 
body just becomes resistant, so if you just keep on taking it…”(mother, three children, 1–14 
years). One parent thought doctors were too conservative in prescribing antibiotics: “The 
whole attitude of waiting too long with antibiotics, I don’t agree with that at all. Not to 
stuff them with antibiotics immediately, but I think nowadays it is too restrained..” (mother, 
two children, 4–5years).
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Experiences of managing a child with a fever
Management of fever at home
Parents mentioned being more alert once they knew their child had a fever: paying extra 
attention to the child and looking for accompanying symptoms. Most parents try to lower 
the temperature with paracetamol, but homeopathic medicines were also mentioned, and 
removal of clothes, cold showers or cold wipes. Parents used paracetamol in various ways: 
(A) waiting for signs that the child is unwell, “I almost never give paracetamol. Because I 
think: the body has to do it on its own and only if they develop such things as pain… But 9 
times out of 10 it just resolves by itself.“ (mother, three children, 2–9 years); (B) as soon as 
there is a fever, “Yes, I give paracetamol when there is fever. And then every 6 hours. I try 
to avoid peaks to help her hopefully a bit.” (mother, one child, 9 months); or (C) based on 
the child’s preference “We use those suppository things, but he hates them anyway, so..” 
(father, two children, 4–6 years).
Help-seeking decisions
Parents decided upon seeking medical attention based on their instincts, often difficult to 
specify: “It’s just a feeling. I couldn’t say: one time the fever is less but he looks more ill, 
while another time he has 39.5 but alert. It is very much just a feeling” (mother, FGD). “It 
is a sort of gut feeling, you really feel when your child is ill. (…) I cannot describe what it is, 
but I know there’s something wrong. And then you just want someone to look at him and 
be reassured” (mother, FGD). Specific reasons to be alarmed and seek medical attention 
were young age (not able to express themselves), high fever, long duration of fever and 
accompanying symptoms like reduced appetite or drowsiness.
Learning about (managing) fever
Many parents mentioned their experience with illness in previous children or in their social 
background and network as a motivation for their behaviour. “It is out of experience and it 
depends on your personal situation. What family you’re from, what social network you have, 
if you have any friends… Parents from school whom you can ask questions…” (mother, five 
children, 1–8 years). Especially during the FGD the role of experience was prominent, and 
how it can affect behaviour. One mother: “My children have fever very often (…), but at a 
certain moment you get used to it. You think: I know a paracetamol works in my children, 
so I give it to him. (…). They have fever so often, it doesn’t surprise me anymore.” Most 
parents recognized this. But another mother on this topic: “sometimes I wait longer with 
the second child, but then he appears to have a pneumonia and then I think: I should have 
gone earlier”. And a mother with a first child suffering from febrile fits: “Febrile fits run in 
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families, so when I would have a second child with fever, I would be extra stressed out. But 
that depends on what you’re used to.”
Experiences with healthcare
Parental concern or instinct was often not recognised by healthcare professionals. “When 
your mother feeling says: hey, something is wrong here. Then it is frustrating when a doctor 
says: no, there’s nothing wrong.” (mother, FGD). Several parents described that when doctors 
say ‘it’s just a fever’, they give parents the feeling they are not listened to or that they should 
not have come. “As soon as you call the GP, they say: ‘yes, but fever is normal for a child’. 
Then I think: you don’t even listen to my story (…), first listen to what I have to say, because 
I don’t only call because he has a fever!” (mother, three children, 5–10 years).
In cases of self-limiting disease, some parents said they would be more reassured when the 
doctor explained which (possibly severe) diseases were excluded, instead of only getting the 
diagnosis ‘another virus’. These negative experiences increased the threshold for seeking 
help in the future. “Then I thought: yes, but when I call, I will be told ‘yes mam, the flu is 
around’. So I didn’t call.” (mother, FGD). Most parents had a good relationship with their 
own general practitioner and felt no threshold for contacting the GP, but there was a high 
threshold for contacting the out-of-hours services. “He [own GP] takes my child very seriously. 
(…) The first time he had fever (…) I thought: he is going to die! But the GP always says: it 
doesn’t matter, if you are worried: call” (mother, FGD). “I find it always a bad experience(…).
To go to my own GP, my experience is: hey, he will come, he knows my child. But as soon 
as you go to the out-of-hours services it becomes difficult. There you have to struggle for 
an appointment.” (father, two children, 7–8 years).
Information seeking
Information needs
Parents expressed their need for information about fever in children, especially before 
deciding to seek medical attention. “For example in the weekend you cannot call the GP 
and you don’t call the out-of-hours service when it’s not severe. So then I look it up myself” 
(mother, one child, 4 years). When asked when they need information: “Especially on Saturday 
or Sunday, who should you call? Then I think: I won’t call 112 [European emergency number], 
that’s nonsense. Out-of-hours service maybe, but I find that also difficult. Then there is 
nobody, besides family, whom you can call” (mother, FGD).
Some parents wanted more background information on fever, but most parents emphasized 
the need for clear instructions about what they can and should do at home. “Often they only 
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look at dehydration, but I would want to know if she can get something against the cold 
and the cough.” (mother, three children, 2–9 years); “It has to state very clearly: where do 
you go? First to the out-of-hours GP service, or to the emergency department (…)?” (father, 
two children, 2–5 years).
Information sources
Parents reported that the internet was the most commonly used source of information at 
home, but mentioned lack of consistency and reliability as its pitfalls. “I always google, but 
that is not always helpful, because of course you also see very contradictory things” (mother, 
three children, 1–14 years). Parents also ask for advice in their social network, like family or 
peer parents. “Parents from school where you can ask things, like ‘my child has this, did you 
experience that once?’ You know, a network surrounding you matters a lot”. (mother, five 
children, 1–8 years).
Information delivery preferences
Parents preferred multiple different formats of information: verbal and/or written, on paper 
and/or online. Most parents preferred verbal information given by a doctor, given the 
possibility to ask questions. “I prefer verbal information. If I don’t understand something, 
I can ask for clarification.” (mother, three children, 1–10 years). Online information should 
be clearly reliable. “Mostly the information is at those general websites, where you’re 
overwhelmed with information. I would like the information to be linked to for example a 
hospital.” (mother, three children, 7 weeks–5 years).
Leaflets could be reread but are often not at hand in the acute situation; written information 
should also be available digitally, and audio-visual material could be supportive in addition 
to other means. “I think a combination of verbal and written information is best. You read 
something, but you want it to be confirmed by someone who has professional knowledge. 
(…) Or maybe with some video support or so” (father, two children, 7 years).
Feasibility and piloting
Based on the parents’ needs and preferences that we discovered during the development 
phase and based on the literature, a concept hospital discharge information package 
was developed: a leaflet (online supplementary file 1) and a website (www.sehzorg.nl/
koortskinderen), including a traffic light system for identifying the risk of serious illness. 
The website also included informative videos about signs and symptoms (www.sehzorg.nl/
koortskinderen).
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Qualitative evaluation
The parents in the FGD judged this concept package to be clear and comprehensive. They 
particularly appreciated the traffic light system, that included clear instructions about to the 
severity of symptoms. However, some parents said that reading the alarming signs could raise 
their anxiety, a feeling not shared by all parents. Also they expressed the need for a clear 
statement that whenever they are worried they should be allowed to contact a healthcare 
professional. The videos of clinical signs and symptoms were judged to be very informative, 
especially for less experienced parents. Still, they expressed the need for clear instructions 
concerning what to do when they identified the displayed symptoms in their child. During 
the FGD some parents raised their concerns about febrile fits. Even though this concern was 
new for some parents, all of them agreed they needed information on this issue. For this 
reason, this was added to the package.
Parents found the combination of the written information, videos and traffic light system 
most helpful. “I just think the combination is great. That there are videos and this leaflet. 
Because I know for example what retractions are, because I’ve seen it at work, but not 
everyone knows it. So I think it is good to see it. And with the leaflet to decide whether to 
do something or not.” (mother, one child, 9 weeks).
Parents said they would be more confident in caring for their children after having read and 
seen the information. Also it would empower them in contacting a healthcare professional, 
as they could support their intuitive worry by mentioning specific signs and symptoms. “It 
makes a clearer impression [on the GP]: ‘I looked, she’s drinking less, blabla’, then you know 
these are important things to pay attention to.” (mother, FGD).
Parents recommended that the information should be available in the waiting rooms of 
general practice, postnatal clinics and on social media.
Quantitative evaluation
Parents valued the information leaflet as well as the website with videos. Parents valued 
the information leaflet as well as the website with videos. Mean scores on all items of self-
reported knowledge and confidence before and after the information package are presented 
in figure 2. We observed an increase in both areas of the survey: knowledge about caring 
for a child with a fever (4.1–4.5 out of 5), and confidence in caring for a child with a fever at 
home (4.1–4.3) and in help-seeking (4.4–4.5), with significance on the area of knowledge 
(p<0.05).
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Parents gave high scores for layout, comprehensibility of the language, clarity of the message 
and usefulness of the package (median score 5 out of 5 (IQR 4–5)).
Figure 2. Knowledge and confidence before and after consulting the information package
Thematic summary
Summarizing our results, we observed that the ability of parents to care for a child with a fever 
after hospital discharge is influenced by many factors, as visualized in figure 3. These factors 
can be healthcare related or parent related, but have either an empowering or disabling 
influence on the parent’s ability to care for their child independently. Some factors have a 
direct influence on parents’ behaviour; other influences are more complex. For example, if 
a doctor dismisses parents’ concerns by saying ‘it is nothing’ (while meaning that parents 
can manage this level of illness without seeking help), parents perceive this as criticism that 
doctors do not consider that the illness warrants medical attention. This perceived criticism 
increases the barrier for the parent to seek medical attention in the future.
4.1
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Figure 3. Positive and negative factors influencing parental ability to manage their febrile child
ED, emergency department
DISCUSSION
Main findings
Our observations in a population of parents of febrile children after hospital discharge 
suggest that parents in The Netherlands are concerned when their child has a fever, especially 
when there is a high fever. Paracetamol is perceived as a safe way to treat fever and is used 
in different ways. Parents preferably do not want antibiotics for their child, as they consider 
that they should be used ‘only when really necessary’, although the explanation of ‘necessary’ 
varies. Help-seeking behaviour was often based on an inexplicable parental intuition that 
‘something is wrong with the child’, a need for reassurance, or on the presence of specific 
symptoms like long duration of fever, reduced appetite or drowsiness. Parents often do not 
feel as though they are taken seriously in their intuition or worry by healthcare professionals, 
and experience a high threshold for contacting healthcare during out-of-hours services.
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Interpretation of findings and comparison to the literature
Even though fever was often seen as alarming, we did not find signs of ‘fever phobia’ and 
overtreatment of fever as has been described in other studies.8,9,19,20
Kai described earlier that help-seeking behaviour is related to the balance between perceived 
threat of the illness and personal control.21 Also others noted that the ability of parents to 
manage a child’s illness is influenced by many factors, like experience, social circumstances 
and expectations, and their own knowledge and health.12,22 A recent review also described 
the importance of attitudes, beliefs and perceived control on the actual behaviour of seeking 
healthcare 23. These dynamics are in line with our results as reflected by the balance we 
presented in Figure 3.
Once parents feel the need to seek healthcare, they often describe this as an intuition, 
which may reflect Van den Bruel’s findings, where parents described their gut feeling as 
‘something is different than usual’.24 However, this felt need for help by parents is not 
always seen as an ‘appropriate’ reason to visit the ED from a healthcare perspective. Ehrich 
described that not being aware of different meanings and viewpoints of ‘appropriateness’ 
of a medical consultation can lead to misunderstanding between doctors and parents.25 This 
might partly explain the mismatch we observed between parents ‘knowing something is 
wrong’ and doctors ‘saying nothing is wrong’ with the child. We observed that when there 
is a good relationship with the doctor, he ‘knows the child’ and when parental intuition is 
taken seriously, parents feel reassured after consultation. However, when they feel criticised, 
or when the diagnostic process is not explained well, this may increase anxiety and increase 
the threshold for seeking healthcare in the future (figure 3), as also described by others.26
Weekends or evenings shifts with limited access to the child’s own GP or their social network 
may be most sensitive to high thresholds for contacting the out-of-hours services, and 
at these moments there is a high need for information. Essential information would be 
practical advice about management of a child with a fever at home, and information about 
when to seek medical attention and where. Parents prefer information given by healthcare 
professionals, in addition to clear information in multiple different formats. These findings 
are consistent with other studies, concluding that parents’ need to be reassured by receiving 
reliable, consistent information about fever and symptoms.12,13,27 The role of leaflets in 
improving patient satisfaction after consultation has been reported in general practice.28,29 
The need for verbal explanation, supported by written and visual cues, has been reported 
to be most successful.30
4.1
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Our information package including a traffic light system with instructions for management 
at home was deduced from the traffic light system of the NICE guideline and appreciated 
by the parents.1 This system has been used before in information about respiratory tract 
infections and has proven its added value in informing parents.31
This study was mainly focused on the ED setting, thereby complementary to studies that have 
been performed in the setting of primary or preventive care. There are several differences 
between the GP setting and hospital setting, like the a priori risk of serious infection, the 
diagnostic value of clinical signs and symptoms,32 the clinical experience in assessing young 
children and the diagnostic process. From a parent’s perspective, visiting the ED is usually a 
stressful experience, and they mostly encounter a doctor whom they do not know. These 
factors emphasize even more the importance of ED healthcare professionals winning parent’s 
trust by taking their concern seriously, clearly explain the diagnostic process and giving 
information that can be re-consulted after the ED visit.33
Strengths and limitations
The qualitative approach provided the opportunity to explore parents’ views and needs in 
depth and to gain a better understanding of their help and information seeking behaviour. 
Through the use of triangulation of methods (interviews and FGD) and due to the flexible 
design, there was room for exploration of important themes in an open and profound way. 
Additional to the interviews that were well suited for exploring experiences and ideas of 
individual parents, the FGD enriched the data through the responses and interaction within a 
group.34,35 An asset is the diversity of the participants, in terms of age, education, experience 
(interviews and FGD) and cultural background (interviews). A limitation is that almost all 
participants were fluent in Dutch reading and writing, limiting the applicability of our 
conclusions to parents with language-barrier or low literacy in our country or generalisation 
to international settings. A further limitation is that all participants of the FGD were women, 
a consequence of the open invitation method. However, since women are mostly the primary 
caregivers in The Netherlands,36 we believe they provided rich information on help-seeking 
decisions. The open invitation method ensured motivated participants who were involved in 
the topic and could contribute to the study. To reduce the effect of a possibly intimidating 
hospital setting, we chose to conduct the FGD in a day nursery. Given the lively and open 
conversations and the fact that also negative experiences with healthcare professionals 
were shared, the influence of the medical background of the researchers seems limited. 
Our quantitative survey was limited in sample size. Also, the difference in knowledge and 
confidence before and after the information package was self-reported by parents, which 
has limitations.
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Implications for clinical practice and future research
The presented positive healthcare factors from figure 3 should be implemented in clinical 
practice, in order to empower parents in their capacity to care for a febrile child and to 
support parents when they are making decisions about seeking help for their child. For 
healthcare providers it is essential to build a non-judgmental relationship with parents, so 
that they feel that they are taken seriously. Recognizing parental concern and being open 
about the diagnostic process (eg, explaining which potentially serious infections are excluded) 
could add to this. Clear hospital discharge instructions should be supported by information 
material that can be consulted at home. These recommendations require education of 
healthcare professionals and the availability of professional and clear information packages. 
Future research should continue to evaluate and improve information material and assess 
its impact. Standardized measurement tools should be developed to measure the impact of 
the information package on healthcare and on parent’s knowledge, skills and confidence. 
The different ideas and needs of subgroups needs further assessment, for example migrant 
communities and those with limited literacy. All research should be conducted in collaboration 
with parents and healthcare professionals.
Conclusion
Parents of children with a fever visiting the ED are concerned about specific symptoms like 
long duration of fever or reduced appetite of the child, or their parental intuition says that 
‘something is wrong with the child’. When they perceive that their concern is not taken 
seriously by healthcare professionals, they feel criticised and this experience increases the 
threshold for future help-seeking. Rather than telling parents that they should manage 
their child’s illness at home, healthcare professionals should recognize parental intuition 
and provide clear and reliable information about alarming signs, considered or excluded 
diagnoses, the management of fever and about available medical services. This information 
is needed in multiple formats, especially for moments when the doctor or social network 
are less available for advice. A broad information package (leaflet and website including 
videos) was produced in collaboration with parents and was found to increase parents’ 
perceived knowledge about fever and improve their perceived confidence in caring for a 
child with fever.
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Supplementary file 5. List of codes and categories
Content area a) and b): Views on, and experiences with managing a child with fever
Theme Subtheme
· Code
Views on fever Causes of fever
· Bacteria or viruses cause fever
· Reaction of the body
· Infection
Fever has a function, but ...
· High fever is alarming
· Long duration of fever is alarming
· Accompanying symptoms alarm
Paying extra attention to the child
· Changed behaviour is alarming
· Drinking must be good
· Urinating must be good
Management of a febrile child Mixed thoughts about paracetamol
· Should always be given in case of fever
· Only needed when the child suffers
· It supresses the function of the fever
Methods to lower the temperature
· Using paracetamol
· Using homeopathic medicine
· Undressing the child
· Giving a cold shower/cold wipes
Thoughts about antibiotics Only when really necessary
· Fear of resistance of the body
· Trust in function of the body
· Needed in specific situations
· It depends on the doctor
Help-seeking behaviour Age of child is important
· Babies aren’t able to express themselves
Role of experience
· Experience with earlier episodes
· Having multiple children
· Social network
Trust in parental intuition
· Taking decisions on intuition
Circumstances of fever
· Long duration of fever
· High fever
· Fever in combination with other symptoms
Insecurity about timing and options
· Child always ill at Fridaynight
· When and who to call?
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Thoughts about health care Feeling reassured after consultation
· Trust in doctor
· I have done everything needed
Feeling not to be taken seriously
· Doctors don’t really listen
· Child doesn’t get a diagnosis
Threshold to seek medical help during out of hours service
· Good doctor-patient relationship with GP
· Fear of rejection
· Child always ill at Fridaynight
Content area c): Information seeking
Theme Subtheme
· Code
Source of searched information Internet as most common resource to...
· Look up the symptoms
· Search where to go for medical help
· Search when to seek medical help
· Read experience from other parents
Asking for advice to surroundings
· Management of the ill child
· Possible diagnosis
Appreciation of searched information Internet is as easily accessible but not always helpful
· Too much information
· Too general information
· Increases anxiety and concerns
· Contains inconsistent information
Leaflets are not easy to reread
· Not easy to find when really needed
Delivery of needed information Prefer a doctor
· Possibility to ask questions
· More personal
Internet is easy but confusing
· Before calling the doctor
Written material with audiovisual support
· Reading information most preferred
· Videos and pictures for better understanding
Content of needed information Needing guidance in care for the child
· Illness management
· Referral to appropriate services
· Timing to seek medical attention
Needing information about children’s illness
Quality criteria of needed information Reliability of information
· Professional endorsement
Consistent information
Easy accessibility of information
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In this chapter, we will summarize and discuss the main findings of this thesis on decision-
making in childhood pneumonia in the ED. In chapter 5.1, we will summarize what the 
knowledge gaps were before this thesis, and what this thesis adds. How these topics fit in 
care pathway of the paediatric ED is depicted in Figure 1. Chapter 5.2 will discuss several 
overarching themes of the thesis in more detail: a) the relevance of studies on practice 
variability; and b) methodological and practical issues related to the application of prediction 
models in clinical practice. In chapter 5.3 we look at future perspectives of diagnostic and 
treatment decisions for childhood pneumonia in the ED.
Figure 1. Knowledge gaps and thesis chapters (between brackets) along the care pathway of the paediatric ED
5.1 Summary of main findings
Knowledge gaps before this thesis
Variability in management of childhood pneumonia in the emergency department
A major challenge in the management of children with fever and respiratory tract infections 
(RTIs) is to identify those with serious bacterial infections that need antibiotic treatment, 
among the majority with self-limiting illness. The NICE guideline for the assessment of febrile 
children recommends to look for warning signs for serious illness, including the routine 
measurement of four vital signs (temperature, heart rate, respiratory rate and capillary refill), 
but adherence to this recommendation in routine practice is unknown (gap 1). Chest X-rays 
have limited reliability for this bacterial pneumonia, and current international guidelines 
recommend against routine use of these X-rays in children with an uncomplicated pneumonia 
presentation. Little is known about how chest X-rays are currently used in treatment decisions 
of children with suspected lower RTIs in the ED (gap 2). In the absence of a gold standard for 
bacterial pneumonia, practice variation in the management of children with fever and RTIs 
has been described in various settings.1,2 However, recent data on antibiotic prescription for 
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children European EDs are lacking, as is insight in the determinants of variability in antibiotic 
prescription for RTIs (gap 3).
Supporting treatment decisions for childhood pneumonia
Clinical prediction models for childhood pneumonia exist, but none of them is well 
implemented in clinical practice. It is unclear if these prediction models – that are mostly 
developed with chest X-ray as their reference standard – can be used to guide antibiotic 
treatment decisions (gap 4). The Feverkidstool is a clinical prediction model combining 
clinical characteristics and c-reactive protein (CRP). This model has been validated in different 
settings, but has not yet been used as a decision rule to guide antibiotic prescription. It is 
unknown how such a decision rule would impact antibiotic prescription rates in clinical 
practice, whether this approach would be safe and what the cost implications would be (gaps 
5, 6). Next to CRP, new biomarkers have been developed with better diagnostic accuracy for 
viral versus bacterial infections, for example the ImmunoXpert. This is a host-protein based 
assay, combining tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon 
gamma induced protein-10 (IP-10), and CRP. Use of the ImmunoXpert instead of CRP in 
the Feverkidstool may improve the diagnosis of bacterial infections in children (gap 7).
Supporting parents’ decisions for their child with a fever
In the period preceding the ED visit, and after ED discharge, parents are the key decision-
makers for their child with fever. Clear discharge information is vital to support parents in 
managing their sick child at home. For this information to be effective, knowledge about 
parents’ views on fever and their needs for information after the ED visit is crucial, but 
information on these topics is currently limited (gap 8).
What this thesis adds
In a national and a European population of children visiting the ED we observed large practice 
variation in the management of children with fever and RTIs. In chapter 2.1 we showed that 
most European hospitals have adopted the NICE guideline recommendation to measure vital 
signs in all febrile children under five, but that adherence to this recommendation in routine 
practice was only moderate. The frequency of measuring vital signs differed across hospitals, 
and was higher in younger children, those with RTIs and those with a higher triage acuity 
level. In chapter 2.2 we observed that in the Dutch ED setting, in 18% of children with fever 
and respiratory symptoms a chest X-ray was performed. Regardless of the result of the X-ray, 
the decision to perform a chest X-ray independently increased the likelihood of antibiotic 
prescription. In chapter 2.3 we showed that RTIs are the most common reason of antibiotic 
prescription in European EDs, due to their high prevalence. Antibiotic prescription was also 
5
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most variable for this diagnosis, which could not be explained by patient characteristics, 
diagnostic workup or hospital characteristics.
In chapter 3.1 we showed that three out of seven existing clinical prediction models for 
childhood pneumonia were associated with a consensus diagnosis of bacterial versus viral 
infection, identifying those children in need for antibiotics. These models could identify 
children at low risk of bacterial pneumonia, having the potential to guide antibiotic treatment 
decisions. In chapter 3.2 we present the results of a stepped wedge cluster randomized trial, 
where we implemented the Feverkidstool as a decision rule to guide antibiotic prescription in 
eight EDs in The Netherlands. The decision rule did not reduce overall antibiotic prescription, 
but was non-inferior to usual care. We observed a reduction of strategy failures and of 
antibiotic prescriptions in children with a low/intermediate risk for pneumonia, suggesting 
improved targeting of antibiotics by the decision rule. In addition, chapter 3.3 shows that use 
of the decision rule was cost-saving from a healthcare and societal perspective, due to less 
frequent and shorter hospitalizations, and fewer lost parental workdays. In the chapter 3.4 
we updated the Feverkidstool by replacing CRP with the combination assay ImmunoXpert in 
a population of children under five with lower RTIs or fever without source, using an expert 
panel as the reference standard for defining pneumonia and other bacterial infections. This 
resulted in improved diagnostic accuracy, especially in a subgroup of children with a low/
intermediate predicted risk of bacterial infection.
Chapter 4.1 deals with the last step in the chain of care for febrile children in the ED. We developed a 
hospital discharge information package, based on qualitative data from parents of young children. 
Parents were concerned about their febrile child either based on specific symptoms of the child 
or based on an undefined parental intuition. Parents reported improved knowledge about fever 
and more confidence in caring for a febrile child after consulting the information package.
5.2. General discussion
Variability studies informing policy and future research
It has since long been recognized that studies on variability in care are important to improve 
quality and resource use in healthcare.3,4 Even though variability itself does not prove high 
or low quality of care, observed practice variation can often only partly be explained by 
differences in population and epidemiology.3,5 This was confirmed by our variability studies 
(chapters 2.1 – 2.3), where we evaluated three important aspects of fever management in 
children: measurement of vital signs, use of chest X-rays and antibiotic prescription. For 
example, our analysis on antibiotic prescription in Europe (chapter 2.3) showed that even 
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after extensive adjustments for population and setting characteristics, substantial variability 
in prescription for RTIs across EDs remained. What can we learn from our variability studies 
about the management of fever in children in the ED?
First, they provide information on the extent and background of a problem and can thereby 
guide interventions to improve paediatric emergency care. We collected data prospectively 
and in a uniform manner, making comparisons across hospitals and countries possible. For 
all three areas that we studied, we observed that practice variability was driven by patient 
characteristics and disease severity, but also by setting (hospital or country). However, the 
potential reasons for this variability, and thereby the clinical implications, may be different. 
Regarding the measurement of vital signs, the NICE guideline advice was very clear and 
specific: ‘measure temperature, heart rate, respiratory rate and capillary refill in all febrile 
children under five’.6 However, high-quality evidence for the predictive ability of these four 
vital signs to identify serious illness is lacking.6,7 Therefore, the observed practice variation 
may indicate poor implementation of the guideline, or that decisions are made to not apply 
the guideline advice to certain patients. Our results call for further scientific underpinning 
of this guideline recommendation, and – if sufficient evidence is available – for a better 
understanding of the reasons for nonadherence. In the case of chest X-ray use in children 
with suspected lower RTIs, we observed practice variability across eight Dutch EDs. Even 
though X-ray use was much lower than in studies from the US,8,9 we discovered that chest 
X-ray results only played a minor role in the decision to prescribe antibiotics. Thereby our 
study confirmed the guideline recommendation to not routinely use chest X-ray in non-
complex patients. We observed a very low frequency of complicated illness (<1%), further 
emphasizing the limited added value of chest X-rays in a low risk population as in the 
paediatric ED. These results can be used to further reduce unnecessary use of chest X-rays 
for uncomplicated pneumonia in the ED in The Netherlands, and serve as an example for 
high-utilizing countries. The observed variability in antibiotic prescription for RTIs may have 
a more complex background. The indications for antibiotic prescription in the guidelines are 
less clear-cut, as a result of the lacking gold standard for childhood bacterial pneumonia. 
However, our findings fit in a growing body of evidence on variation in antibiotic use, pointing 
out that reduction of antibiotic prescription in the paediatric ED is possible.5,9-15
Second, variability studies show where most potential gain of an intervention is, in terms of 
geographical regions or specific patient groups. Countries or hospitals with poor adherence 
to the NICE recommendation to measure vital signs should find out reasons for nonadherence 
and improve implementation of this advice. Hospitals that perform most chest X-rays or 
prescribe most antibiotics should improve their management of febrile children on these 
5
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fronts. It has been shown previously that high use of diagnostic tests is associated with 
more aggressive treatment, also after correction for disease severity of patients.9 This was 
confirmed by our finding that the mere performance of chest X-ray increased the likelihood 
of prescribing antibiotics, and not the result. In addition to specific settings, we could also 
identify specific patient groups who may gain most of interventions to improve diagnostic 
testing or treatment. Most benefit in improving vital sign measurement can be expected in 
patients with a higher prior risk of serious illness, e.g. fever without source.
Efforts to reduce unnecessary antibiotic prescription should target children with RTIs. In the 
first place because RTIs are the most common reason to prescribe antibiotics in the ED due 
to their high prevalence. In addition, because antibiotic prescription rates for RTIs showed 
most variability across hospitals, suggesting most room for improvement.
Third, our studies provide input for the design of intervention studies to improve management 
of children with fever and RTIs. Baseline antibiotic prescription rates varied across and within 
European countries, affecting sample size calculations of studies aiming to improve antibiotic 
prescription. For example, if 500 patients are needed in a trial to show a 10% reduction in 
antibiotic prescription in The Netherlands by a certain intervention, fewer patients will be needed 
in a country with a higher baseline prescription rate. The observed variability also emphasizes 
the importance of performing multi-centre and multi-national studies. This will improve 
generalizability of findings to the wider European setting and increase standardization of care at 
the international level. It must be noted that antibiotic prescription in the paediatric ED care still 
is a small proportion, when compared to prescription in primary care and in adult care.16-19
Decision rules in clinical practice
Decision thresholds
When translating a clinical prediction model – that provides a probability of having the outcome 
– into a decision rule for clinical practice, decision thresholds need to be defined. In case of the 
STRAP trial (chapter 3.2), the Feverkidstool was translated into a decision rule with a specific 
threshold below which antibiotics would be withheld. Choosing a decision threshold warrants 
careful consideration of the potential benefit of the intervention (in our case the reduction 
of unnecessary antibiotic treatment) versus the potential harm (under treatment of bacterial 
infections). We chose a threshold of 10%. In the validation cohort of the original publication 
of the Feverkidstool this threshold provided a sensitivity of 75%, which rule out value was 
considered sufficient to be a safe threshold, while still having the potential to reduce antibiotic 
prescription.20 Figure 2a shows the observed effect of our intervention on antibiotic prescription 
in a complete case analysis of the STRAP population. We observed a 65% reduction in antibiotic 
BNW_Josephine_v1.indd   216 19-Sep-20   14:52:47
217
Summary and general discussion 
prescription in the low/intermediate risk children (from 17% [29/172] to 6% [15/234]). At the 
same time prescriptions increased by 25% in the high-risk children (from 47% [75/159] to 59% 
[83/140]). This resulted in an overall reduction of 16% in the whole population, which – in 
the multilevel and adjusted for time analysis described in chapter 3.2 – appeared not to be 
significant. In our validation study (chapter 3.1) we also explored a threshold of 15% for the 
Feverkidstool in two populations, which would result in greater benefit, with a minor increase 
in potential harm. If we applied this threshold to the STRAP pre-intervention population, and 
assumed the same changes in antibiotic treatment would occur (-65% in low/intermediate 
risk and +25% in high risk children), 14 extra children would have been managed without 
antibiotics. This would have resulted in a sharper decline of overall antibiotic prescription: a 
reduction of 29% instead of 16% (Figure 2b). It is difficult to predict what the consequences 
of a higher decision threshold would have been on strategy failure. In our trial we observed a 
reduction in strategy failures (from 23% [131/572] to 16% [61/381]). Using a 15% threshold, 
14 extra children would have been discharged without antibiotics. Still, even if we assumed 
that all these 14 children would have strategy failure, this would not have led to an increase 
in strategy failure in the whole group (expected change in strategy failure from 23% to 21%). 
The risk of strategy failure is also safeguarded in the follow-up strategy of children after the 
ED visit. It has been shown that if children with pneumonia deteriorate clinically, they usually 
revisit the ED after 48 hours.21 This relatively slow disease course legitimates a watchful waiting 
approach, provided that good safety-netting is in place and patients have good access to 
care. Good safety-netting implies that the patient information is tailored to parents’ needs, 
and includes precise information on how to manage the febrile child at home and when to 
return to a healthcare professional.22-24 This is essential to ensure the safety of interventions 
that change clinical decision-making in young febrile children in the ED.
Figure 2. Antibiotic prescription during the pre-intervention period.
A) observed impact of the Feverkidstool at the 10% decision threshold; B) expected impact at 15% threshold.
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Presentation of risks
The observed increase in antibiotic prescription in the high-risk population was not expected, 
and raises another practical issue. When implementing prediction models as decision rules in 
clinical practice, the question is how to visualize the predicted risk of the individual child to 
the healthcare provider. In the STRAP trial we chose to provide a qualitative risk classification 
to the treating physician, instead of the exact percentage: the predicted risk was presented 
as either ‘low (<3%)’, ‘intermediate (4-10%)’ or ‘high (>10%)’. Even though it was explicitly 
stated to perform usual care in children with a high predicted risk, this term ‘high risk’ 
may have influenced the clinician and increased prescriptions. However, the exact median 
predicted risk in the high-risk children that received antibiotics was slightly higher in the 
intervention group than in the pre-intervention group (29% [IQR 18-43%] versus 21% [IQR 
16-43%]). This may indicate that these children had a more severe clinical presentation, and 
may partly justify the increase in antibiotic prescription during the intervention period.
Evaluation of impact: more than effectiveness
The evaluation of a decision rules in clinical practice includes more than studying the change 
in clinical outcome. Interventions in healthcare are usually complex in nature and have an 
impact on multiple aspects of the health system.25-28 These can include costs, process 
outcomes (for example length of stay) or patient-reported outcomes. These system-wide 
effects are especially important when deciding to scale up an intervention to the national 
or international level. In the case of the Feverkidstool, we showed that the decision rule was 
cost-saving for the most important cost drivers of children with RTIs: hospitalization and 
parental absenteeism. The main cost drivers and the high prevalence of RTIs are similar in 
other European settings, so the decision rule is likely to have a cost benefit in other settings 
as well. Regarding the improving of antibiotic prescriptions, the underlying goal is to prevent 
antimicrobial resistance. Even though this could not be captured in our study, it remains an 
important outcome that should be considered in the evaluation of decision rules supporting 
antibiotic treatment decisions.
The role of biomarkers in the management of fever and RTIs
CRP-testing in febrile children: yes or no?
In current clinical practice CRP is the only routinely available, easy to perform and affordable 
point-of-care biomarker in the ED setting.29 The association between CRP and bacterial 
pneumonia has been well described in studies in children as well as in adults.30-35 It has a 
good rule-in value at a threshold of >100mg/L, but a moderate rule-out value even at a low 
threshold.31 The use of CRP testing in the routine assessment of febrile children in the ED 
is an issue of ongoing debate. Recently, some authors have argued to test CRP in all febrile 
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children already at the moment of triage 36, but others raised questions on the feasibility and 
validity of such approach.37 The Feverkidstool does include CRP, so implementation of the tool 
in routine practice required a capillary blood sample in all children with fever and respiratory 
complaints. What can we learn from this thesis on how to balance clinical assessment and 
biomarkers in the management of the febrile child in the ED?
CRP during the STRAP trial
During the conduct of the STRAP trial we encountered that many paediatricians preferred 
not to measure CRP routinely in all children meeting the inclusion criteria, even though in 
the Feverkidstool CRP was combined with clinical characteristics. It has been described that 
more diagnostic testing is associated with more aggressive treatment of children in the ED.9 
Physicians in the STRAP trial were most concerned about false-positive tests (and overuse 
of antibiotics) in children with viral infections, false reassurance by low CRP-values in early 
stage disease, uncertain aetiology and thereby overtreatment of children in the ‘grey area’ 
of intermediate CRP-levels (between 20-80 mg/L). They stated that clinical assessment of the 
doctor should be leading in treatment decisions, not a CRP-value (unpublished qualitative 
data). The majority of included children in our trial (54%) had a CRP-value below 20 mg/L. 
In 10% of cases CRP was >80 mg/L, and 36% were in the intermediate, grey area (Table 1). 
This distribution is comparable to other cohorts of febrile children in the ED that have been 
described.20,36,38 We observed that across all CRP-categories, antibiotic prescription slightly 
decreased during the intervention period, suggesting that the combination of CRP with 
clinical findings in the Feverkidstool was beneficial. In addition, when we looked at antibiotic 
prescription across hospitals with varying levels of CRP-testing in the pre-intervention period, 
we found no evidence for increased antibiotic prescription in hospitals that started to test 
CRP more often in the intervention period (Figure 3). A notable finding was that in both 
phases of the trial, some children with presumed viral infections still received antibiotics (e.g. 
22/196, 11% of all children diagnosed with bronchiolitis). Introduction of the Feverkidstool, 
including CRP measurement, did not influence prescriptions in these children. Based on our 
findings and the available literature, we conclude that CRP should be interpreted together 
with clinical signs and symptoms for optimal diagnostic accuracy in children with suspected 
lower RTIs.39-42 In this way CRP does not increase unnecessary antibiotic prescriptions, and 
can safely be used to guide treatment decisions.
5
BNW_Josephine_v1.indd   219 19-Sep-20   14:52:54
220
Chapter 5
Table 1. Antibiotic prescription by CRP categories
Overall Pre-intervention Intervention
CRP categories
CRP <20 51/404 (13%) 30/195 (15%) 21/209 (10%)
CRP 20 - 80 99/270 (37%) 52/136 (38%) 47/134 (35%)
CRP >80 70/80 (88%) 39/43 (91%) 31/37 (83%)
Figure 3. Antibiotic prescription rates (%) in hospitals with varying levels of CRP-testing in pre-intervention care
Legend: A-H = hospitals; n=total included children; %CRP= percentage of children in whom CRP was measured in 
the pre-intervention period. In the intervention period in >90% of children CRP was tested in all hospitals.
Improving diagnosis by new biomarkers?
Even though CRP and clinical judgment should be combined for optimal diagnostic accuracy, 
they are still imperfect diagnostics for bacterial infection and some diagnostic uncertainty 
remains. More accurate biomarkers are being developed to reduce this diagnostic uncertainty 
of bacterial versus viral infections in children.38,43 How can they be added to the diagnostic 
pathway in routine care? In chapter 3.4 we observed that the diagnostic accuracy of the 
Feverkidstool increased when we updated the tool by replacing CRP with a host-protein 
based assay (the ImmunoXpert) that combines bacterial and viral biomarkers. We found most 
added value of the updated Feverkidstool in the group of children with low to moderate 
predicted risk by the original Feverkidstool. This points out that a combination of clinical 
findings and CRP may identify a subgroup of children that will benefit from new, more 
accurate biomarkers.
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5.3. Future perspectives
Pneumonia reference standard for diagnostic research
As mentioned frequently throughout this thesis, no gold standard exists for childhood 
pneumonia. This hampers the proper judgment of the accuracy of diagnostic tests and of 
the appropriateness of antibiotic use. In this thesis, we have used different approaches to 
handle this problem: in our validation study of prediction models for childhood pneumonia 
(chapter 3.1) we used a predefined algorithm, based on available clinical information to 
define bacterial pneumonia.44 In our update of the Feverkidstool with the ImmunoXpert 
(chapter 3.4) we used an expert panel diagnosis as a reference standard.45 In the STRAP trial 
(chapter 3.2), we did not define a reference standard for bacterial pneumonia, but focused on 
consequences of the diagnosis (need for antibiotics, strategy failure) instead of the diagnosis 
itself.28 Consensus about the optimal reference standard for bacterial pneumonia in children 
is urgently needed. A prospective study comparing the different approaches would be useful 
to judge the different pros and cons, to come to a consensus and to interpret existing studies 
on childhood pneumonia.
Improving treatment decisions for childhood pneumonia
Appreciating the results of the Feverkidstool so far, next steps would be to evaluate the 
impact of the Feverkidstool in high-prescribing settings, in settings with a low prevalence of 
bacterial infections, or using a higher decision threshold. Another future perspective for the 
Feverkidstool is to use this model to position new diagnostic tests for childhood pneumonia. 
New biomarkers are being developed, raising questions about their use in research and 
clinical practice: how accurate are the new biomarkers, who should be tested, how can they 
guide treatment, what is the availability and affordability of the tests? As we have shown in 
the update study of the Feverkidstool with ImmunoXpert, the benefit of this new biomarker 
was found in a subgroup of patients. Such a hierarchical approach should be developed for 
diagnosing pneumonia, in order to make the most accurate diagnosis, without overuse of 
expensive and scarce resources. It should start with readily available and cheap diagnostics 
(like clinical assessment and CRP) and save the more advanced testing for patients in whom 
diagnostic uncertainty remains.
Outcomes in paediatric emergency care
In the STRAP trial we focused on the impact of the Feverkidstool on antibiotic prescription, 
safety and costs. These are important clinical outcomes, but also other factors should be 
explored. Patient reported outcome measures (PROM) are widely used in current research and 
clinical practice. For example, a recent study showed that parents of febrile children in the 
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ED care most about reducing visit times, avoiding painful procedures and getting diagnostic 
information faster.46 In the development or evaluation of new interventions, such outcomes 
should be taken into account.
Improving decision support for parents
In our qualitative study we developed a discharge information package for parents, including 
videos on how to recognize signs of severe illness, for example nasal flaring or retractions. 
However, a recent publication showed that there is a large discrepancy in the assessment 
of disease severity in children with RTIs between parents and physicians.47 Parents focused 
more on behavioural symptoms like ‘change in cry’, ‘disturbed sleep’ or ‘reduced eating’, 
while physicians relied almost exclusively on physical examination. This discrepancy has 
consequences for the way we provide discharge instructions after the ED, but also how we 
value the history the parents tell. Future research should evaluate the predictive value of 
behavioural symptoms that parents use to judge disease severity, and discharge information 
should be tailored accordingly.
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Inleiding
Koorts en luchtweginfecties komen heel vaak voor bij kinderen en zijn de belangrijkste 
reden waarom kinderen naar de huisarts of de spoedeisende hulp (SEH) worden gebracht. 
Luchtweginfecties geven klachten zoals koorts, hoesten en benauwdheid. Meestal worden 
ze veroorzaakt door virussen en gaan vanzelf over. Echter, soms heeft een kind een 
longontsteking door een bacterie, die ernstig kan verlopen en met antibiotica moet worden 
behandeld. Antibiotica werken niet tegen virusinfecties. Het verschil tussen een virusinfectie 
of een infectie door een bacterie is soms moeilijk te maken. De klachten lijken erg op elkaar, 
en er zijn geen perfecte testen om dit verschil aan te tonen. Bloedtesten en longfoto’s zijn 
wel beschikbaar, maar die zijn niet 100% betrouwbaar voor het aantonen van een bacteriële 
longontsteking. Het is belangrijk om niet onnodig antibiotica te gebruiken, want dat draagt 
bij aan resistentie van bacteriën. Dat wil zeggen dat bacteriën ongevoelig worden voor 
antibiotica, waardoor het moeilijker wordt om ze te bestrijden. In de praktijk beslist de arts 
bij een kind met koorts en luchtwegklachten of hij/zij antibiotica nodig heeft op basis van een 
combinatie van symptomen, lichamelijk onderzoek en aanvullende testen. In dit proefschrift 
onderzoeken we of de beslissingen over diagnose en behandeling kunnen verbeteren bij 
kinderen die met koorts en luchtweginfecties op de SEH komen.
Variatie in de behandeling van kinderen met koorts en luchtweginfecties
Een internationale richtlijn (de NICE-richtlijn voor de behandeling van kinderen met 
koorts) adviseert om bij alle kinderen met koorts onder de vijf jaar standaard vier vitale 
parameters te meten: temperatuur, hartslag, ademhalingssnelheid en capillaire refill (maat 
van doorbloeding). In hoofdstuk 2.1 hebben we onderzocht hoe goed dit advies werd 
opgevolgd in de praktijk. We hebben hiervoor data gebruikt van meer dan 5000 kinderen 
met koorts die de SEH bezochten van 28 ziekenhuizen in 11 verschillende Europese landen. 
We constateerden dat het advies matig werd opgevolgd: bij minder dan de helft van de 
kinderen onder de vijf jaar waren alle vier parameters gemeten en geregistreerd. Er waren 
grote verschillen tussen ziekenhuizen en de metingen waren vaker compleet bij jonge 
kinderen, kinderen met luchtweginfecties en bij kinderen met urgent ziektebeeld (waarvoor 
snelle beoordeling nodig is).
De longfoto is lange tijd gezien als beste test om een longontsteking aan te tonen. 
Tegenwoordig is veel bekend over de beperkingen van deze test. Ten eerste, wanneer 
meerdere beoordelaars naar dezelfde foto kijken, komen ze vaak tot een verschillende uitslag. 
Ten tweede is het niet te zien of de afwijkingen op de foto door een virus of een bacterie 
worden veroorzaakt. Daarom adviseren internationale en Nederlandse richtlijnen om niet 
bij alle kinderen met luchtwegklachten een foto te maken, maar alleen bij kinderen met een 
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gecompliceerd ziektebeloop. Hoofdstuk 2.2 beschrijft hoe vaak tegenwoordig een longfoto 
wordt gemaakt bij jonge kinderen die met luchtwegklachten op de SEH komen, en of die 
foto invloed heeft op beslissing om antibiotica voor te schrijven. Bij een groep van bijna 600 
kinderen onder de vijf jaar uit acht Nederlandse ziekenhuizen stelden we vast dat een op de 
vijf kinderen een longfoto krijgt, terwijl geen van hen een gecompliceerd beloop had. Het 
maken van deze foto – ongeacht de uitslag ervan – leidde tot het vaker voorschrijven van 
antibiotica. Dit laat zien dat de longfoto weinig toegevoegde waarde heeft in het maken van 
de beslissing om wel of geen antibiotica voor te schrijven. Daarmee bevestigt ons onderzoek 
het advies van de richtlijn om niet standaard een longfoto te maken bij kinderen met een 
ongecompliceerde luchtweginfectie.
In de literatuur is regelmatig beschreven dat er grote verschillen zijn in het voorschrijven van 
antibiotica. Er was alleen geen recent onderzoek naar verschillen in antibioticavoorschrift 
bij kinderen op de SEH in Europa. Ook was niet bekend waardoor eventuele verschillen 
verklaard kunnen worden. In hoofdstuk 2.3 hebben we dit onderzocht, in dezelfde groep 
kinderen als hoofdstuk 2.1. We zagen dat de meeste antibiotica werden voorgeschreven voor 
luchtweginfecties, omdat die het vaakst van alle infecties voorkomen. Binnen deze groep 
van kinderen met luchtweginfecties waren grote verschillen te zien in antibioticavoorschrift 
tussen de 28 ziekenhuizen. Er waren dus ziekenhuizen waarbij de dokters relatief weinig 
antibiotica voorschreven en ziekenhuizen waar veel meer antibiotica werd gegeven. Deze 
verschillen konden niet worden verklaard door het feit dat kinderen in het ene ziekenhuis 
ernstiger ziek waren dan in het andere ziekenhuis. Deze bevinding wijst op overbehandeling 
met antibiotica, en geeft dus aan dat antibioticavoorschrift verminderd kan worden.
Ondersteuning van behandelbeslissingen voor longontsteking bij kinderen
De beslissing van de arts om wel of geen antibiotica te geven, kan op verschillende 
manieren worden ondersteund. Zoals genoemd zijn er diverse richtlijnen beschikbaar voor 
de behandeling van koorts en longontsteking bij kinderen. Hoewel richtlijnen zeer nuttig en 
nodig zijn, zijn ze niet altijd gebaseerd op hoogstaand bewijs, zijn de adviezen vaak algemeen 
en niet altijd toepasbaar op de individuele patiënt. Een andere vorm van beslisondersteuning 
kan worden gegeven door beslisregels. Beslisregels zijn gebaseerd op voorspelmodellen die 
aan de hand van strikte methodologische stappen zijn ontwikkeld. Deze voorspelmodellen 
geven een precieze uitslag voor de individuele patiënt, bijvoorbeeld de kans (%) dat een 
kind een bepaalde ziekte heeft.
In hoofdstuk 3.1 hebben we de literatuur doorzocht om te kijken welke modellen er zijn 
om de kans op een bacteriële longontsteking bij kinderen te voorspellen. Ook hebben we 
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onderzocht of deze modellen gebruikt zouden kunnen worden om de beslissing wel/geen 
antibiotica te verbeteren. We vonden in de literatuur zeven voorspelmodellen voor een 
bacteriële longontsteking, maar die werden nog niet in de praktijk toegepast. Drie van de 
zeven konden het risico op een bacteriële longontsteking goed voorspellen. Omdat deze drie 
voorspelmodellen een groep kinderen met een laag risico konden identificeren, zouden ze 
gebruikt kunnen worden om de behandelbeslissing van de arts te sturen.
Een van de voorspelmodellen die we vonden is de Feverkidstool. Dit is een voorspelmodel 
dat aan de hand van klinische gegevens (zoals leeftijd, hartslag en ademhalingssnelheid) 
en een ontstekingswaarde (CRP) het risico op een longontsteking kan voorspellen. Dit 
model is al uitgebreid gevalideerd in verschillend groepen patiënten, maar nog niet in de 
praktijk gebruikt als ondersteuning van de behandelbeslissing. Hoofdstuk 3.2 beschrijft de 
resultaten van een grote studie (de STRAP-studie), waarin de Feverkidstool als beslisregel 
is gebruikt om het voorschrijven van antibiotica te sturen. Het advies was daarbij dat alle 
kinderen met een laag of gemiddeld risico op een bacteriële longontsteking (<10%) geen 
antibiotica zouden krijgen. We hebben daarvoor een stepped-wedge design gebruikt, 
waarbij acht Nederlandse ziekenhuizen één voor één overgingen van ‘gewone zorg’ naar 
‘antibioticavoorschrift volgens de beslisregel Feverkidstool’. We stelden vast dat de beslisregel 
het algehele antibioticavoorschrift tijdens het onderzoek niet heeft verlaagd. Wel zagen 
we dat er minder therapie-falen was, en dat aan de kinderen met een laag/gemiddeld 
risico minder antibiotica werd voorgeschreven. Dit wijst op een betere, meer doelgerichte 
behandeling met antibiotica van de kinderen in de studie. In hoofdstuk 3.3 vonden we 
ook dat de invoering van de beslisregel leidde tot een kostenbesparing, doordat er minder 
ziekenhuisopnames waren en ouders minder werkverzuim hadden tijdens de ziekte van 
hun kind.
In hoofdstuk 3.4 onderzochten we of de voorspellingen van de Feverkidstool verder verbeterd 
konden worden als we een nieuwe bloedtest daaraan toevoegden: de ImmunoXpert. Deze 
bloedtest combineert de ontstekingswaarde CRP – die ook in de Feverkidstool zat – met 
twee andere eiwitten: tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) en 
interferon gamma induced protein-10 (IP-10). We keken of de ge-update Feverkidstool (met 
ImmunoXpert in plaats van alleen CRP) beter kon voorspellen of een kind een bacteriële 
infectie had. Deze bacteriële infecties werden vastgesteld door een panel van drie experts. 
In een groep van bijna 600 Nederlandse en Israëlische kinderen met koorts zonder focus en 
kinderen met lage luchtweginfecties vonden we dat de ge-update Feverkidstool inderdaad 
meer accuraat een bacteriële infectie kon voorspellen, met name in de groep kinderen met 
een laag/gemiddeld risico.
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Ondersteunen van beslissingen door ouders voor hun kind met koorts
Zowel voor als na het bezoek aan de SEH, zijn ouders degene die de belangrijkste beslissingen 
maken in het zorgen voor hun kind met koorts. Daarbij is het belangrijk dat ze goede 
informatie krijgen over wat ze moeten doen in de thuissituatie, zodra ze ontslagen worden 
vanaf de SEH. Deze informatie moet goed aansluiten bij de beleving en verwachtingen van de 
ouders. In hoofdstuk 4.1 onderzochten we die verwachtingen en informatiebehoefte door 
middel van een kwalitatief onderzoek onder ouders. Ouders gaven aan vaak bezorgd te zijn 
om hun kind vanwege specifieke symptomen, maar vaak ook op basis van een onbestemde 
intuïtie. Als zij zich hierin niet serieus genomen voelden door behandelaren, verhoogde dat 
de drempel om een volgende keer hulp te zoeken. We ontwikkelden een informatiepakket 
over koorts bij kinderen, bestaand uit een website met video’s, en een folder. Ouders gaven 
aan meer kennis over koorts en meer vertrouwen te hebben in het zorgen voor een kind 
met koorts, nadat ze het informatiepakket hadden geraadpleegd.
6
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‘It takes a village to raise a child’. Dit Afrikaanse spreekwoord geeft aan hoeveel er nodig 
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vertrouwen dat jullie in mij hadden om het STRAP-project tot een goed einde te brengen.
Lieve Henriette, wat ben ik blij met jou als promotor. Je bent een slimme en bevlogen 
onderzoeker, inspirerende leider van de groep en empathische moederfiguur in een. Ik 
waardeer je nuchtere kijk op het onderzoek (‘mijn gezonde verstand zegt…’, en ‘je moet 
het ook aan de Telegraaf kunnen uitleggen’), je humor en maatschappelijke betrokkenheid. 
Ik kon altijd bij je terecht, ook voor een goed gesprek los van dit proefschrift. Dank voor je 
open blik en je wijsheid, ook in gesprekken over de toekomst, toen ik uiteindelijk tóch geen 
kinderarts wilde worden…
Lieve Rianne, dankjewel voor alles wat je mij hebt geleerd als co-promotor. Je bent een 
ontzettend goede, intelligente en snelle onderzoeker met het hart op de juiste plek. Ik kwam 
binnen als SPSS-leek, en je hebt me afgeleverd als enthousiaste master in de epidemiologie. 
Af en toe ging je wat te snel voor mij, maar ook dat heeft mij in de samenwerking veel 
geleerd. Dank voor je kritische blik, juiste dosis pragmatisme en voor de ruimte die je me gaf 
om ook de international health tijdens mijn promotie te blijven doen.
Prof. dr. Louis Bont, prof. dr. Ewout Steyerberg en prof. dr. Stephanie Klein Nagelvoort 
– Schuit: dank dat jullie als leescommissie mijn manuscript hebben beoordeeld. Louis, ik 
herinner me nog de eerste telefonische kennismaking voor het ImmunoXpert artikel, waarin 
we kennismaakten aan de hand van een foto uit een Noorse krant, wat het begin was van 
mooie ontmoetingen. Heel leuk dat je in mijn commissie zit, en hopelijk blijven we elkaar ook 
na de verdediging tegenkomen op het gebied van global health en luchtweginfecties. Ewout, 
onze eerste ontmoeting was ongetwijfeld tijdens een ‘groot overleg’ over predictiemodellen, 
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waar ik de eerste keer zeker niets van begreep, maar inmiddels zelf ook enthousiast over ben 
geworden. Stephanie, dank voor de leuke eerste kennismaking, en voor je voorbeeldfunctie 
als vrouw in de wetenschap. 
Prof. dr. Michael Boele van Hensbroek, dr. Suzanne Polinder, dr. Gertjan Driessen, prof. dr. 
De Jongste: dank voor jullie deelname aan mijn grote commissie. Michael, heel leuk om 
elkaar bij deze gelegenheid weer te treffen, na alle bezoekjes die ik de afgelopen 8 jaar 
aan het AMC heb gebracht in mijn zoektocht naar ‘iets met tropengeneeskunde’. Gertjan, 
ook jou heb ik voor het eerst ontmoet in de tropen-scene als NTC-docent, dank voor al je 
enthousiasme en inspiratie, ook tijdens de STRAP-studie. Suzanne, ik heb altijd genoten van 
jouw nuchtere inbreng tijdens de ‘grote overleggen’ en van de ontspannen samenwerking 
in het kostenartikel. 
Graag wil ik alle mensen bedanken die hebben bijgedragen aan de STRAP-studie, het 
grootste project van mijn onderzoek. Dank aan alle lokale onderzoekers en jullie teams: 
Anne-Marie van Wermeskerken en Michael van der Ven (Flevoziekenhuis), Frank Smit 
(Maasstad Ziekenhuis), Jeroen Noordzij (Reinier de Graaf Gasthuis), Gertjan Driessen en 
Daphne Peeters (Juliana Kinderziekenhuis), Charlie Obihara (Elisabeth Tweesteden Ziekenhuis), 
Gerdien Tramper (Franciscus Ziekenhuis) en Jeanine Punt (Langeland Ziekenhuis). Ik weet dat 
het niet altijd makkelijk was om in de hectiek van een SEH patiënten te (laten) includeren, 
maar jullie hebben het gedaan! Ik heb genoten van de samenwerking en de tripjes door het 
land, van Almere tot Tilburg. We hebben een prachtig resultaat bereikt met elkaar. Onmisbaar 
bij de STRAP was ook de hulp en inzet van jou, Marianne Maliepaard. Je hebt mij geduldig 
alles geleerd over het reilen en zeilen van een klinische trial, en was daarbij ontzettend fijn 
en gezellig in de samenwerking. We hebben veel gelachen en bereikt, dankjewel! 
Dank aan alle masterstudenten die ik mocht begeleiden: Daphne, Anine, Dani, Hein en Levi. 
Ik heb minstens zoveel geleerd van jullie als jullie (hopelijk) van mij. Jullie hebben ontzettend 
veel goed werk geleverd, onder andere zichtbaar in de hoofdstukken van dit proefschrift, 
en het was heel mooi om een tijd met jullie op te trekken. 
I thank all the co-authors of the Research in European Pediatric Emergency Medicine (REPEM). 
Elles, we hebben elkaar nooit live ontmoet, maar dank voor al het voorwerk aan de REPEM-
database. All co-authors, in particular Silvia Bressan, Santiago Mintegi and Alain Gervaix: 
thanks for your continuous support and feedback on the manuscripts. Our collaboration 
resulted in two very nice publications, which I hope will support the future research of the 
REPEM group.   
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Dan mijn collega-onderzoekers. Lieve Sp-ers, dank voor wie jullie zijn! Joany, Maartje en 
Myrthe, met jullie begon mijn avontuur als onderzoeker, al snel gevolgd door Nienke, naast 
wie ik in de afgelopen jaren misschien wel de meeste uren heb doorgebracht ☺. Jesminne, 
Linda, Leontien en alle komende en gaande studenten. Dank voor de mooie herinneringen 
samen, die voor altijd verbonden zullen blijven aan dit boekje: bios op het plein, Parade in 
de regen, Sinterklaas bij Nienke, uitje naar De Verleiders, boekenclub, lunchen in het park, 
uithuilen over niet-werkende R-packages en gemene reviewers etcetera. Dan ons nerden-
infectie-clubje Eat the Beast: Fleur, Ruben en (alweer) Nienke. Er is nooit echt iets gekomen 
van ons voornemen om een journal club te starten, maar de koffiemomenten, favoriete 
pathogenen en ESPID-netwerk/dans-events waren legendarisch. Mijn TULIPS-collega’s: wat 
heerlijk (!) om met jullie op te trekken de afgelopen twee jaar. Ik ben benieuwd wie van 
ons nu echt een leader in paediatric science gaat worden, maar wat maakt het uit: ik heb 
genoten van de openheid en gezelligheid in de groep en veel geleerd van jullie en van de 
trainingen die we hadden. 
I would like to thank Kristina Keitel from the Swiss institute of Tropical and Public Health. 
Thanks for coming to Rotterdam only after some emails and skype calls, it feels as if we 
have known each other for years. Thank you for trusting me with the ePOCT data, for 
supervising my master thesis on triage of children in Tanzania, for your personal advice in 
life and for being a role model for me in global health research. Hopefully the next meeting 
place is TZ.  
Naast al deze collega’s zijn de mensen buiten mijn werk minstens zo belangrijk geweest in 
de afgelopen jaren, en hebben bijgedragen door me juist af te houden van het werk. Inge 
en Han, onze vriendschap begon lang geleden in de eerste klas, samen van Rijssen naar 
Leiden en nu naar (regio) Utrecht. We lopen inmiddels alle drie een andere route, maar ik 
ben heel blij dat we nog steeds onze levens met elkaar delen! Gerdien en Wietse, Anne en 
Marnix, Karlijn en Claudio, Joost en Annemarie, Derk, Ingrid, Hans en Eva, Sjoerd en Yolin, 
Rob en Jedid, Reinier en Maartje, Willemijn en Jeroen, Huib, Ed en Iloon en alle andere 
vrienden en vriendinnen: dank voor jullie vriendschap. In het bijzonder Joost en Annemarie: 
wat een heftige tijd hebben jullie gehad met Rosalia in het Sophia. Ik heb bewondering 
voor jullie doorzettingsvermogen, liefde en blijvende interesse in anderen, ondanks de 
zorgen die er waren. Ik ben dankbaar dat ik dichtbij was en er af en toe voor jullie kon zijn. 
Elies en Hannebeth: oud-collega’s in het LLZ en toekomstig collega-huisarts, maar vooral: 
glitter-buufjes en vriendinnetjes, dank voor jullie! De helft van mijn promotie speelde zich 
af in het hofje, waar we lief en leed deelden en jullie altijd paraat stonden met goede en 
slechte gewoontes ☺. Al is het hofjes-tijdperk afgesloten, onze vriendschap gaat door! JW-
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fanclub, lieve Jans, BJ en Caro: we delen onze liefde voor tropen, geneeskunde, John Wyatt 
(‘suffering is…’), Gene Rudd (‘flying in enemy territory’) en onze afkeer voor grijze muizen 
met ellebogen. Laten we zo doorgaan! 
Een bijzondere dank aan Joany en Hannebeth, lieve Jones en Hb, dank dat jullie mijn 
paranimfen zijn op deze speciale dag! Ik waardeer jullie als collega’s en als vriendinnen, 
en ben heel blij dat jullie mij willen bijstaan bij (de voorbereidingen van) mijn verdediging, 
zowel wat betreft de inhoud als de uiterlijkheden. Ik heb er alle vertrouwen in dat het met 
jullie support goed gaat komen. 
Lieve pap en mam, dank voor alles dat jullie mij hebben gegeven en nog steeds doen. 
Jullie hebben mij altijd gestimuleerd voor het hoogst haalbare te gaan, onder het 
motto ‘je wordt nooit ergens dommer van’. Dat heb ik soms wat te letterlijk genomen 
denk ik, waardoor kiezen soms lastig is omdat ik alles leuk vind, maar het heeft mij 
heel veel gebracht. Dank voor jullie steun en veilige thuisbasis. Gineke en Arco, ik 
bewonder jullie om de dankbaarheid waarmee jullie in het leven staan en hoe jullie je 
prachtige gezin laten bloeien. Joost, ‘kleine’ broer, ik bewonder jou om je creativiteit, 
enthousiasme en doorzettingsvermogen, ook als dingen soms niet makkelijk zijn. 
Lieve ma, Alja en Marcus, Marnix en Inge, Bernard en Marith, Chris en Michel: wat ben ik 
blij met de van Grootheesten als schoonfamilie. Dank voor jullie interesse en gezelligheid. 
Pa zou genoten hebben van deze promotie, hij is erbij in ons hart.   
Tot slot: lieve Peet, tijdens mijn promotietijd ben ik jou tegen het lijf gelopen. Dat is het beste 
dat me ooit is overkomen. We hebben in de afgelopen jaren al veel mooie avonturen beleefd, 
met als hoogtepunten ons huwelijk, kamperen in Afrika en Zeezuipers bij de Morgenster. 
Dank dat je er altijd voor me bent, ook als het wel eens schuurt of er verdrietige dingen zijn. 
Met je humor, liefde en daadkracht weet je me altijd te waarderen, te laten lachen en zo 
nodig te relativeren. Ik hou van je, en kijk uit naar alle avonturen die nog gaan volgen! 
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